CN1537117A - Interferon gamma polypeptide variants - Google Patents

Interferon gamma polypeptide variants Download PDF

Info

Publication number
CN1537117A
CN1537117A CNA028078918A CN02807891A CN1537117A CN 1537117 A CN1537117 A CN 1537117A CN A028078918 A CNA028078918 A CN A028078918A CN 02807891 A CN02807891 A CN 02807891A CN 1537117 A CN1537117 A CN 1537117A
Authority
CN
China
Prior art keywords
lys
variant
seq
ifng
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CNA028078918A
Other languages
Chinese (zh)
Other versions
CN1257186C (en
Inventor
D��ղɭ
安妮·D·詹森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Maxygen Holdings Ltd
Original Assignee
Maxygen Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxygen Holdings Ltd filed Critical Maxygen Holdings Ltd
Publication of CN1537117A publication Critical patent/CN1537117A/en
Application granted granted Critical
Publication of CN1257186C publication Critical patent/CN1257186C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to novel interferon gamma polypeptide variants having interferon gamma (IFNG) activity, methods for their preparation, pharmaceutical compositions comprising the polypeptide variants and their use in the treatment of diseases, in particular for the treatment of interstitial pulmonary diseases, such as idiopathic pulmonary fibrosis. These novel polypeptide variants all comprise the substitution S99T as compared to the amino acid sequence of huIFNG or fragments thereof. By performing this mutation the naturally occurring N-glycosylation site present at position 97 is significantly beter utilized. Preferably, the variants comprise further modifications, e.g. in order to increase the AUC of such variatns when administered subcutaneously.

Description

Interferon gamma polypeptide variants
Invention field
(IFNG) the active new interferon gamma polypeptide variants that the present invention relates to have interferon-gamma, its preparation method, contain the pharmaceutical composition of this polypeptide variants and the purposes in disease treatment thereof, especially at the treatment interstitial lung disease, as the purposes in the spontaneous lung fibrosis.
Background of invention
Interferon-(IFNG) is a kind of cytokine of being produced by T-lymphocyte and natural killer cell and exists with the homodimer of two non-covalent bonded polypeptide subunits.Each dimeric mature form contains 143 amino-acid residues (shown in the SEQ ID NO 2), and its precursor forms comprises the signal sequence (shown in the SEQ ID NO 1) of 166 amino-acid residues.
Each subunit has two potential N-glycosylation sites (Aggarwal etc., human cell's factor, Blackwell Science Press, 1992) in the position 25 and 97.According to glycosylated degree, the IFNG molecular weight of dimeric forms be 34-50kDa (Farrar etc., the immunology yearbook, 1993,11:571-611).
(nature such as Gray, 298:859-863,1982), Taya etc. (EMBO J.1:953-958,1982), (nucleic acids research such as Devos, 10:2487-2501,1982) and (journal of biological chemistry, 259:6790-6797 such as Rinderknecht, 1984) reach at EP 77670, reported the primary sequence of wild-type people IFNG (huIFNG) among EP 89676 and the EP 110044.Ealick etc. (science, 252:698-702,1991) have reported the three-dimensional structure of huIFNG.
Reported the form of the various naturally occurring of IFNG subunit polypeptide or sudden change, the form that comprises a kind of Cys-Tyr-Cys of comprising-terminal amino acid sequence (with respect to position (3)-(1) of SEQ ID NO 17), the form of the terminal methionine(Met) of a kind of N-of comprising (with respect to the position-1 of SEQ ID NO 17) and contain the terminal clipped forms of various C-of 127-134 amino-acid residue.Known IFNG activity that can not destroy this molecule from 1-15 amino-acid residue of C-terminal deletion.And Pan etc. (european journal of biological chemistry, 166:145-149,1987) have described the heterogeneity of huIFNG C-end.
Slodowski etc. (European journal of biological chemistry, 202:1133-1140,1991), Luk etc. (journal of biological chemistry, 265:13314-13319,1990), Seelig etc., (biological chemistry, 27:1981-1987,1988), (Invest.Ophthalmol.Vis.Sci. such as Trousdale, 26:1244-1251,1985) and in EP 146354, reported the HuIFNG mutain.Nishi etc. (journal of biological chemistry, 97:153-159,1985) have reported natural huIFNG variant.
US 6,046, and 034 discloses and inserts heat-resisting reorganization huIFNG (rhuIFNG) variant that 4 pairs of cysteine residues make disulfide linkage form and therefore stablize the IFNG variant with the form of homodimer.
WO 92/08737 discloses the IFNG variant that contains the methionine(Met) of interpolation at the N-terminal of the total length of wild-type people IFNG (residue 1-143) or part (residue 1-132) aminoacid sequence.EP 219781 discloses the part huIFNG sequence that contains amino-acid residue 3-124 (among the SEQ ID NO 17).US4,832,959 disclose the residue 1-127 that contains aminoacid sequence, and the part huIFNG sequence of 5-146 and 5-127, this sequence are compared the-terminal amino acid residue (CYC) with 3 interpolations with SEQ ID NO 2.US 5,004, and 689 disclose coding does not have the dna sequence dna of huIFNG of 3-terminal amino acid residue CYC and the expression in intestinal bacteria thereof.EP 446582 discloses the rhuIFNG that does not contain the terminal methionine(Met) of N-that intestinal bacteria produce.US 6,120, and 762 disclose the huIFNG peptide fragment that contains its residue 95-134 (with respect to SEQ ID NO 18).
Wang etc. (Sci.Sin.B 24:1076-1084,1994) have reported the high level expression of rhuIFNG.
Curling etc. (journal of biological chemistry, 272:333-337,1990) and Hooker etc., (Interferon, rabbit and cytokine research magazine, 1998,18:287-295) reported the glycosylation variant among the rhuIFNG.
Kita etc. (Drug Des.Deliv., 6:157-167,1990) and in EP 236987 and US5109120, reported the polymer-modified of rhuIFNG.
WO 92/22310 has reported Interferon, rabbit, particularly the derivative of the asialoglycoprotein conjugate of huIFNG.
The IFNG fusion rotein is existing to be described.For example, EP 237019 discloses to have and has shown the active zone of interferon beta and a single chain polypeptide that shows the active zone of IFNG.
EP 0158198 discloses to have and has shown the active zone of IFNG and show the single chain polypeptide in the active zone of IL-2.Some document descriptions strand dimer IFNG protein, for example Landar etc. (the molecular biology magazine, 2000,299:169-179).
WO 99/02710 discloses single chain polypeptide, and one of them example is IFNG.
WO 99/03887 discloses the variant of the PEG connection of the polypeptide that belongs to the tethelin superfamily, and wherein, a non-essential amino acid residue that is positioned at the polypeptide specific region is replaced by a cysteine residues.IFNG is mentioned as an example of tethelin superfamily member, but does not go through its modification.
Existing suggestion is used for the treatment of interstitial lung disease (being also referred to as a matter pulmonary fibrosis (IPF)) ((New England Journal of Medicine such as Ziesche with IFNG, 341:1264-1269,1999 and division of chest disease, 110: supplementary issue: 25S, 1996) and EP 795332), IFNG can be used in combination with prednisolone for this reason.Except IPF, and granulomatous disease (Bolinger etc., clinical medicine is learned, 1992,11:834-850), some mycobacterium infects (New England Journal of Medicine, 330:1348-1355,1994), kidney (urology magazine, 152:841-845,1994), Osteopetrosis (New England Journal of Medicine, 332:1594-1599,1995), scleroderma (rheumatology magazine, 23:654-658,1996), hepatitis B (liver gastroenterology, 45:2282-2294,1998), (international liver is learned communication, 6:264-273 to hepatitis C, 1997), the also available IFNG treatment of septic shock (natural medical science, 3:678-681,1997) and rheumatoid arthritis.
As medicinal compound, rhuIFNG is used to, and for example resists some virus infection and tumour and has obtained certain success.RhuIFNG uses through parenteral usually, and preferably by subcutaneous, injection is used.Find maximum serum-concentration after 7 hours, the blood plasma half life is behind intravenous administration 30 minutes.Therefore effectively treat with rhuIFNG and need often injection.Main deleterious effect comprises fever, and shiver with cold is perspired, headache, myalgia and drowsiness.These effects interrelate with injection rhuIFNG and observe in first hour after injection.Rare side effect is local pain and erythema, and liver enzyme raises, reversible granulocyte and thrombocytopenia and cardiac toxic.
WO 01/36001 discloses new IFNG conjugate, and it comprises the non-polypeptide fraction that links to each other with the IFNG polypeptide, and wherein said IFNG polypeptide is by introducing and/or deletion is modified at the connection site of above-mentioned non-polypeptide fraction (as PEG) and glycosylation site.
As everyone knows, when N-glycosylation molecule (as IFNG) produces in the glycosylation host, be not that all potential glycosylation sites all are utilized.This means the glycosylated egg white mixture of N-in the body that usually obtains to have in various degree, cause to carry out purifying subsequently.And it usually is consuming time and thorny separating the same protein with different degree of glycosylation.Unexpected now the discovery, by replace N-glycosylation site in the body (no matter in the described body N-glycosylation site be among the IFNG natural site or as N-glycosylation site in the body of WO 01/36001 described introducing) near one or more amino-acid residue, might promote fractional separation to intact glycosyl IFNG molecule.Especially find, the 97th, 98 and 99 natural N-glycosylation site N-Y-S among the hIFNG is replaced with N-Y-T, promote fractional separation greatly intact glycosyl IFNG molecule.
The invention summary
Therefore, first aspect present invention relates to interferon gamma polypeptide variants, and it has the IFNG activity, and has aminoacid sequence shown in the SEQ ID NO:1 ([S99T] huIFNG), or it has the active fragment of IFNG.
The present invention relates to the variant of SEQ ID NO:1 on the other hand, comprises the variant of the fragment (as SEQ ID NO:2-16) of SEQ ID NO:1, and wherein said variant comprises at least one other modification and shows the IFNG activity.
A further aspect of the present invention relates to the nucleotide sequence of code book invention variant polypeptide.
A further aspect of the present invention relates to the expression vector that comprises nucleotide sequence of the present invention, and the glycosylation host cell that comprises grace invention nucleotide sequence or expression vector of the present invention.
The invention still further relates to the pharmaceutical composition that comprises polypeptide variants of the present invention, and the medicinal use of polypeptide variants of the present invention or pharmaceutical composition of the present invention.
A further aspect of the present invention relates to polypeptide variants of the present invention or the purposes of pharmaceutical composition of the present invention in the medicine of preparation treatment interstitial lung disease.
Similarly, the invention still further relates to the method for treatment or prevention interstitial lung disease, described method comprise to have in requisition for Mammals, the especially mankind, use the polypeptide variants of the present invention or the pharmaceutical composition of the present invention of significant quantity.
A further aspect of the present invention relates to the colony of IFNG polypeptide variants, or relates to the composition of the colony that comprises the IFNG polypeptide variants, and wherein said colony comprises at least 70% IFNG polypeptide variants of the present invention.
The present invention relates to the method for N-degree of glycosylation in the body that increases parent IFNG polypeptide on the other hand, described parent IFNG polypeptide comprises N-glycosylation site at least one body with aminoacid sequence N-X-S, wherein X is any amino acid except proline(Pro), described method comprises the serine residue in the described N-X-S aminoacid sequence is replaced with threonine residues, to obtain the IFNG variant.
A further aspect of the present invention relates to the method for preparing IFNG polypeptide variants of the present invention, and this method comprises:
(a) cultivate the glycosylation host cell, this cell comprises the nucleotide sequence of code book invention IFNG polypeptide variants, and used culture condition helps the expression of described polypeptide variants;
(b) randomly, make described polypeptide variants and a kind of non-polypeptide fraction carry out reacting under the link coupled condition in external helping; And
(c) reclaim described polypeptide variants.
Others of the present invention can obviously be found out from following description.
Description of drawings
Fig. 1 is the result of the glycosylation variant Western trace through optimizing of rhuIFNG.Left side Western trace: swimming lane 1: standard substance, swimming lane 2:Actimmune , swimming lane 3:rhuIFNG, swimming lane 4:[E38N] rhuIFNG.Middle part Western trace: swimming lane 1: standard substance, swimming lane 2:rhuIFNG, swimming lane 3:[E38N+S40T] rhuIFNG.Right side Western trace: swimming lane 1: standard substance, swimming lane 2:rhuIFNG, swimming lane 3:[S99T] rhuIFNG, swimming lane 4:[E38N+S40T+S99T] rhuIFNG.
Fig. 2 shows after the subcutaneous rat administration, the IFNG activity in serum-time curve.●：Actimmune，■：rhuIFNG，▲：[E38N+S40T+S99T]rhuIFNG。
The dosage (1.15 * 10 that all compound administration are identical 7AU/kg).
Fig. 3 shows after the subcutaneous rat administration, the IFNG activity in serum-time curve.●: [N16C+S99T] rhuIFNG (linking to each other) with 5kDa mPEG, ■: [N16C+S99T] rhuIFNG (linking to each other) with 10kDa mPEG, ▲: [E38N+S40T+S99T] rhuIFNG.
The dosage of [E38N+S40T+S99T] variant is 1.15 * 10 7AU/kg, and the dosage of two kinds of PEGization variants is 4.6 * 10 6AU/kg.
Detailed Description Of The Invention
Definition
In the specification of the application and invention, used following definition:
Term " conjugate " (or interchangeable " polypeptide of coupling ") means to be connected to by one or more polypeptid covalences (referring to compound or chimeric meaning) molecule of the heterozygosis that forms on one or more non-polypeptide fractions. The covalently bound meaning of term is that polypeptide and non-polypeptide fractions are directly covalently bound on another component, perhaps by such as bridge, and the interval, or connecting component etc., one or more to interleave component indirectly covalently bound on another component. Preferably, conjugate is soluble under relevant concentration and condition, is soluble in such as physiology liquid such as blood namely. The example of coupling polypeptide of the present invention comprises the polypeptide that glycosylation and/or PEG connect. Polypeptide portion for conjugate can use term " the not polypeptide of coupling ".
Term " non-polypeptide fractions " means the molecule of energy coupling to the linking group of IFNG polypeptide. The preferred example of this molecule comprises polymer molecule, lipophilic compound, saccharic composition or organic derivative. Should understand the linking group of non-polypeptide fractions by polypeptide when using in conjugate environment of the present invention is connected on the polypeptide portion of conjugate.
The term " polymer " molecule " be defined as by the covalently bound molecule that forms of two or more monomers, wherein the neither one monomer is amino acid residue, unless this polymer is human albumin or another high abundance plasma protein. Term " polymer " " can with the term " polymer " molecule " Alternate.
Term " saccharic composition " means by in the body or external glycosylation, for example the carbohydrate molecule that connects of N-or O-glycosylation.
" N-glycosylation site " has sequence N-X-S/T/C, and wherein X is any amino acid except proline, and N is asparagine, and S/T/C is serine, threonine or cysteine, preferred serine or threonine, most preferably threonine. " O-glycosylation site " is serine or threonine residues-OH base.
Term " linking group " means energy coupling to such as the amino acid residue group on the relevant non-polypeptide fractions of polymer molecule or saccharic composition. The non-polypeptide fractions of useful linking group and coupling thereof is apparent from following table.
Linking group Amino acid The example of non-polypeptide fractions Coupling method/-activation PEG List of references
-NH 2 N is terminal, Lys, His, Arg Polymer, for example PEG is with amide groups or imido grpup mPEG-SPA Tresylated mPEG Shearwater Inc.Delgado et al.， Critical reviews in Therapeutic Drug Carrier Systems 9(3，4)： 249-304(1992)
-COOH C is terminal, Asp, Glu Polymer, for example PEG is with ester or amide groups oligosaccharide compositions The external coupling of mPEG-Hz Shearwater Inc.
-SH Cys Polymer, for example PEG is with disulfide bond, maleimide or vinyl sulfone(RemzaolHuo Xingranliaodehuoxingjituan) group oligosaccharide compositions The external coupling of PEG-vinyl sulfone(RemzaolHuo Xingranliaodehuoxingjituan) PEG-maleimide Shearwater Inc.Delgado et al.， Critical reviews in Therapeutic Drug Carrier Systems 9(3，4)： 249-304(1992)
-OH Ser，Thr， -OH，Lys Oligosaccharide compositions has ester, ether, carbamate, the PEG of carbonate The glycosylation that O-connects in the body
-CONH 2 Asn is as the part of N glycosylation site Oligosaccharide compositions polymer, for example PEG N glycosylation in the body
Aromatic residue Phe，Tyr， Trp Oligosaccharide compositions External coupling
-CONH 2 Gln Oligosaccharide compositions External coupling Yan and Wold, Biochemistry, 1984, Jul 31; 23 (16): 3759-65
Aldehyde ketone The oligosaccharides of oxidation Polymer, PEG for example, PEG-hydrazides PEGization Andresz et al.，1978， Makromol.Chem.179：301， WO92/16555，WO02/23114
Guanidine Arg Oligosaccharide compositions External coupling Lundblad and Noyes, Chemical Reagents for Protein Modification, CRC Press Inc., Florida, USA
Imidazole ring His Oligosaccharide compositions External coupling Identical with guanidine
For N-glycosylation in the body, term " linking group " uses in unconventional mode, refer to form the N-glycosylation site and (have sequence N-X-S/T/C, wherein X is the arbitrary amino acid residue except proline, N is asparagine, and S/T/C is serine, threonine or cysteine, preferred serine or threonine, and threonine most preferably) amino acid residue. Although the asparagine residue of N-glycosylation site is to connect the residue of saccharic composition during the glycosylation, unless there is other amino acid residue of N-glycosylation site, otherwise can not realize this connection. Therefore, when non-polypeptide fractions is saccharic composition, and coupling is when realizing by the N-glycosylation, changing the term " amino acid residue that contains non-polypeptide fractions linking group " that uses that links with the amino acid sequence of IFNG polypeptide is interpreted as, form of N-glycosylation site, two or all amino acid residues change by this way, being about to functional N-glycosylation site introduces amino acid sequence or remove this site from described sequence, or (for example in described amino acid sequence, kept a functional N-glycosylation site, by replace the serine residue as a N-glycosylation site part with threonine residues, vice versa).
The name of amino acid whose name and atom (as, CA, CB, CD, CG, SG, NZ, N, O, C etc.) use by albumen database (PDB) definition (www.pdb.org), these titles are according to the name of IUPAC nomenclature (IUPAC Nomenclature and Symbolism for Amino Acids and Peptides (residue names, atom names etc.), Eur.J.Biochem.138,9-37 (1984), and at Eur.J.Biochem.152, they are corrected in 1 (1985). term " amino acid residue " expression is included in the amino acid residue in lower group: alanine (Ala or A), cysteine (Cys or C), aspartic acid (Asp or D), glutamic acid (Glu or E), phenylalanine (Phe or F), glycine (Gly or G), histidine (His or H), isoleucine (Ile or I), lysine (Lys or K), leucine (Leu or L), methionine (Met or M), asparagine (Asn or N), proline (Pro or P), glutamine (Gln or Q), arginine (Arg or R), serine (Ser or S), threonine (Thr or T), valine (Val or V), tryptophan (Trp or W) and tyrosine (Tyr or Y) residue.
The numbering of amino acid residue never contains the terminal beginning of N-of signal peptide [S99T] huIFNG (being SEQ ID NO 1) in this article, or is equivalent to never contain the terminal beginning of N-of the huIFNG (being SEQ ID NO 17) of signal peptide.
Term for the identification of amino acid position/replacement illustrates as follows: G18 represents shown in SEQ ID NO.1 or 17 the 18th amino acid in the amino acid sequence. G18N represents that the 18th Gly residue is replaced by Asn. Multiple replacement represents a kind of amino acid sequence with "+" expression such as G18N+S20T, and wherein the 18th Gly residue is replaced by Asn, and the 20th Ser residue is replaced by Thr. Alternative replacement available "/" expression represents following each replacement such as G18S/T: G18S and G18T. Disappearance represents with asterisk. For example, G18*Represent the 18th Gly disappearance. Insert following expression: after the 18th Gly residue, insert a Ser residue, be expressed as G18GS. The following expression of combination that replaces and insert: the 18th Gly residue is replaced by the Ser residue, and inserts the Ala residue after the 18th, is expressed as G18SA.
Term " nucleotide sequence " means the continuous chain of two or more nucleic acid molecules. Nucleotide sequence can be genome, cDNA, and RNA, semisynthetic, synthetic source, or the nucleotide sequence of its any combination.
Term " polymerase chain reaction " or " PCR " refer generally to the method for the required nucleotide sequence of amplification in vitro, and for example, as US 4,683,195 is described.In general, PCR method relates to use and can carry out primer extension synthetic recirculation with the Oligonucleolide primers of the preferential hybridization of template nucleic acid.
" cell ", " host cell ", " clone " and " cell culture " is used interchangeably in this article and all these terms are understood to include the cell growth or cultivate the offspring who produces.
" conversion " and " transfection " is used interchangeably, and refers to DNA is introduced the process of cell.
" be operably connected " refer to by enzyme connect or mutually between configuration make that the mode of the normal function that can exercise sequence is covalently bound with two or more nucleotide sequences.For example, if the nucleotide sequence of coding presequence or secretion leader as participating in protein expression before the polypeptide excretory then it is operably connected with the nucleotide sequence of polypeptide; It is operably connected with encoding sequence if promotor or enhanser influence transcribing of sequence; If the position of ribosome bind site helps translation, then it is operably connected with encoding sequence.In general, " being operably connected " means that the nucleotide sequence of connection is a successive, and is successive and in reading phase (reading phase) for the excretory leader.Realize this connection through connecting at restriction site easily.If there is no this site, but the combined standard recombinant DNA method is used synthetic oligonucleotide connector or joint so.
Term " modification " comprises replacement in this article, inserts and disappearance.
Term " sudden change " and " replacement " are used interchangeably in this article.
Term " introducing " at first is meant the replacement of existing amino-acid residue, but also can refer to insert other amino-acid residue.
Term " removes " and is meant that at first the amino-acid residue that is removed is replaced by another amino-acid residue, but also refers to the amino-acid residue that disappearance (not have replacement) is removed.
Term " amino-acid residue that contains non-polypeptide fraction linking group " right and wrong polypeptide fraction bonded amino-acid residue (for the amino-acid residue of introducing), or bonded amino-acid residue (for the amino-acid residue of removing) with it once.
When term " difference " or " being different from " and specific modification logotype, be meant the difference that allows except that the amino acid difference of formulating, also to exist other.Therefore, except some that are intended to optimize the utilization of glycosylation site or remove and/or introduce the amino-acid residue that has non-polypeptide fraction linking group disclosed herein change, in case of necessity, the IFNG polypeptide variants can comprise and other irrelevant modifications of above-mentioned change.This may comprise, for example, and terminal one or more amino-acid residue of brachymemma of C-, terminal one or more the extra residue that adds of N-and/or C-, for example, at Met residue of the terminal interpolation of N-, at the terminal interpolation of N-aminoacid sequence Cys-Tyr-Cys, and " conserved amino acid replacement ", promptly, the replacement of in the amino acid with similar characteristics is formed a team, carrying out, described forming a team as small molecules amino acid, acidic amino acid, polare Aminosaeren, basic aminoacids, hydrophobic amino acid and die aromatischen Aminosaeuren.The present invention is conservative, and the example that replaces specifically can be selected from following table.
????1 L-Ala (A) Serine (S) Threonine (T)
????2 Aspartic acid (D) L-glutamic acid (E)
????3 L-asparagine (N) glutamine (Q)
????4 Arginine (R) Methionin (K)
????5 Isoleucine (I) leucine (L) methionine(Met) (M) Xie Ansuan (V)
????6 Phenylalanine (F) tyrosine (Y) tryptophane (W)
Term " at least one " is used for non-polypeptide fraction, and amino-acid residue during situations such as replacement, is meant one or more.
Term " AUCsc " or " area under curve of subcutaneous administration " are used its conventional sense, i.e. the following area of IFNG activity in serum-time curve, and IFNG polypeptide variants described here is a subcutaneous administration, specifically is subcutaneous administration in rat.In case measured IFNG activity-time point by experiment, just can utilize computer program, as GraphPad Prism 3.01, the conventional AUCsc that calculates.
Term " function gonosome in half life " uses its common implication, promptly polypeptide in vivo/still had for 50% bioactive time in the target organ, perhaps the activity of polypeptide is time of 50% of initial activity.
As in the function gonosome half life assay method alternative approach, can measure " serum half life ", that is, 50% polypeptide or conjugate molecule before being eliminated in blood plasma or blood flow the round-robin time.The mensuration of serum half life is usually simple than the mensuration of half life in the function gonosome, and the size of serum half life usually well in the functions gonosome half life size.Other replaceable term of serum half life comprises " blood plasma half life ", " circulation half life ", " serum removing ", " plasma clearance " and " removing half life ".The serum half life, can be measured in rat according to ordinary method, referring to this paper material and method chapters and sections.Be important to note that: herein, " the serum half life " of given IFNG polypeptide variants must with vein (iv) the sample of administration measure.
Term " serum " uses its common implication, i.e. the blood plasma of fibrinogen and other thrombin not.
Polypeptide generally passes through one or more effect in reticuloendothelial system (RES), kidney, spleen or the liver, or removes by special or non-specific proteolyzing.Term " kidney removing " uses its common implication, promptly occurs in any removing of kidney, for example, finishes by glomerular filtration, tubular excretion or the degraded in renal tubular cell.Usually, kidney is removed the physical property that depends on polypeptide, comprises molecular weight, size (for the cutoff value of glomerular filtration), symmetry, shape/rigidity and electric charge, the sugar chain that is attached thereto, and the existence of the cellularity acceptor of this polypeptide.The cutoff value that kidney is removed is commonly considered as the about 67kDa of molecular weight.Kidney is removed and can be measured by any suitable test, as the in vivo test of having set up.For example, can with mark (as, radio-labeled or fluorescent mark) the coupling polypeptide give the patient, and measure marker activity in collected patient's urine and measure kidney and remove.The minimizing that kidney is removed can be passed through and the reference molecule, and as huIFNG, [S99T] huIFNG or Actimmune  compare and determine.The function that will keep is selected from antiviral activity, antiproliferative activity usually, immunoregulatory activity or IFNG receptor-binding activity.
The term " increase " that relates to half life in the function gonosome or serum half life is used in reference to, when the IFNG variant is measured when intravenously administrable and under comparable conditions, corresponding half life, have statistics to increase significantly with respect to the reference molecule, described with reference to molecule such as glycosylation huIFNG (SEQ ID NO:17), glycosylation [S99T] huIFNG (SEQ ID NO:1) or Actimmune  (SEQ ID NO:34 originates in the intestinal bacteria).Therefore, interesting IFNG polypeptide variants is to compare the variant of half life or serum half life increase in the function gonosome with reference to molecule with above-mentioned.
More specifically, required IFNG variant is such variant, work as intravenously administrable, especially when in the administration of rat medium sized vein, the ratio of they and huIFNG or [S99T] huIFNG serum half life (or in the function gonosome half life) when the glycosylation form is at least 1.25, more preferably at least 1.5, as at least 1.75, for example at least 2, more preferably at least 3, as at least 4, for example at least 5.
Other example of interesting IFNG variant is such variant, works as intravenously administrable, especially when in the administration of rat medium sized vein, they and Actimmune  (SEQ ID NO:34, originate in the intestinal bacteria) the ratio of serum half life (or function gonosome in half life) be at least 2, preferably be at least 3, as be at least 4, for example be at least 5, also preferably be at least 6, as be at least 7, for example be at least 8, most preferably be at least 9, as be at least 10.
The term " increase " that relates to AUCsc is used in reference to, when measuring when intravenously administrable and under comparable conditions, the area under curve of IFNG variant of the present invention has statistics to increase significantly with respect to the area of reference molecule, described with reference to molecule such as glycosylation huIFNG (SEQ ID NO:17), glycosylation [S99T] huIFNG (SEQ ID NO:1) or Actimmune  (SEQ ID NO:34 originates in the intestinal bacteria).Therefore, preferred IFNG variant is to compare the variant that AUCsc increases with reference to molecule with above-mentioned.Obviously, use IFNG variant of the present invention the IFNG activity level should with use identical with reference to molecule.The result is, for directly more different IFNG molecules, can be with the stdn of AUCsc value, and promptly they can be expressed as the AUCsc/ application dosage.
Particularly preferred IFNG variant is such variant, and the ratio of the AUCsc of they and glycosylation huIFNG or glycosylation [S99T] huIFNG is at least 1.25, more preferably at least 1.5, as at least 2, more preferably at least 3, as at least 4, for example at least 5 or at least 6, more preferably at least 7, as at least 8, for example at least 9 or at least 10, most preferably at least 12, as at least 14, for example at least 16, at least 18 or at least 20, especially when (subcutaneous) administration in rat.
Other example of particularly preferred IFNG variant is such variant, and the ratio of the AUCsc of they and Actimmune  (SEQ ID NO:34 originates in the intestinal bacteria) is at least 100, more preferably be at least 150, as be at least 200, and for example be at least 250, also preferably be at least 300, as be at least 400, for example be at least 500, most preferably be at least 750, as be at least 1000, for example at least 1500 or at least 2000, especially when the time in the administration of rat medium sized vein.
Term " T Max, sc" be used in reference in the active serum-time curve of IFNG, observe the active time of highest level IFNG in the serum.The preferred IFNG variant of the present invention is such variant, and they compare T with Actimmune  or with glycosylation huIFNG Max, scIncrease.More specifically, the T of described preferred variant Max, sc(the subcutaneous rat administration is measured later on) is at least 200 minutes, as is at least 250 minutes, for example is at least 300 minutes, more preferably is at least 350 minutes, as is at least 400 minutes.
Term " immunogenicity of reduction " be meant IFNG polypeptide variants of the present invention than under suitable condition, measure with reference to molecule, for example huIFNG or Actimmune  produce the lower immune response that can measure.Immunne response can be cell or antibody-mediated reaction (referring to, for example, Roitt: basic immunology (the 8th edition Blackwell), can obtain immunogenic further definition).Generally speaking, the reduction of the reactivity of antibody shows that immunogenicity reduces.Immunogenicity reduces can be by using any suitable method known in the art, as in the body or in vitro method measure.
Term " glycosylation increase " herein, " the N-degree of glycosylation increases in the body " or " increases of N-degree of glycosylation " are meant that the level of the glycan molecule that is connected increases, and this is normally to the result of the utilization increase of glycosylation site.(Hooker etc., 1998, J.Interferon and Cytokine Res.18,287-295 as everyone knows; Sarenva etc., 1995, Biochem J., 308,9-14), and when huIFNG expresses in Chinese hamster ovary celI, the whole two kinds of glycosylation sites of only about 50% IFNG molecule utilization, about 40% utilizes a kind of glycosylation site (1N), and about 10% by glycosylation (ON).The increase of N-degree of glycosylation can be passed through any suitable method in this area in the body, measures as SDS-PAGE.A convenient test of the glycosylation that measure to increase is that " measuring the glycosylation that increases " chapters and sections of material and method part herein are described.
Term " IFNG polypeptide variants group " or " composition that comprises the homogeneous population of IFNG polypeptide of the present invention " are meant and comprise at least two kinds of compositions that the glycosylated IFNG polypeptide in different Chengdu is arranged herein.Just as is understood, the invention provides the means (means) that obtain IFNG polypeptide colony, the IFNG molecule of being on the increase in the wherein said colony is by thoroughly glycosylation.
Therefore, the invention still further relates to the homogeneous population (being such colony, wherein is all thoroughly glycosylations of IFNG polypeptide mostly) of IFNG polypeptide of the present invention or comprise the composition of the homogeneous population of IFNG polypeptide of the present invention.For example, described IFNG polypeptide colony may comprise at least 70% IFNG polypeptide of the present invention, and preferably at least 75%, as at least 80%, for example at least 85%, more preferably at least 90%, as at least 95%, for example at least 96%, also more preferably at least 97%, as at least 98%, for example at least 99%.
Term " shows the IFNG activity " and is meant that polypeptide has one or more functions of natural huIFNG or rhuIFNG, comprise measure in the external or body in conjunction with the ability of IFNG acceptor and cause the ability (being external or the interior biological activity of body) of signal transduction by huIFNG and its receptors bind.(Proc.Natl.Acad.Sci.USA, 85:4837-4841,1988) such as Aguet etc. (Cell, 55:273-280,1988) and Calderon have described the IFNG acceptor.One is suitable for checking the active test of IFNG is herein " tentative experiment ".When utilizing " tentative experiment " as herein described, the specific activity of the polypeptide of " showing the IFNG activity " is at least 5% of rhuIFNG.Should be appreciated that because concrete difference of modifying (for example described variant whether PEGization), activity can be in the scope of a broad.Therefore, the specific activity with respect to rhuIFNG can be low to moderate 5% or high to 150%.For example, described specific activity can be 10% (for example 10-125%) of rhuIFNG, as at least 15% (for example 15-125%), as at least 20% (as 20-125%), at least 25% (for example 25-125%), at least 30% (for example 30-125%), at least 35% (for example 35-125%), at least 40% (for example 40-125%), at least 45% (for example 45-125%), at least 50% (for example 50-125%), at least 55% (for example 55-125%), at least 60% (for example 60-125%), at least 65% (for example 65-125%), at least 70% (for example 70-125%), at least 75% (for example 75-125%), at least 80% (for example 80-125%) or at least 90% (for example 90-110%).
" IFNG polypeptide " is to show the active polypeptide of IFNG, that is, term " IFNG polypeptide " is used in reference to any IFNG molecule (no matter this molecule is huIFNG, its truncation type, or its variant), as long as this IFNG molecule shows IFNG activity as herein described.Term " IFNG polypeptide " is used to represent the polypeptide of monomer or dimeric forms in this article on demand.For example, when representing concrete replacement, the replacement of their ordinary representation huIFNG polypeptide monomers.Dividing the period of the day from 11 p.m. to 1 a.m when relating to IFNG of the present invention, generally is dimeric forms (and therefore, for example, comprising two IFNG polypeptide monomers by described modification).The dimeric forms of IFNG polypeptide can provide by two monomeric normal combinations, and perhaps the form with strand dimer IFNG polypeptide provides.
Term " parent " is meant the IFNG polypeptide that has improved glycosylation site according to the present invention.Parent's polypeptide of modifying by the present invention can be any IFNG polypeptide, and therefore can be derived from any source, and for example non-human mammal is originated, but preferred parent's polypeptide is to have aminoacid sequence SEQ IDNO:17 or its segmental huIFNG polypeptide.
" fragment " is (for example to show the active part of IFNG in the total length IFNG peptide sequence, a kind of fragment of total length huIFNG polypeptide is shown in SEQ ID NO:17, a kind of fragment of total length [S99T] huIFNG polypeptide variants is shown in SEQ ID NO:1), the terminal truncation type of its C-end or N-for example.The segmental specific examples of IFNG polypeptide variants comprises, [S99T] huIFNG of 1-15 amino-acid residue of the terminal brachymemma of C-, 1 amino-acid residue of brachymemma (SEQ ED NO:2) for example, 2 amino-acid residues (SEQ ID NO:3), 3 amino-acid residues (SEQ ID NO:4), 4 amino-acid residues (SEQ IDNO:5), 5 amino-acid residues (SEQ ID NO:6), 6 amino-acid residues (SEQ ID NO:7), 7 amino-acid residues (SEQ ID NO:8), 8 amino-acid residues (SEQ DD NO:9), 9 amino-acid residues (SEQ ID NO:10), 10 amino-acid residues (SEQ ID NO:11), 11 amino-acid residues (SEQ ID NO:12), 12 amino-acid residues (SEQ ID NO:13), 13 amino-acid residues (SEQID NO:14), 14 amino-acid residues (SEQ ID NO:15) or 15 amino-acid residues (SEQ IDNO:16), and/or [S99T] huIFNG of 1-3 amino-acid residue of the terminal brachymemma of N-.The segmental specific examples of huIFNG comprises, the huIFNG of 1-15 amino-acid residue of the terminal brachymemma of C-, 1 amino-acid residue of brachymemma (SEQ ID NO:19) for example, 2 amino-acid residues (SEQ H) NO:10), 3 amino-acid residues (SEQ ID NO:21), 4 amino-acid residues (SEQ ID NO:22), 5 amino-acid residues (SEQ ID NO:23), 6 amino-acid residues (SEQ ID NO:24), 7 amino-acid residues (SEQ IDNO:25), 8 amino-acid residues (SEQ ID NO:26), 9 amino-acid residues (SEQ ID NO:27), 10 amino-acid residues (SEQ ID NO:28), 11 amino-acid residues (SEQ ID NO:29), 12 amino-acid residues (SEQ ID NO:30), 13 amino-acid residues (SEQ ID NO:31), 14 amino-acid residues (SEQ ID NO:32) or 15 amino-acid residues (SEQ ID NO:33), and/or the huIFNG of 1-3 amino-acid residue of the terminal brachymemma of N-.
As mentioned above, the IFNG polypeptide variants also can comprise at least one other modification except S99T replaces, as long as this variant shows the IFNG activity, promptly described variant can be the variant of [S99T] huIFNG, or the segmental variant of [S99T] huIFNG.The specific examples of this class variant comprises to be introduced and/or has removed amino-acid residue, comprises the variant of non-polypeptide fraction linking group.Other example of the variant of [S99T] huIFNG (and fragment) comprises the variant described in above " background technology " chapters and sections, for example comprise the Cys-Tyr-Cys that the N-end has added or added [S99T] huIFNG of Met, and US6, the variant of disclosed cysteine modified in 046,034.
Generally speaking, variant of the present invention is by nucleotide sequence coded, and this nucleotide sequence is compared with the encoding sequence of parent IFNG polypeptide, modifies according to the present invention.
But such was the case with, because described variant polypeptide can carry out C-end or the terminal brachymemma of N-in translation post-treatment process, for example in cell, express in the medium, during the purifying etc. by proteolytic enzyme from C-end or the terminal cracking of N-, cause the gained variant polypeptide for the truncation type of the initial variant polypeptide that produces (for example, although initial generation is the total length variant, but owing to translation post-treatment, can obtain the variant polypeptide of the terminal brachymemma of C-) to this total length variant polypeptide.In this case, term " parent " is interpreted as the clipped form that will modify according to the present invention.
" variant " is a peptide species, and it and its parent's polypeptide (being SEQ ID NO:17 or its truncation type under the normal circumstances, shown in SEQ ID NOS:19-33) have the difference of one or more amino-acid residues, generally are that 1-15 amino-acid residue is (as 1,2,3,4,5,6,7,8,9,10,11,12,13,14 or 15 amino-acid residues) difference, 1-10 amino-acid residue for example, 1-5 amino-acid residue, or 1-3 amino-acid residue.
Term " functional site " is meant function or the necessary or associated one or more amino-acid residues of effect of IFNG.This amino-acid residue " is positioned at " functional site.Functional site can and preferably be identified with the associated receptor compound polypeptide structure such as the IFNG acceptor by analysis with methods known in the art mensuration.
Term " huIFNG " is meant the mature form with aminoacid sequence SEQ ID NO:17 of wild-type people IFNG.
Term " rhuIFNG " is meant by the recombinant means mature form with aminoacid sequence SEQ ID NO:17 preparation, wild-type people IFNG.
Term " [S99T] huIFNG " is meant among the wild-type people IFNG mature form (seeing SEQ ID NO:1) that the 99th serine residue has been replaced by threonine residues.
Term " glycosylation huIFNG " is meant can make in its glycosylated cells in the described hulFNG polypeptide and produces herein, and therefore at its natural N-glycosylation site (SEQ ID NO:17 the 25th and 97) by glycosylation.
Similarly, term " glycosylation huIFNG variant " is meant can make in its glycosylated cells in the described IFNG polypeptide variants and produces.
Herein term " Actimmune  " be meant IFNG 140 amino acid whose forms (Actimmune  in the terminal brachymemma of C-4 amino acid and comprise a Met residue at the N-end) (seeing SEQ ID NO:34), it obtains by making genetically engineered Escherichia coli fermentation.Further information about Actimmune  is seen www.actimmune.Com.
Interferon gamma polypeptide variants of the present invention
IFNG variant of the present invention with interior glycosylation site of body of optimization
As indicated above, the unexpected discovery, replace with threonine residues by serine residue with the 99th of huIFNG (or its fragment), the glycosylation of the natural N-glycosylation site of the 97th of huIFNG is increased, thorough glycosylation or thorough basically glycosylated IFNG molecule proportion are increased.Fig. 1 shows that the remarkable increase of the glycosylated IFNG polypeptide of substrate can realize.In the situation of [S99T] huIFNG (SEQ ID NO:1) polypeptide variants, can observe, this polypeptide variants of gathering in the crops in the substratum about 90% has utilized whole two kinds of N-glycosylation sites, and the rhuIFNG polypeptide of gathering in the crops in the substratum only has an appointment 60% by thoroughly glycosylation.
Correspondingly, one aspect of the invention relates to the IFNG polypeptide variants (i.e. [S99T] huIFNG) that shows the IFNG activity and have aminoacid sequence SEQID NO:1, or it has the active fragment of IFNG.
As indicated above, the terminal clipped form of the C-of known huIFNG is compared with hulFNG, and retentive activity still is in enhanced activity in some cases even also.Therefore, in a preferred embodiment of the present invention, IFNG polypeptide variants of the present invention is the fragment of SEQ ID NO:1, this fragment in the terminal brachymemma of C-1-15 amino-acid residue, usually at 1-10 amino-acid residue of C-end brachymemma.The specific examples of the terminal clipped form of this class C-of SEQ ID NO:1 is referring to SEQ ID NOS:2-16.IFNG polypeptide fragment in this embodiment of the present invention has the IFNG activity.
The glycosylation IFNG polypeptide variants that should be understood that this respect should be recombinant expressed in the glycosylation host cell, and the preferred mammal host cell is as those cells of mentioning in " with the coupling of sugar component " joint.
As explained above, rhuIFNG is in Chinese hamster ovary celI the time, and only about 50-60% is by thoroughly glycosylation in the expressed IFNG polypeptide colony.Therefore, one of major advantage of IFNG polypeptide variants of the present invention is the height utilization to glycosylation site in the 97th the body, and this causes obtaining the colony of homogeneous more with respect to huIFNG.Because this colony of homogeneous more, the composition (as results in substratum) that comprises such IFNG polypeptide variants colony need not to resemble and carries out loaded down with trivial details and consuming time purifying the rhuIFNG.
Therefore, the present invention relates to the colony of IFNG polypeptide variants on the other hand, or comprises the composition of IFNG polypeptide variants colony, and wherein said colony comprises the IFNG polypeptide variants of the present invention at least about 70%.Preferred described composition comprises at least 75%, and more preferably at least 80%, also more preferably at least 85%, as at least about 90% IFNG polypeptide variants of the present invention.
More specifically, the present invention relates to the colony of IFNG polypeptide variants, or comprise the composition of IFNG polypeptide variants colony, wherein said colony comprises at least 70%, preferably at least 75%, more preferably at least 80%, also more preferably at least 85%, as at least about 90% IFNG polypeptide variants of the present invention with aminoacid sequence SEQ ID NO:1.
Similarly, the invention still further relates to the colony of IFNG polypeptide variants, or comprise the composition of IFNG polypeptide variants colony, wherein said colony comprises at least 70%, preferably at least 75%, more preferably at least 80%, also more preferably at least 85%, as at least about 90% the IFNG polypeptide variants of the present invention of aminoacid sequence: SEQ ID NO:2 with the group of being selected from down, SEQ ID NO:3, SEQ ID NO:4, SEQBD NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ IDNO:14, SEQ ID NO:15 or SEQ ID NO:16.
Except mentioned above, optimize among the rhuIFNG the required S99T sudden change of glycosylation site in the 97th the body, also can optimize glycosylation site in other body of having introduced SEQ ID NO:1 or its fragment (for example, in order to increase the serum half life and/or to increase AUCsc).Generally speaking, glycosylation site is the N-glycosylation site in the described body, but the present invention also relates to the O-glycosylation site.Described optimization can realize by modifying (the preferred replacement) in the position of close glycosylation site (especially near glycosylation site in the body).Usually, so interior N-glycosylation site of body is a N-glycosylation site in the body of introducing.The correct position that is suitable for introducing N-glycosylation site in the body can be referring to WO 01/36001, and will be described below.
The amino-acid residue of " close " glycosylation site is usually located at position-4 ,-3 ,-2 ,-1 ,+1 ,+2 ,+3 or+4 (for the amino-acid residues of the glycosylation site that links to each other with sugar), optimum position-1 ,+1, or+3, especially position+1 or+3.Amino-acid residue near N-glycosylation site (having sequence N-X-S/T/C) in the body can be positioned at position-4 ,-3 ,-2 ,-1 ,+1 ,+2 ,+3 or+4 (for the N-residues).
When the position for the N-residue+2 were modified, should understand only limited amount being modified with may take place, because in order to keep/introduce N-glycosylation site in the body, the amino-acid residue of this position must be Ser, Thr or Cys.
In particularly preferred embodiment of the present invention, the modification of carrying out in the position for the N-residue+2 is to replace, and wherein the target amino acid residue is replaced by the Thr residue.If it is but this amino-acid residue has been the Thr residue, preferred usually or must carry out any replacement in this position.When X is modified, X should not be Pro, preferably is not Trp, Asp, Glu or Leu.The amino-acid residue that is introduced into is preferably selected from Phe, Asn, Gln, Tyr, Val, Ala, Met, Ile, Lys, Gly, Arg, Thr, His, Cys or Ser, more preferably Ala, Met, Ile, Lys, Gly, Arg, Thr, His, Cys or Ser, especially Ala or Ser.
When the position for the N-residue+3 were modified, the amino-acid residue that will introduce was preferably selected from His, Asp, Ala, Met, Asn, Thr, Arg, Ser or Cys, more preferably Thr, Arg, Ser or Cys.When the X residue is the Ser residue, preferred especially above-mentioned modification.
Therefore, aspect the N-glycosylation, the 97th N-glycosylation site can be modified (as replacement) by the site of group under being selected from and be further optimized: E93 in natural body, K94, L95, T96, Y98, V100 or T101 (that is, the position-4 of relative N97 ,-3,-2,-1 ,+1 ,+3 or+4).The 98th specific examples that replaces at SEQID NO:1 (or its fragment) comprises Y98F, Y98N, Y98Q, Y98V, Y98A, Y98M, Y98I, Y98K, Y98G, Y98R, Y98T, Y98H, Y98C or Y98S, preferred Y98A, Y98M, Y98I, Y98K, Y98G, Y98R, Y98T, Y98H, Y98C or Y98S, especially Y98S.The 100th specific examples that replaces at SEQ ID NO:1 (or its fragment) comprises V100H, V100D, V100A, V100M, V100N, V100T, V100R, V100S, or V100C, especially V100T, V100R, V100S or V100C.
Similarly, the N-glycosylation site can be further optimized by modify (as replacing) in the site that is selected from following group in the 25th the body: D21, V22, A23, D24, G26, L28 or F29 (that is, the position for N25-4 ,-3,-2 ,-1 ,+1 ,+3 or+4).The 26th specific examples that replaces at SEQ ID NO:1 (or its fragment) comprises G26F, G26N, G26Y, G26Q, G26V, G26A, G26M, G26I, G26K, G26R, G26T, G26H, G26C or G26S, preferred G26A, G26M, G26I, G26K, G26R, G26T, G26H, G26C or G26S, more preferably G26A or G26S, especially G26A.The 28th specific examples that replaces at SEQ ID NO:1 (or its fragment) comprises G28H, G28D, G28A, G28M, G28N, G28T, G28R, G28S, or G28S, especially G28A, G28T, G28R, G28S or G28C.
Obviously, any modification combination that any modification that glycosylation above-mentioned and optimization position 97 is relevant can be relevant with glycosylation above-mentioned and optimization position 25.
AUC ScThe IFNG variant of the present invention of increase and/or serum half life increase
The present invention relates to the IFNG polypeptide variants with aminoacid sequence SEQ ID NO:1 on the other hand, and described variant has the IFNG activity.
The invention still further relates to the variant of IFNG polypeptide fragment, it has and is selected from following aminoacid sequence SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15 or SEQID NO:16, wherein said variant has the IFNG activity.
Therefore, described variant is compared with SEQ ID NOS:1-16 and is comprised at least one further modification.
For fear of the 26S Proteasome Structure and Function of too much destruction [S99T] huIFNG polypeptide variants (or its fragment), generally be no more than 15 according to the sum of modified amino acid residue of the present invention.Usually, the IFNG polypeptide variants has 1-10 modification with respect to aminoacid sequence SEQ ID NO 1,1-8 for example, 2-8,1-5,1-3 or 2-5 modification.The preferred described replacement that is modified to.Should be understood that similar consideration also is suitable for for the segmental variant of the IFNG polypeptide variants with aminoacid sequence SEQ ID NO:1.Therefore, when described variant was the variant of any sequence among the SEQ ID NOS:2-16, such variant was compared with the related amino acid sequence shown in the SEQ ID NOS:2-16, usually have less than 15 places and modify, the 1-10 place is modified usually, for example 1-8,2-8,1-5,1-3 or 2-5 modification.Preferred described modification is to replace.
Therefore, IFNG polypeptide variants under the normal circumstances (variant that promptly also comprises at least one modification except S99T replaces) comprises following aminoacid sequence, and this sequence and aminoacid sequence SEQ ID NO:1 (or its fragment) have 1,2,3,4,5,6,7,8,9,10,11,12,13,14 or 15 amino-acid residue differences.
Preferably in the embodiment, at least one amino-acid residue is introduced and/or removed to described IFNG variant (further) one of the present invention, and this residue contains the linking group of non-polypeptide fraction.
By removing or introduce the amino-acid residue that comprises non-polypeptide fraction linking group, this polypeptide is adapted to especially, be easier to carry out the link coupled molecule so that prepare with selected non-polypeptide fraction, thereby optimize coupling pattern (as guaranteeing that non-polypeptide fraction distributes in the optimization on IFNG polypeptide variants surface), therefore and obtaining to have the active new coupling molecule of IFNG, this molecule has in addition one or more than the improved characteristic of existing molecule based on huIFNG or rhuIFNG.For example, by introducing linking group, the content with relevant non-polypeptide fraction bonded specific amino acid residue can be strengthened or change to the IFNG polypeptide variants, thereby obtain more effective, more single-minded and/or coupling widely.By removing one or more linking group, might on polypeptide, have the position of negative consequence to avoid such coupling with non-polypeptide fraction coupling, described position as the functional site of this polypeptide or near the amino-acid residue it (because the site carry out coupling may cause gained coupling polypeptide because the acceptor recognition capability is impaired inactivation or IFNG reduced activity).In addition, will remove to have to be beneficial near the linking group of another linking group and avoid and the coupling of this group generation unhomogeneity.In preferred embodiments, more than amino-acid residue of IFNG polypeptide is changed, and for example described change relates to the amino-acid residue of removing or introduce the linking group that has selected non-polypeptide fraction.This embodiment is preferred especially, because it might specificity design the IFNG polypeptide variants, thus the optimization coupling of acquisition and non-polypeptide fraction.
Except introducing and/or remove amino-acid residue, described polypeptide variants also can comprise the introducing that do not change the amino-acid residue that has non-polypeptide fraction linking group and/or other modification of removal, as replacing.The example that this class is modified comprises that conserved amino acid replaces and/or Cys-Tyr-Cys or Met is introduced the N-end.
The definite number that can be used for link coupled and appear at the linking group in the dimerization IFNG polypeptide variants depends on the effect that coupling will reach.And the effect that will reach depends on, for example the link coupled nature and extent (for example, the identity of non-polypeptide fraction, should carry out that coupling maybe should be avoided in the link coupled situation wishing or may with the quantity of the non-polypeptide fraction of polypeptide link coupled, etc.).
Should be understood that the amino-acid residue that has non-polypeptide fraction linking group, no matter be removed or be introduced into, to its selection all based on the characteristic of selected non-polypeptide fraction, and in most applications, based on used coupling method.For example, when non-polypeptide fraction is the branch period of the day from 11 p.m. to 1 a.m of polymer molecule such as polyoxyethylene glycol-deutero-or polyethylene oxide examination, can be selected from halfcystine as the amino-acid residue of linking group, Methionin, aspartic acid, L-glutamic acid or arginine.Preferred especially halfcystine.When non-polypeptide fraction was sugar component, linking group for example was a glycosylation site in the body, preferred N-glycosylation site.
When introducing in the IFNG polypeptide with aminoacid sequence SEQ ID NO:1 (or its fragment) or removing the linking group of non-polypeptide fraction, need the modified polypeptides position to be performed as follows suitable selection:
This optimum seeking site is positioned at the surface of IFNG polypeptide, more preferably this position is exposed to solvent by the side chain that has at least 25% (amino-acid residue that preferred at least 50% side chain is exposed to solvent occupies, this amino-acid residue), as measuring based on the three-dimensional structure of dimerization IFNG or model, this structure or model option further comprise one or two IFNG acceptor molecule.List among this paper embodiment 1 such position.
Interested in addition is any 23 C-terminal amino acid residues (amino-acid residue that especially contains the linking group of non-polypeptide fraction by introducing) of modifying parent IFNG, is positioned at the surface of IFNG polypeptide because it is believed that such residue.
In addition, preferably one or more amino-acid residue in IFNG polypeptide ring district is modified, because the most of amino-acid residues in these ring districts all are exposed to surface and enough far away from functional site, can not influence the function of this molecule as far as introducing non-polypeptide fraction (as polymer molecule, especially PEG molecule) and/or N-glycosylation site.Such ring district can determine by the three-dimensional structure of observing huIFNG.The amino-acid residue of forming described ring district is residue N16-K37 (an A-B ring), F60-S65 (B-C ring), N83-S84 (C-D ring) and Y98 L103 (D-E ring).
The amino-acid residue of forming the IFNG receptor binding site is Q1, D2, Y4, V5, E9, K12, G18, H19, S20, D21, V22, A23, D24, N25, G26, T27, L30, K34, K37, K108, H111, E112, I114, Q115, A118, E119 (seeing this paper embodiment 2).Usually preferred this site of a plurality of linking groups (as extra N-glycosylation site and/or cysteine residues) of a non-polypeptide fraction not being introduced this molecule.
For the optimization of measuring linking group distributes, according to the distance of three-dimensional structure calculating between the amino-acid residue on IFNG polypeptide surface of IFNG dimer polypeptide.More specifically, mensuration contains the distance between the CB of amino-acid residue of described linking group, perhaps measure (the NZ of Methionin of functional group of one of them amino-acid residue, the CG of aspartic acid, the CD of L-glutamic acid, the SG of halfcystine) and contain distance between the CB of another amino-acid residue of linking group.In the situation of glycine, with CA replaced C B.In IFNG polypeptide portion of the present invention, any described distance preferably surpasses 8 , particularly surpasses 10 , to avoid or to reduce the unhomogeneity coupling.
In addition, the difference of the aminoacid sequence of IFNG polypeptide variants and SEQ ID NO:1 (or its fragment) is, one or more amino-acid residues of forming the part of epi-position have been removed, preferably the amino-acid residue that contains non-polypeptide fraction linking group by replacement is removed, so that destroy or this epi-position of deactivation.By using methods known in the art, be also referred to as the epitope mapping method, can identify [S99T] huIFNG, the epi-position of huIFNG or rhuIFNG, referring to, Romagnoli et al. for example, Biol Chem, 1999,380 (5): 553-9, DeLisser EN, Methods Mol Biol, 1999,96:11-20, Van de Water et al., Clin Immunol Immunopathol, 1997,85 (3): 229-35, Saint-Remy JM, Toxicology, 1997,119 (1): 77-81, and Lane DP and Stephen CW, Curr Opin Immunol, 1993,5 (2): 268-71.A kind of method is to set up to express for example phage display library of the oligopeptides at random of 9 amino-acid residues.From anti-[S99T] huIFNG, the specific antisera IgG purification l antibody of huIFNG or rhuIFNG is by immunoblotting identification reaction phage by immuno-precipitation.The dna sequence dna of reactive phage by measuring purifying can be measured the sequence of oligopeptides, subsequently this sequence of location on the three-dimensional structure of IFNG.The structural zone of this of Jian Dinging constitutes epi-position thus, can select the target region of this epi-position as the linking group that imports non-polypeptide fraction then.
Half life and serum half life, depend in the function gonosome, for example, and the molecular weight of polypeptide variants, and make half life increase the molecular weight that required linking group number depends on selected non-polypeptide fraction.In one embodiment, through Laemmli, U.K., Nature Vol 227 (1970), and the described SDS-PAGE of p680-85 measures, and IFNG polypeptide variants of the present invention has the molecular weight of 67kDa, 70kDa especially at least at least.The molecular weight ranges of IFNG is about 34-50kDa, therefore also needs about 20-40kDa to obtain required effect.This can, for example, by the PEG molecule of 2-4 10kDa or make up that glycosylation site and extra PEG molecule provide in the extra body, as described in this paper other parts.
Preferred link coupled IFNG polypeptide variants of the present invention has 1-10 (extra) non-polypeptide fraction, as 1-8, and 2-8,1-5,1-3 or 2-5 (extra) non-polypeptide fraction.Usually, the link coupled variant has 1-3 (extra) non-polypeptide fraction, as 1,2 or 3 (extra) non-polypeptide fraction.
As mentioned above, under physiological condition, huIFNG is the dimer polypeptide.Described polypeptide is homodimer form (for example, preparing by combining with two IFNG peptide molecules by preparation described herein) normally.Yet if desired, the IFNG polypeptide variants can provide with single stranded form, and wherein two IFNG polypeptide monomers can connect by peptide bond or peptide linker.Provide the advantage of IFNG polypeptide variants to be with single stranded form, two IFNG polypeptide wherein can be different, and this difference helps, and for example, allow the asymmetric mutagenesis of polypeptide.For example, remove the PEGization site, but keep another monomeric site from one of them monomeric receptor binding site.So, after the PEGization, a monomer has complete receptor binding site, and therefore another by thorough PEGization (and providing the molecular weight that enlarges markedly).
IFNG variant of the present invention when non-polypeptide fraction is sugar component
In a preferred embodiment of the invention, at least one glycosylation site is introduced and/or removed to the IFNG variant at least shown in the SEQ ID NO:1 (or its fragment).Preferred this glycosylation site is a glycosylation site in the body, and promptly non-polypeptide fraction is a sugar component, for example the O-connection or that N-connects sugar component, the sugar component that preferred N-connects.
In interested embodiment of the present invention, described variant is introduced at least one glycosylation site, especially an individual interior N-glycosylation site.The preferred glycosylation site of introducing is introduced by replacement.
For example, N-glycosylation site in the body can be introduced a position in the IFNG polypeptide shown in the SEQ ID NO:1 (or its fragment), described polypeptide has the amino-acid residue that is exposed to the surface, preferential this amino-acid residue has at least 25% side chain to be exposed to the surface, and especially at least 50% side chain is exposed to the surface.Mensuration to this class position sees this paper embodiment 1 for details.
Introduce the N-glycosylation site, used introducing mode makes the N-residue in this site be arranged in described position.Similarly, introduce the O-glycosylation site, make S or the T residue of forming this site be arranged in described position.Should be understood that term " side chain of at least 25% (or at least 50%) is exposed to the surface " when with body in during the introducing coupling of N-glycosylation site, its expression in fact with position that sugar component is connected in the surface of amino acid side chain can be near characteristic.Under many circumstances, must be with respect in fact for asparagine residue that sugar component links to each other, introducing Serine or threonine residues on for+2 position (certainly, unless this position is occupied by Serine or threonine residues), these positions of having introduced Serine or threonine residues can be covered, and promptly it has the side chain less than 25% to be exposed to the surface.
In addition, in order to guarantee effective glycosylation, N residue or the S of O-glycosylation site or 118-terminal amino acid residues that the T residue is positioned at the IFNG polypeptide of glycosylation site, particularly N-glycosylation site in the preferred body are more preferably in 97-terminal amino acid residues.In addition more preferably, the position that glycosylation site is introduced in the body is only to need a sudden change just can produce the position (that is, producing required any other amino-acid residue in functional glycosyl site has been present in this molecule) in this site.
For example, cause introducing the replacement of another N-glycosylation site and comprising being exposed to IFNG polypeptide surface and being had at least 25% side chain to be exposed to position that this surperficial amino-acid residue occupies: Q1N+P3S/T, P3N+V5S/T, K6N+A8S/T, E9N+L11S/T, K12S/T, K13N+F15S/T, Y14N+N16S/T, G18S/T, G18N, G18N+S20T, H19N+D21S/T, D21N+A23S/T, G26N+L28S/T, G31N+L33S/T, K34N+W36S/T, K37S/T, K37N+E39S/T, E38N, E38N+S40T, E39N+D41S/T, S40N+R42S/T, K55N+F57S/T, K58N+F60S/T, K61S/T, K61N+D63S/T, D62N+Q64S/T, D63N, D63N+S65T, Q64N+I66S/T, S65N+Q67S/T, Q67N, Q67N+S69T, K68N+V70S/T, E71N+I73S/T, T72N+K74S/T, K74N+D76S/T, E75N+M77S/T, K80S/T, V79N+F81S/T, K80N+F82S/T, N85S/T, S84N+K86S/T, K87S/T, K86N+K88S/T, K87N+R89S/T, D90N+F92S/T, E93N+L95S/T, K94N, K94N+T96S, T101N+L103S/T, D102N+N104S/T, L103N+V105S/T, Q106S/T, E119N, E119N+S121T, P122N+A124S/T, A123N+K125S/T, A124N, A124N+T126S, K125N+G127S/T, T126N+K128S/T, G127N+R129S/T, K128N+K130S/T, R129N+R131S/T, K130N, K130N+S132T, R131N+Q133S/T, S132N+M134S/T, Q133N+L135S/T, M134N+F136S/T, L135N+R137S/T, F136N+G138S/T, R137N+R139S/T, G138N+R140S/T, R139N+A141S/T, R140N or R140N+S142T, shown replacement is with respect to [S99T] huIFNG with aminoacid sequence SEQ ID NO 1 (or have the associated clip of aminoacid sequence SEQ ID NOS:2-16 with respect to it).S/T represents to be substituted by Serine or threonine residues, preferred threonine residues.
The replacement that causes importing another N-glycosylation site at least in the position that is exposed to IFNG polypeptide (it has 50% side chain and is exposed to surface (having in the structure of acceptor molecule)) surface comprises: P3N+V5S/T, K6N+A8S/T, K12S/T, K13N+F15S/T, G18S/T, D21N+A23S/T, G26N+L28S/T, G31N+L33S/T, K34N+W36S/T, K37N+E39S/T, E38N, E38N+S40S/T, E39N+D41S/T, K55N+F57S/T, K58N+F60S/T, K61S/T, D62N+Q64S/T, Q64N+I66S/T, S65N+Q67S/T, K68N+V70S/T, E71N+I73S/T, E75N+M77S/T, N85S/T, S84N+K86S/T, K86N+K88S/T, K87N+R89S/T, K94N, K94N+T96S, T101N+L103S/T, D102N+N104S/T, L103N+V105S/T, Q106S/T, P122N+A124S/T, A123N+K125S/T, A124N, A124N+T126S, K125N+G127S/T, T126N+K128S/T, G127N+R129S/T, K128N+K130S/T, R129N+R131S/T, K130N, K130N+S132T, R131N+Q133S/T, S132N+M134S/T, Q133N+L135S/T, M134N+F136S/T, L135N+R137S/T, F136N+G138S/T, R137N+R139S/T, G138N+R140S/T, R139N+A141S/T, R140N and R140N+S142T, shown replacement is with respect to [S99T] huIFNG with aminoacid sequence SEQ ID NO 1 (or have the associated clip of aminoacid sequence SEQ ID NOS:2-16 with respect to it).S/T represents to be substituted by Serine or threonine residues, preferred threonine residues.
Only need those replacements of an amino acid mutation to comprise K12S/T, G18S/T, G18N, K37S/T when importing a N-glycosylation site, E38N, M45N, I49N, K61S/T, D63N, Q67N, V70N, K80S/T, F82N, N85S/T, K87S/T, K94N, Q106S/T, E119N, A124N, K130N and R140N, especially K12S/T, G18N, G18S/T, K37S/T, E38N, K61S/T, D63N, Q67N, K80S/T, N85S/T, K94N, Q106S/T, A124N, K130N, and R140N (have and surpass the position that 25% side chain is exposed to surface (in the structure that does not contain acceptor molecule)), or more preferably G18N, E38N, D63N, Q67N, K94N, S99N, A124N, K130N and R140N (side chain that has in the structure that does not contain acceptor molecule above 50% is exposed to the surface).
Usually, preferably the N-glycosylation site introduce is not constituted in the zone of receptor binding site (except under special circumstances, referring to being entitled as " receptor affinity reduce variant ").Correspondingly, should not implement the Q1N+P3S/T that suddenlys change, E9N+L11S/T, G18N usually, G18N+S20T, H19N+D21S/T, D21N+A23S/T, G26N+L28S/T, K34N+W36S/T, K37N+E39S/T, E119N or E119N+S121T reduce unless wish receptor affinity.
The particularly preferred variant of the present invention comprises SEQ ID NO:1 (or it has the fragment of aminoacid sequence SEQID NOS:2-16), and wherein said variant has the IFNG activity and comprises the replacement that at least one is selected from down group: K12S, K12T, G18S, G18T, E38N, E38N+S40T, K61S, K61T, N85S, N85T, K94N, Q106S or Q106T, more preferably be selected from K12T, G18T, E38N+S40T, K61T, N85T, K94N or Q106T also more preferably are selected from K12T, G18T, E38N+S40T, K61T or N85T, especially E38N+S40T.
In another interested embodiment of the present invention, SEQ ID NO:1 (or it has the fragment of aminoacid sequence SEQ ID NOS:2-16) comprises the glycosylation site of at least two introducings, especially the N-glycosylation site of at least two introducings.At least two modifications (especially replacing) that cause introducing at least two N-glycosylation sites are preferably selected from K12S, K12T, G18S, G18T, E38N, E38N+S40T, K61S, K61T, N85S, N85T, K94N, Q106S or Q106T, more preferably be selected from K12T, G18T, E38N+S40T, K61T, N85T, K94N or Q106T also more preferably are selected from K12T, G18T, E38N+S40T, K61T or N85T.The specific examples that produces this class replacement of variant (it comprises at least two extra N-glycosylation sites) comprises: K12T+G18T, K12T+E38N+S40T, K12T+K61T, K12T+N85T, G18T+E38N+S40T, G18T+K61T, G18T+N85T, E38N+S40T+K61T, E38N+S40T+N85T and K61T+N85T.
From top listed replacement, the preferred selection is positioned at 118 intra-residue replacements of-terminal amino acid, particularly is positioned at 97 intra-residue replacements of-terminal amino acid.
Each monomer of IFNG polypeptide variants of the present invention can contain glycosylation site (comparing with SEQID NO:1 or its fragment) in the single body.Yet,, need this polypeptide to comprise N-glycosylation site in the more than extra body usually in order to become enough sizes to increase the serum half life, N-glycosylation site in 2-7 or 2-5 extra body particularly, for example 2,3,4,5,6 or 7 individual interior N-glycosylation sites.The N-glycosylation site preferably replaces by listed one or more above and introduces in such body.
In addition, should be understood that above-mentioned any modification can save disclosed any modification combination with " the IFNG variant of the present invention with interior glycosylation site of body of optimization ", especially with replacement G26A combination.
IFNG variant of the present invention, wherein non-polypeptide fraction has halfcystine as linking group Molecule
In another preferred embodiment, IFNG variant of the present invention comprises the cysteine residues of at least two introducings shown in the SEQ ID NO:1 (or its fragment).For example, cysteine residues can be introduced and have SEQ ID NO:1 (or its fragment) and have in the IFNG polypeptide of the amino-acid residue that is exposed to the surface.The preferred described amino-acid residue that is exposed to the surface has at least 25% side chain to be exposed to the surface, and especially at least 50% side chain is exposed to the surface.This class position determined to see for details this paper embodiment 1.
For example, cause comprising: Q1C, D2C, P3C in the replacement that is exposed to IFNG polypeptide surface and had at least 25% side chain to be exposed to the cysteine residues of position (having in the structure of acceptor molecule) introducing that this surperficial amino-acid residue occupies, K6C, E9C, N10C, K13C, Y14C, N16C, G18C, H19C, D21C, N25C, G26C, G31C, K34C, N35C, K37C, E38C, E39C, S40C, K55C, K58C, N59C, K61C, D62C, D63C, Q64C, S65C, Q67C, K68C, E71C, T72C, K74C, E75C, N78C, V79C, K80C, N83C, S84C, N85C, K86C, K87C, D90C, E93C, K94C, T101C, D102C, L103C, N104C or E119C, shown replacement is with respect to [S99T] huIFNG with aminoacid sequence SEQ ID NO 1 (or have the associated clip of aminoacid sequence SEQ ID NOS:2-16 with respect to it).
Cause comprising: P3C, K6C, N10C in the replacement that is exposed to IFNG polypeptide surface and had at least 50% side chain to be exposed to the cysteine residues of position (having in the structure of acceptor molecule) introducing that this surperficial amino-acid residue occupies, K13C, N16C, D21C, N25C, G26C, G31C, K34C, K37C, E38C, E39C, K55C, K58C, N59C, D62C, Q64C, S65C, K68C, E71C, E75C, N83C, S84C, K86C, K87C, K94C, T101C, D102C, L103C or N104C, shown replacement is with respect to [S99T] huIFNG with aminoacid sequence SEQ ID NO 1 (or have the associated clip of aminoacid sequence SEQ ID NOS:2-16 with respect to it).
Usually, preferably cysteine residues introduce is not constituted (and subsequently this cysteine residues being connected with non-polypeptide fraction) in the zone of receptor binding site (except under special circumstances, referring to being entitled as " receptor affinity reduce variant ").Correspondingly, should not implement the Q1C that suddenlys change usually, E9C, G18C, H19C, D21C, G26C, K34C, K37C and E119C are unless wish to reduce receptor affinity.
More preferably described cysteine residues is by being selected from N10C, N16C, and E38C, N59C, N83C, K94C, the replacement of N104C or A124C is introduced.
In another interested embodiment of the present invention, SEQ ID NO:1 (or it has the fragment of aminoacid sequence SEQ ID NOS:2-16) comprises the cysteine residues of at least two introducings.At least two modifications (especially replacing) that cause introducing at least two cysteine residues are preferably selected from N10C, N16C, E38C, N59C, N83C, K94C, N104C or A124C.The specific examples that produces this class replacement of variant (it comprises the cysteine residues of at least two introducings) comprises: N10C+N16C, N10C+E38C, N10C+N59C, N10C+N83C, N10C+K94C, N10C+N104C, N10C+A124C, N16C+E38C, N16C+N59C, N16C+N83C, N16C+K94C, N16C+N104C, N16C+A124C, E38C+N59C, E38C+N83C, E38C+K94C, E38C+N104C, E38N+A124C, N59C+N83C, N59C+K94C, N59C+N104C, N59C+A124C, N83C+K94C, N83C+K94C, N83C+N104C, N83C+A124C, K94C+N104C, K94C+A124C and N104C+A124C.
Be appreciated that the cysteine residues that preferably makes introducing and non-polypeptide fraction (PEG or more preferably mPEG) coupling.Containing the polypeptide variants of halfcystine and the coupling of polymer molecule can realize with any suitable mode, as the described mode of " with the coupling of polymer molecule " joint, and for example should described single stage method of joint or mode progressively.Make the preferred method of IFNG polypeptide variants PEGization be, make PEG and cysteine residues covalently bound with the reactive PEG of halfcystine.Existing in the market multiple have not isoplastic high specific, the reactive PEG of halfcystine (as, positive pyridyl-disulphide, maleimide and vinyl sulfone(Remzaol) and the PEG (2-20kDa that varies in size, as 5kDa, 10kDa, 12kDa or 15kDa), Shearwater Polymers Inc. for example, Huntsville, AL, the product of USA.
Should be understood that above-mentioned any modification can save disclosed any modification combination with " the IFNG variant of the present invention with interior glycosylation site of body of optimization ", especially with replacement G26A combination.
IFNG variant of the present invention, wherein first kind of non-polypeptide fraction is sugar component, second kind of non-polypeptide Component is to have the molecule of cysteine residues as linking group
In preferred embodiments, the IFNG variant of the present invention shown in the SEQ ID NO:1 (or its fragment) comprises the N-glycosylation site of at least one introducing and the semicanal propylhomoserin residue of at least one introducing.Described variant can prepare by the residue of selecting to be suitable for described in the first-half, respectively to introduce N-glycosylation site and cysteine residues.But in a preferred embodiment of the present invention, described variant comprises and is selected from following replacement: K12T+N16C, K12T+E38C, K12T+N59C, K12T+N83C, K12T+K94C, K12T+N104C, K12T+A124C, G18T+N10C, G18T+E38C, G18T+N59C, G18T+N83C, G18T+K94C, G18T+N104C, G18T+A124C, E38N+S40T+N10C, E38N+S40T+N16C, E38N+S40T+N59C, E38N+S40T+N83C, E38N+S40T+K94C, E38N+S40T+N104C, E38N+S40T+A124C, K61T+N10C, K61T+N16C, K61T+E38C, K61T+N83C, K61T+K94C, K61T+N104C, K61T+A124C, N85T+N10C, N85T+N16C, N85T+E38C, N85T+N59C, N85T+K94C, N85T+N104C, N85T+A124C, K94N+N10C, K94N+N16C, K94N+E38C, K94N+N59C, K94N+N83C, K94N+N104C, K94N+A124C, Q106T+N10C, Q106T+N16C, Q106T+E38C, Q106T+N59C, Q106T+N83C, Q106T+K94C or Q106T+A124C more preferably are selected from E38N+S40T+N10C, E38N+S40T+N16C, E38N+S40T+N59C, E38N+S40T+N83C, E38N+S40T+K94C or E38N+S40T+N104C.
Be appreciated that the cysteine residues that preferably makes introducing and non-polypeptide fraction (PEG or more preferably mPEG) coupling.Containing the polypeptide variants of halfcystine and the coupling of polymer molecule can realize with any suitable mode, as, the described mode of " with the coupling of polymer molecule " joint for example should described single stage method of joint or mode progressively.Suitable polymkeric substance is VS-mPEG or OPSS-mPEG.
In addition, should be understood that above-mentioned any modification can save disclosed any modification combination with " the IFNG variant of the present invention with interior glycosylation site of body of optimization ", especially with replacement G26A combination.
IFNG variant with receptor affinity of reduction
A kind of method that increases the serum half life of IFNG polypeptide is to reduce receptor-mediated internalization and therefore reduce receptor-mediated removing.
Therefore the avidity of IFNG dimer and IFNG receptor complex is depended in receptor-mediated internalization, estimates, the IFNG variant that has reduced with the avidity of IFNG receptor complex is weakened by internalization and the degree that therefore is eliminated.
The avidity of IFNG dimer and its receptor complex can be carried out one or more modification (especially replacing) by the receptor binding site at the IFNG polypeptide and be reduced.The amino-acid residue that constitutes receptor binding site is seen this paper embodiment 2.It is the aminoacid replacement of guarding that the class that might implement replaces.In another embodiment, described replacement causes introducing the N-glycosylation site.
So in an especially preferred embodiment, IFNG variant of the present invention comprises at least one modification at receptor binding site (as described herein) shown in the SEQ ID NO:1 (or its fragment), as replacing.More specifically, the IFNG polypeptide comprises the modification that at least one can produce N-glycosylation site in the body at described receptor binding site, as replacing.For example, described replacement is selected from Q1N+P3S/T, D2N+Y4S/T, Y4N+K6S/T, V5N+E7S/T, E9N+L11S/T, K12N+Y14S/T, G18N, G18N+S20T, H19N+D21S/T, S20N+V22S/T, D21N+A23S/T, V22N+D24S/T, D24N+G26S/T, G26N+L28S/T, L30N+I32S/T, K34N+W36S/T, K37N+E39S/T, K108N+I110S/T, H111N+L113S/T, E112N+I114S/T, I114N+V116S/T, Q115N+M117S/T, A118N+L120S/T, E119N or E119N+S121T are preferably selected from Q1N+P3S/T, D2N+Y4S/T, E9N+L11S/T, K12N+Y14S/T, G18N, G18N+S20T, H19N+D21S/T, S20N+V22S/T, D21N+A23S/T, K34N+W36S/T, K37N+E39S/T, H111N+L113S/T, Q115N+M117S/T, A118N+L120S/T, E119N or E119N+S121T (the N-glycosylation site is introduced the position comprise following amino-acid residue, and this amino-acid residue has at least 25% side chain to be exposed to the surface) more preferably are selected from Q1N+P3S/T, D2N+Y4S/T, E9N+L11S/T, G18N, G18N+S20T, H19N+D21S/T, S20N+V22S/T, D21N+A23S/T, K34N+W36S/T, K37N+E39S/T, Q115N+M117S/T, A118N+L120S/T, E119N or E119N+S121T (introduce the N-glycosylation site position that comprises following amino-acid residue, this amino-acid residue has at least 50% side chain to be exposed to the surface), also more preferably be selected from Q1N+P3T, D2N+Y4T, E9N+L11T, G18N+S20T, H19N+D21T, S20N+V22T, D21N+A23T, K34N+W36T, K37N+E39T, Q115N+M117T, A118N+L120T or E119N+S121T, most preferably be selected from G18N+S20T, H19N+D21T, D21N+A23T or E119N+S121T, especially D21N+A23T.
Described variant is considered to compare receptor affinity with hulFNG or Actimmune  to be reduced.Receptor affinity can be measured by any suitable test and test known in the art.A kind of test that is suitable for measuring receptors bind avidity is the described BIAcore  test of Michiels et al.Int.J.Biochem.Cell Biol.30:505-516 (1998).By utilizing above-mentioned test, the IFNG variant that is considered to can be used for the object of the invention is such IFNG variant, and its binding affinity (Kd) is the 1-95% of the Kd value of glycosylation [S99T] huIFNG or Actimmune .For example, the Kd value of IFNG polypeptide is the 1-75% or the 1-50% of the Kd value of glycosylation [S99T] huIFNG or Actimmune , as 1-25%, and 1-20% or even be low to moderate 1-15%, 1-10% or 1-5% for example.
Usually, when, for example, when detecting in " tentative experiment " described herein, this IFNG variant that has reduced receptor affinity has the IFNG activity that weakens.For example, this IFNG polypeptide variants has the 1-95% of the specific activity of Actimunne  or rhuIFNG, 1-75% for example, and as 1-50%, for example 1-20% or 1-10%.
As mentioned above, such IFNG variant is considered to owing to receptor-mediated removing causes the half life increase of its serum.Therefore, this IFNG polypeptide variants on the one hand of the present invention be considered to meet preamble in the definition of the serum half life that increases about the requirement of the serum half life that increases.
Obviously, cause above-mentioned any modification of receptors bind avidity to make up with any other modification disclosed herein, especially with the modification combination of in following chapters and sections, mentioning: " IFNG variant of the present invention " with N-glycosylation site of optimization, " IFNG variant of the present invention; non-polypeptide fraction wherein is to have the molecule of cysteine residues as linking group " and " IFNG variant of the present invention; wherein first kind of non-polypeptide fraction is sugar component; second kind of non-polypeptide fraction is to have the molecule of cysteine residues as linking group ", as with G26A, the combination of E38N+S40T and combination thereof.
Coupling method
Non-polypeptide fraction
As mentioned above, the non-polypeptide fraction of conjugate of the present invention is preferably selected from polymer molecule, lipophilic compound, sugar component (by glycosylated mode in the body) and organic derivating agent.All these materials all can be the IFNG polypeptide variants desired characteristic are provided, and particularly increase AUCsc, increase the serum half life and/or weaken immunogenicity.Described polypeptide variants usually only with one type non-polypeptide fraction coupling, but also can with two or more dissimilar non-polypeptide fraction couplings, for example, with polymer molecule and sugar component coupling, with lipophilic group and sugar component coupling, with organic derivating agent and sugar component coupling, with lipophilic group and polymer molecule coupling, etc.When with two kinds of dissimilar non-polypeptide fraction couplings, preferred sugar component and polymeric constituent.In following chapters and sections " with the coupling of lipophilic compound ", the coupling with the non-polypeptide fraction of all kinds is described in " with the coupling of polymer molecule ", " with the coupling of sugar component " and " with the coupling of organic derivating agent ".
Coupling with lipophilic compound
Polypeptide and lipophilic compound can directly or pass through to use the mutual coupling of joint.Lipophilic compound can be a natural compounds, for example saturated or unsaturated fatty acids, lipid acid diketone, terpenes, prostaglandin(PG), VITAMIN, carotenoid or steroid, or synthetic compound, for example have one or more alkyl, aromatic base, the carboxylic acid of alkenyl or other a plurality of unsaturated compounds, alcohol, amine and sulfonic acid.Optionally between polypeptide and the lipophilic compound can carry out according to methods known in the art by the coupling of joint, for example, Bodanszky is synthetic peptide, John Wiley, New York, 1976 and described in the WO96/12505.
Coupling with polymer molecule
With polypeptide variants link coupled polymer molecule can be the polymer molecule of any appropriate, for example natural or synthetic homotype polymkeric substance or heteropolymer, the molecular weight ranges that generally has is 300-100,000Da or 1000-50,000Da, as 2000-40,000Da or 2000-30,000Da, 2000-20 for example, 000Da, 2000-10,000 or 10005000Da.More preferably, described polymer molecule, as PEG, especially the common molecular weight of mPEG is about 2,5, and 10,12,15,20,30,40 or 50kDa, especially about 5kDa, about 10kDa, about 12kDa, about 15kDa or about 20kDa.
" pact " when mentioning polymer molecule herein is meant approximate molecular-weight average, and it has reflected the fact that molecular weight distribution is to a certain degree arranged usually in given polymer formulations.
The example of homopolymer comprise polyalcohols (that is, poly--OH), polyamine (that is poly--NH, 2) and poly carboxylic acid (that is, gather-COOH).Heteropolymer is the polymkeric substance that contains different coupling group (as hydroxyl and amino).
The example of suitable polymers molecule comprises and is selected from following polymer molecule: polyalkylene oxide (PAO), comprise polyalkylene glycol (PAG), as polyoxyethylene glycol (PEG) and polypropylene glycol (PPG), ramose PEG, polyvinyl alcohol (PVA), polycarbonate, polyvinylpyrrolidone, polyethylene is maleic anhydride altogether, polystyrene is maleic anhydride altogether, dextran comprises Sensor Chip CM 5, or any other is suitable for reducing immunogenicity and/or increases half life in the function gonosome and/or the biological polymer of serum half life.Another example of polymer molecule is human albumin or another abundant plasma proteins.In general, polyalkylene glycol-derived polymers is biocompatible, nontoxic, no antigen, non-immunogenicity, has various water-soluble characteristics and be easy to secrete from the biology of living.
PEG is preferred polymer molecule because its with, for example polysaccharide such as dextran are compared the crosslinked reactive group of energy that only has minute quantity.Interested especially is single function PEG, as mono methoxy polyethylene glycol (mPEG) because its coupling chemofacies to simple (only reactive group can be used for polysaccharide on the linking group coupling).Therefore, eliminated crosslinked risk, the reaction better and polymer molecule and this polypeptide of the coupling type polypeptide variants homogeneity of gained is easier to control.
In order to realize the covalently bound of polymer molecule and polypeptide variants, the hydroxyl terminal groups of polymer molecule must provide with activated form, promptly, (example of this group comprises primary amine group to have reactive functional groups, hydrazides (HZ), sulfydryl, succinate (SUC), succinimido succinate (SS), succinimido succinic diamide (SSA), succinyl phosphorons amino propyl acid ester (SPA), carboxymethylation succinimide (SCM), benzotriazole carbonic ether (BTC), N-hydroxy-succinamide (NHS), aldehyde, oil of mirbane carbonic ether (NPC) and Tresylate(TRES)).Suitably the activatory polymer molecule is commercially available, for example from Shearwater Polymer, and Inc., Huntsville, AL, USA obtains.In addition, polymer molecule can for example be pressed WO 90/13540 disclosed method by ordinary method activation known in the art.The object lesson that is used for activatory linearity of the present invention or branched polymer molecule is at ShearwaterPolymer, Inc.1997 and product catalogue in 2000 (are used to study the functionalization biocompatible polymer with pharmacy, polyoxyethylene glycol and derivative, this paper quotes for your guidance) the middle description.The object lesson of activatory PEG polymkeric substance comprises following linear PEGs:NHS-PEG (SPA-PEG for example, SSPA-PEG, SBA-PEG, SS-PEG, SSA-PEG, SC-PEG, SG-PEG, and SCM-PEG), and NOR-PEG, BTC-PEG, EPOX-PEG, NCO-PEG, NPC-PEG, CDI-PEG, ALD-PEG, TRES-PEG, VS-PEG, IODO-PEG and MAL-PEG, and the PEGs of branch, PEG2-NHS and for example at US 5,932,462 and US 5,643, those disclosed molecule in 575, this paper are quoted these two pieces of documents for your guidance.In addition, the following document that this paper quotes as a reference discloses the chemical property of useful polymer molecule and/or PEG connection: US 5,824, and 778, US 5,476,653, and WO 97/32607, EP 229,108, and EP 402,378, US 4,902,502, and US 5,281,698, US 5,122,614, US 5,219, and 564, WO 92/16555, and WO 94/04193, and WO 94/14758, and WO 94/17039, WO 94/18247, and WO 94/28024, and WO 95/00162, and WO 95/11924, W095/13090, WO 95/33490, and WO 96/00080, and WO 97/18832, WO 98/41562, and WO 98/48837, and WO 99/32134, and WO 99/32139, WO 99/32140, and WO 96/40791, and WO 98/32466, and WO 95/06058, EP 439,508, and WO 97/03106, and WO 96/21469, WO 95/13312, and EP 921,131, and US 5,736,625, WO 98/05363, and EP 809996, US 5,629, and 384, WO 96/41813, and WO 96/07670, and US 5,473,034, US 5,516,673, EP 605963, US 5,382, and 657, EP 510356, and EP 400472, EP 183503 and EP 154316.
The specific examples of preferred especially and cysteine residues link coupled activated form PEG polymer molecule comprises with lower linear PEG: vinyl sulfone(Remzaol-PEG (VS-PEG) optimal ethylene sulfone-mPEG (VS-mPEG); Maleimide-PEG (MAL-PEG), preferred maleimide-mPEG (MAL-mPEG) and positive pyridyl-disulphide-PEG (OPSS-PEG), preferred positive pyridyl-disulphide-mPEG (OPSS-mPEG).The size of described PEG or mPEG polymkeric substance is about 5kDa, about 10kD, about 12kDa or about 20kDa usually.
The coupling of polypeptide variants and activatory polymer molecule can be carried out with any ordinary method, for example, undertaken by following reference described (also having described the proper method of activated polymer molecule in the described reference): R.F.Taylor, (1991), " Protein immobilisation.Fundamental and applications ", Marcel Dekker, N.Y.; S.S.Wong, (1992), " Chemistry of Protein Conjugation and Crosslinking ", CRC Press, Boca Raton; G.T.Hermanson etc., (1993), " Imnobilized Affinity Ligand Techniques ", Academic Press, N.Y.).In order to make cysteine residues PEGization (seeing above), described IFNG uses earlier reductive agent usually, handles as dithiothreitol (DTT) (DDT), and then carry out PEGization.Reductive agent by any ordinary method, is removed as desalination process subsequently.PEG and halfcystine in suitable damping fluid, kept maximum 16 hours and the generation coupling at pH6-9,4-25 ℃ usually.
The technician knows, the functional group that activation method that will use and/or coupling chemistry depend on the linking group (the above example that provided) of described polypeptide and polymkeric substance (for example, be amine, hydroxyl, carboxyl, aldehyde, sulfydryl, succinimide, maleimide, vinysulfone or halogenated acetic acid salt).PEGization can relate to polypeptide on all available linking groups (that is, being exposed to the linking group on polypeptide surface) coupling, or can with one or more specific linking groups as, the direct coupling of N-terminal amido (as US 5,985,265 is described).And, coupling can one the step in finish or with the multistep mode finish (as, WO 99/55377 is described).
Should be understood that PEG turns into can being designed to, make the gained molecule number, these bulks of molecule and the form of the PEG molecule that connects (as, linearity or branch), and connection Ei site each side the best of peptide molecule.For example, can select the molecular weight of employed polymkeric substance according to the effect that need reach.。For example, if the link coupled primary and foremost purpose is to realize having the high-molecular weight coupling (for example, so that reduce the kidney clearance rate), need the least possible high molecular weight polymers molecule of coupling usually to obtain the desired molecule amount.When needs high shielded epi-position, low-molecular weight polymer that can be by using abundant quantity (for example, have about 5, the molecular weight of 000Da) obtain with all or most of epi-position of effective this polypeptide of shielding.For example, can use 2-8, for example 3-6 this polymkeric substance.
Only with protein on single linking group coupling the time (as US 5,985, described in 265), preferred linearity or ramose polymer molecule have high molecular, for example, about 20kDa.
In general, under the condition of all available linking groups that can make polymkeric substance and reacted polymer molecule, carry out the polymkeric substance coupling.Be typically, the mol ratio of activated form polymer molecule and polypeptide is 1000-1,200-1 particularly, and preferred 100-1, for example 10-1 or 5-1 are so that obtain optimum response.Yet, molar ratio such as also can use.
Also comprise by joint coupling polymer molecule and polypeptide according to the present invention.Suitable joint is that the technician knows.Preferred example is cyanuryl chloride (Abuchowski etc., (1977), journal of biological chemistry, 252,3578-3581; US 4,179, and 337; Shafer etc., (1986), polymer science and polymer chemistry magazine, editor, 24,375-378).
After the coupling, according to methods known in the art, for example, by in reaction mixture, adding primary amine sealing remaining activated form polymer molecule, and the inactivation type polymer molecule by suitable method removal gained.
Coupling with sugar component
The coupling of sugar component can be in vivo or external generation.In order to realize through modifying glycosylation in the body imported glycosylation site in one or more bodies (seeing " conjugate of the present invention; wherein non-polypeptide fraction is a sugar component " part), the nucleotide sequence of the polypeptide portion of coding conjugate is inserted among the glycosylated eukaryotic expression host with the active polypeptide of IFNG.Expression host cell can be selected from fungi (filamentous fungus or yeast), insect or zooblast or be selected from transgenic plant cells.In addition, when the nucleotide sequence of polypeptide portion that in gene therapy, uses coding conjugate of the present invention or polypeptide of the present invention, can in human body, realize glycosylation.In one embodiment, host cell is a mammalian cell, Chinese hamster ovary celI for example, BHK or HEK cell, HEK293 for example, or insect cell, for example SF9 cell, perhaps yeast cell, Saccharomyces cerevisiae (Saccharomyces cerevisiae) for example, Pichiapastoris or any other suitable glycosylation host, for example, as described below.Optional is, the sugar component that is connected on the IFNG polypeptide through glycosylation in the body can for example, use Neose by using glycosyltransferase, Horsham, and PA, the glycoAdvanceTM technology of USA listing is further modified.Thereby can increase, for example express the interior glycosylation of body of the sialylated and Chinese hamster ovary celI of the glycosylated IFNG polypeptide in back.
Can use the external coupling of covalency of the amino-acid residue of glucosides and IFNG polypeptide to modify or increase the number or the characteristic of sugar component.According to the coupling mode of using, carbohydrate can be connected to a) on the arginine and Histidine, b) on the free carboxy, c) free sulfhydryl groups is for example on the free sulfhydryl groups of halfcystine, d) free hydroxyl group, Serine for example, Threonine is on the free hydroxyl group of tyrosine or oxyproline, e) aromatic residue, for example on the aromatic base of phenylalanine or tryptophane or f) on the amide group of glutamine.These amino-acid residues are formed the example of the linking group of sugar component, can import and/or remove this residue in the IFNG of conjugate of the present invention polypeptide.External link coupled appropriate method is for example, WO 87/05330 and Aplin etc., and the biochemical emphasis of CRC is looked back, and the 259-306 page or leaf is described in 1981.The external coupling of sugar component or PEG and protein and peptide bonded Gln-residue can be passed through trans-glutaminases (TGases) and realize, for example, presses Sato etc., and 1996, biological chemistry, 35,13072-13080 or described in the EP 725145.
Coupling with organic derivatizing agent
The covalent modification of IFNG polypeptide variants can be by making polypeptide linking group and organic derivatizing agent react and carry out.Suitable derivating agent and method are well known in the art.For example, the most normal and alpha-halogen acetic ester (with corresponding amine) of cysteinyl residue as Mono Chloro Acetic Acid or chlor(o)acetamide reaction, produces carboxymethyl or carboxy and amide groups methyl-derivatives.The cysteinyl residue also can be derived with following substance reaction: bromine trifluoroacetone, α-bromo-β-(4-imidazolyl) propionic acid, chloracetyl phosphoric acid ester, N-alkyl maleimide, 3-nitro-2-pyridine disulphide, methyl 2-pyridine disulphide, pCMBA salt, 2-chloromercuri-4-nitrophenol or chloro-7-nitro benzo-2-Evil-1,3-diazole.The histidyl-residue is by deriving in the pH5.5-7.0 reaction with the diethyl pyrocarbonate, because this reagent is specific to the histidyl-side chain relatively.The PBPB thing is also effective; This reaction is preferably reacted in the 0.1M of pH6.0 cacodylic acid sodium.Lysyl and n terminal residue can react with succinyl oxide or other carboxylic acid anhydride.Derive with these reagent and to have the effect of the charge reversal that makes the lysyl residue.Be suitable for making containing alpha-amino other reagent of residue deutero-and comprising the inferior acid amides (methylpicolinimidate) of imino esters such as picoline, phosphoric acid Vitamin B6, Vitamin B6, chloro borohydride, trinitro-benzene-sulfonic acid, adjacent methyl-isourea, 2 the catalytic reaction with glyoxylate of 4-diacetylmethane and transaminase.The arginyl residue is by modifying with the reaction of one or more conventional reagent, described reagent comprise the phenyl oxalic dialdehyde, 2,3-dimethyl diketone, 1,2-cyclohexanedione and triketohydrindene hydrate.The requirement of deriving of arginine residues is reflected under the alkaline condition to be carried out, because the pKa of guanidine functional group is higher.In addition, these reagent can react with Methionin and arginine guanidine radicals.Carboxyl side group (aspartyl or glutamyl) carries out selective modification by reacting with carbodiimide (R-N=C=N-R '); wherein R is different alkyl with R '; as 1-cyclohexyl-3-(2-morpholinyl-4-ethyl) carbodiimide or 1-ethyl-3-(4-nitrogen-4,4-dimethyl amyl group) carbodiimide.And aspartyl and glutamyl are by being converted into asparagus fern acyl amide group (asparaginyl) and glutamy amide group (glutaminyl) with the ammonium ion reaction.
The sealing in functional site
Existing report: too much polymkeric substance coupling can cause and polymkeric substance link coupled polypeptide loss of activity.This problem can be by for example, removes the linking group that is positioned at functional site or eliminate by closing function site before coupling.After strategy form other embodiments of the present invention, first kind of strategy above illustrating, and for example method is to remove near the lysine residue in functional site and/or in the position in interference function site not to introduce glycosylation site in cysteine residues and/or the body.
In particular, according to second kind of strategy, carry out under the condition that is coupled at the functional site that to seal this polypeptide variants with the functional site bonded accessory molecule of IFNG polypeptide variants between polypeptide variants and the non-polypeptide fraction.Preferably, accessory molecule is the molecule in the functional site of specific recognition polypeptide variants, for example acceptor.Perhaps, accessory molecule can be an antibody, particularly discerns the monoclonal antibody of this polypeptide variants.Specifically, accessory molecule can be the monoclonal antibody with neutralizing effect.
Then, polypeptide variants and accessory molecule are interacted.Guarantee the functional site conductively-closed of polypeptide variants or protection and subsequently can not be by such as non-polypeptide fraction derivatizes such as polymkeric substance like this.Its behind the accessory molecule wash-out, the conjugate between recyclable non-polypeptide fraction and the polypeptide variants, it has partly conservative functional site at least.
Subsequently, have the polypeptide and the polymkeric substance in the functional site of having sealed, lipophilic compound, sugar component, organic derivatizing agent or arbitrarily other compounds with the normal way coupling, for example, press title for " with .... coupling " described the carrying out of above-mentioned part.
In another embodiment, accessory molecule at first covalent coupling to such as column material, for example on the solid phase of sephadex or sepharose 4B, perhaps on the surface, reactor surface for example.Subsequently, sample on the polypeptide is carried out coupling to the column material that carries accessory molecule and according to methods known in the art, for example, press title for " with .... coupling " described the carrying out of above-mentioned part.This method allows by wash-out from accessory molecule isolated polypeptide conjugate.Do not causing under a large amount of physical and chemical conditions of degrading of polypeptide conjugate with this polypeptide conjugate of routine techniques wash-out.The liquid phase that contains the polypeptide conjugate keeps covalently bound solid phase thereon to separate from accessory molecule.Separating available other modes realizes: for example, using can be by second molecule (biological example element) the derivatize accessory molecule of specific-binding agent (for example streptavidin) identification.Specific-binding agent can be connected on the solid phase, thereby allows by crossing post isolated polypeptide conjugate from accessory molecule-second molecular complex in the second accessory molecule solid phase column of being detained accessory molecule-second molecular complex rather than polypeptide conjugate when the wash-out subsequently.Can discharge the polypeptide conjugate from accessory molecule in any suitable manner.Dissociated condition realizes going protection from the functional site of its bonded IFNG by accessory molecule is provided.For example, the antibody of coupling polymer and the mixture between the antiidiotypic antibody can be by being transferred to acidity with pH or alkaline pH dissociates.
Coupling through the polypeptide variants of mark
In another embodiment, the IFNG polypeptide variants can be expressed as the fusion rotein with marker, promptly usually by 1-30, as the aminoacid sequence or the peptide section of 1-20 amino-acid residue formation.Except can be fast and easily carry out purifying, marker be to finish link coupled convenient tool between labeling polypeptide and the non-polypeptide fraction.Particularly, marker is used on titer plate or other carrier such as the paramagnetic beads and finishes coupling, and the polypeptide of mark can fix by marker like this., for example, the polypeptide link coupled advantage with mark on the titer plate is, the polypeptide of mark can directly be fixed on the titer plate (in principle without any purifying) and carry out coupling from culture broth.Therefore, can reduce the sum of operation steps (from expressing coupling).And marker can play the work of spacerarm molecule in order to guarantee the making fixed polypeptide be easier to coupling.The coupling that the applying marking polypeptide carries out can be the coupling with any non-polypeptide fraction disclosed herein, as with the coupling of polymer molecule such as PEG.
It is not crucial using which kind of concrete marker, as long as this marker can be expressed and can be fixed on the suitable surface or carrier substance with polypeptide.Many suitable markers can obtain by the commercial channel, for example, can purchase the Laboratories in Unizyme, Denmark.For example, described marker can be following arbitrary sequence:
His-His-His-His-His-His(SEQ?ID?NO：35)
Met-Lys-His-His-His-His-His-His(SEQ?ID?NO：36)
Met-Lys-His-His-Ala-His-His-Gln-His-His(SEQ?ID?NO：37)
Met-Lys-His-Gln-His-Gln-His-Gln-His-Gln-His-Gln-His-Gln(SEQ?IDNO：38)
(all can be, the Unizyme laboratory obtains) or following arbitrary sequence from Denmark:
EQKLI SEEDL (SEQ ID NO:39) (being described in Mol.Cell.Biol.5:3610-16,1985 C-end marker)
DYKDDDDK (SEQ ID NO:40) (C-or N-end marker)
YPYDVPDYA(SEQ?ID?NO：41)
The antibody of anti-above-mentioned marker can obtain by the commercial channel usually, for example purchases in ADI AvesLab and Research Diagnostics.
Available subsequently commercially available enzyme cuts off marker from polypeptide.
The method for preparing IFNG polypeptide variants of the present invention
Can produce the IFNG polypeptide variants with any suitable method known in the art, choose wantonly and produce with the glycosylation form.This method comprises the nucleotide sequence that makes up this polypeptide of coding and express this sequence in the host cell of suitable conversion or transfection.Yet although efficient is not high, the process chemosynthesis or the combination of chemosynthesis or the combination of chemosynthesis and recombinant DNA technology also can be produced polypeptide of the present invention.
The nucleotide sequence of the present invention of coding IFNG polypeptide variants (monomer or single stranded form) can followingly make up: separate or the nucleotide sequence of composite coding parent IFNG (for example having aminoacid sequence SEQ ID NO 17 or its segmental huIFNG), change nucleotide sequence then with the introducing that realizes the related amino acid residue (promptly insert or replace) or disappearance (promptly remove or replace).
According to the method for knowing, referring to for example, Mark etc., " site-directed mutagenesis of fibroblast interferon's gene ", Proc.Natl.Acad.Sci.USA, 81, the 5662-66 pages or leaves (1984); And US4,588,585 method can conventional modified nucleotide sequence through site-directed mutagenesis.
Perhaps, can prepare nucleotide sequence through chemosynthesis, for example,,, and preferably select those favourable codons in the host cell of producing this recombinant polypeptide wherein according to the aminoacid sequence design oligonucleotides of desired polypeptides through using oligonucleotide synthesizer.For example, through PCR, some small oligonucleotides of the part of coding desired polypeptides can be synthesized and assemble to connection or connection chain reaction (LCR).Single oligonucleotide generally contains 5 ' or the 3 ' overhang that is useful on complementary assembling.
In case assembling (through synthetic, site-directed mutagenesis or other method), the nucleotide sequence of coded polypeptide can be inserted recombinant vectors and be operably connected with the necessary regulating and controlling sequence of expression IFNG in required transformed host cell.
Certainly should understand that not all carrier and expression regulation sequence can both be brought into play function equally preferably in order to express the nucleotide sequence of coding IFNG polypeptide variants as herein described.Host that neither be all can both bring into play function equally preferably with same expression system.Yet those skilled in the art does not need too much experiment just can make one's options at these carriers among expression regulation sequence and the host.For example, when selecting carrier, must consider the host, in the host because carrier must duplicate or can be integrated in the karyomit(e).Also should consider the copy number of carrier, control the ability of this copy number and by any other protein of this vector encoded, for example expression of antibiotic marker.In the selection of expression regulation sequence, also should consider various factors.These comprise, for example, the relative length of sequence, its ability of regulation and control, the consistency of the nucleotide sequence of itself and coded polypeptide particularly will be considered the potential secondary structure.Host's selection should be taken into account the consistency of itself and selected carrier, the toxicity of the product that this is nucleotide sequence coded, and it secretes feature, and it is the ability of folding polypeptide correctly, its fermentation or the purifying simplicity of cultivating requirement and this nucleotide sequence coded product.
Recombinant vectors can be an autonomously replicationg vector, and promptly as the carrier of the outer entity existence of karyomit(e), it duplicates and is independent of THE REPLICATION OF CHROMOSOME, for example plasmid.As selection, carrier is the carrier that is integrated into the host cell gene group and duplicates with the karyomit(e) that it is integrated into when introducing host cell.
Preferably a kind of expression vector of this carrier, the nucleotide sequence of the IFNG polypeptide variants of wherein encoding is operably connected to this nucleotide sequence and transcribes on other required fragments.This carrier is generally derived from plasmid or viral DNA.This paper mentions is used for being commercially available or describing in the literature in many suitable expression vector that host cell is expressed.The useful expression vector that is used for eucaryon host comprises, for example, contains from SV40 bovine papilloma virus, the carrier of the expression regulation sequence of adenovirus and cytomegalovirus.Concrete carrier is, for example, pCDNA3.1 (+) Hyg (Invitrogen, Carlsbad, CA, USA) and pCI-neo (Stratagene, La Jola, CA, USA).The useful expression vector that is used for host bacterium comprises known bacterial plasmid, for example from colibacillary plasmid, comprises pBR322, pET3a and pET12a (both is from Novagen Inc., WI, USA), the plasmid of wide spectrum host range, RP4 for example, phage DNA s, for example, numerous derivatives of lambda particles phage, as NM989 and other DNA phages, as M13 and thread single stranded DNA phage.The useful expression vector of yeast cell comprises 2 μ plasmid and derivatives thereof, POT1 carrier (US 4,931,373), in (Okkels, NYAS's annual report, 782,202-207,1996) pJSO37 carrier and the pPICZ A described in, B or C (Invitrogen).The useful carrier that is used for insect cell comprises pVL941, pBG311 (Cate etc., " ox separates and expressing human gene in zooblast with people Mullerian inhibitory substance gene ", cell, 45,685-98 page or leaf (1986), pBluebac 4.5 and pMelbac (both can obtain from Invitrogen).
Be used for other carriers of the present invention and comprise the nucleotide sequence of permission coding IFNG polypeptide variants those carriers with the copy number amplification.These carriers that can increase are well known in the art.They comprise, for example, can through the DHFR amplification (referring to, Kaufman for example, U.S. Patent number 4,470,461, Kaufman and Sharp, " structure of module Tetrahydrofolate dehydrogenase cDNA gene: be used for the signal analysis of effective expression ", molecular cytobiology, 2, the 1304-19 pages or leaves (1982)) and glutamine synthetase (" GS ") amplification (referring to, for example, US 5,122,464 and EP 338,841) carrier that is amplified.
Recombinant vectors can further comprise the dna sequence dna that carrier is duplicated in described host cell.An example (when host cell is mammalian cell) of this sequence is the replication orgin of SV40.When host cell was yeast cell, the proper sequence that carrier is duplicated was yeast plasmid 2 μ replicator REP 1-3 and replication orgin.
Carrier also can comprise selective marker, and for example its product replenishes the gene of host cell defective, the gene of the Tetrahydrofolate dehydrogenase (DHFR) of for example encoding or the TPI gene (P.R.Russell of grain wine fragmentation sugar yeast (Schizosaccharomycespombe), gene, 40,1985, the 125-130 page or leaf is described), perhaps, provide medicine, penbritin for example, kantlex, tsiklomitsin, paraxin, Xin Meisu, Totomycin, or the gene of methotrexate resistance.For filamentous fungus, selective marker comprises AmdS, pyrG, arcB, NiaD, SC
The term " regulating and controlling sequence " of this paper definition comprises expresses necessary or favourable all elements of IFNG polypeptide variants.Each regulating and controlling sequence can be natural or with respect to the coding this polypeptide nucleotide sequence be external source.This regulating and controlling sequence includes, but are not limited to leader sequence, poly-adenosine sequence, propeptide sequence, promotor, enhanser or upstream activation sequences, signal peptide sequence, and transcription terminator.Minimum, regulating and controlling sequence comprises promotor.
The present invention can use various expression regulation sequences.This useful expression regulation sequence comprises the expression regulation sequence that the structure gene with above-mentioned expression vector interrelates and the arbitrary sequence of known control protokaryon or eukaryotic cell or its viral gene expression, and various combination.
Be used for instructing the example of the suitable regulating and controlling sequence of transcribing of mammalian cell to comprise the early stage and late promoter of SV40 and adenovirus, for example, adenovirus 2 major late promoters, MT-1 (metallothionein gene) promotor, human cytomegalic inclusion disease virus immediate early gene promotor (CMV), people's EF-1 α (EF-1 α) promotor, the most small-sized heat shock protein 70 promotor of Drosophila, Rous sarcoma virus (RSV) promotor, people's ubiqutin C (UbC) promotor, human growth hormone terminator, SV40 or adenovirus Elb zone poly-adenosine signal and Kozak consensus sequence (Kozak, M., molecular biology magazine, on August 20th, 1987; 196 (4): 947-50).
In order to improve the expression in mammalian cell, the synthetic intron can be inserted 5 ' non-translational region of the nucleotide sequence of coding IFNG polypeptide variants.The example of synthetic intron is the synthetic intron from plasmid pCI-Neo (can be from Promega Corporation, WI, USA acquisition).
Be used for instructing the example of the suitable regulating and controlling sequence of transcribing to comprise the polyhedrin promotor at insect cell, the P10 promotor, autographa california (Autographa californica) polyhedrosis virus basic protein promoter, baculovirus immediate early gene 1 promotor and baculovirus 39K delay-early gene promoter and SV40 poly-adenosine sequence.
The example that is used for the suitable regulating and controlling sequence of yeast host cell comprises the promotor of yeast α-mating system, yeast triose-phosphate isomerase (TPI) promotor, from the promotor of Yeast sugar glycolysis gene or alcohol dehydrogenase gene, ADH2-4c promotor and induction type GAL promotor.
The example that is used for the suitable regulating and controlling sequence of filamentous fungal host cell comprises ADH3 promotor and terminator, come own coding aspergillus oryzae (Aspergillus oryzae) TAKA amylase triose-phosphate isomerase or Sumizyme MP, black aspergillus (A.niger) α-Dian Fenmei, black aspergillus or Aspergillus nidulans (A.nidulans) glucoamylase, the Aspergillus nidulans acetamidase, promotor, TPI1 terminator and the ADH3 terminator of Rhizomucor miehei (Rhizomucor miehei) aspartate protease or lipase gene.
The example that is used for the suitable regulating and controlling sequence of bacterial host cell comprises the lac system, trp system, the promotor of TAC or TRC system, the main promoter region of lambda particles phage.
Nucleotide sequence of the present invention, synthetic no matter be still with other method preparation with site-directed mutagenesis, can comprise or not contain the nucleotide sequence of coded signal peptide.When need secreting, polypeptide has signal peptide from the cell of expressing it.If present, this signal peptide should be the signal peptide of cell recognition that can selected this polypeptide of expression.Signal peptide can or can be a homologous or allogenic with host cell with this homologous peptide (for example general with huIFNG link) or allogenic (promptly from another source that is different from huIFNG), promptly from the signal peptide of this host cell normal expression or generally not from the signal peptide of this host cell expression.Therefore, signal peptide can be a protokaryon, from such as colibacillary bacterium, perhaps can be eucaryon for example, for example from Mammals, or insect or yeast cell.
Whether signal peptide exists depends on, and for example is used to produce this polypeptide expression host cell, protein to be expressed (being in the cell or extracellular protein) and whether need to obtain secretion.In order to be used for filamentous fungus, signal peptide can come from the gene of coding Aspergillus kind amylase or glucoamylase easily, the gene of coding Rhizomucor miehei lipase or proteolytic enzyme or Humicola lanuginosa lipase.Signal peptide preferably comes own coding aspergillus oryzae TAKA amylase, the neutral α-Dian Fenmei of black aspergillus, black aspergillic acid stabilizing starch enzyme, the perhaps gene of black aspergillus glucoamylase.In order to be used for insect cell, signal peptide can come from insect genes (referring to WO 90/05783) easily, and for example the maduca sexta of lepidopterous insects (Manduca sexta) adipokinetic hormone precursor is (referring to US 5,023,328), the mellitin of honeybee (Invitrogen), ecdysteroids UDP glucanotransferase (egt) (Murphy etc., protein expression and purifying, 4,349-357 (1993)) or human pancreas's lipase (hpl) (Enzymology method, 284, the 262-272 page or leaf, 1997).
The preferred signals peptide that is used for mammalian cell be the signal peptide of huIFNG or mouse Ig κ light chain signal peptide (Coloma, M (1992), the immunological method magazine, 152:89-104).In order to be used for yeast cell, found that the appropriate signal peptide is that signal peptide from Saccharomyces cerevisiae α-factor is (referring to US 4,870,008), the signal peptide of mouse salivin (referring to O.Hagenbuchle etc., nature, 289,1981, the 643-646 page or leaf), the carboxypeptidase signal peptide of modifying (referring to L.A.Valls etc., cell, 48,1987, the 887-897 page or leaf), yeast BAR1Signal peptide (referring to WO 87/02670) and yeast aspartate protease 3 (YAP3) signal peptide (referring to M.Egel-Mitani etc., yeast 6,1990,127-137 page or leaf).
Can use any appropriate host to produce the polypeptide portion of polypeptide of the present invention or conjugate of the present invention, comprise bacterium, fungi (comprising yeast), plant, insect, Mammals or other suitable zooblast or clone and transgenic animal or plant.The example of bacterial host cell comprises gram positive bacterium such as bacillus, as bacillus brevis or subtilis, Pseudomonas or streptomyces, or gram negative bacterium, as coli strain.Carrier is introduced bacterial host cell can be passed through, for example, protoplast transformation is (referring to as Chang and Cohen, 1979, Molecular GeneralGenetics 168:111-115), use experience attitude cell is (referring to as Young and Spizizin, 1961, Journal of Bacteriology 81:823-829, or Dubnau and Davidoff-Abelson, 1971, Journal of Molecular Biology 56:209-221), electroporation is (referring to as Shigekawa and Dower, 1988, Biotechniques 6:742-751), or coupling (referring to as Koehler and Thorne, 1987, Journal of Bacteriology 169:5771-5278) carry out.
The example of suitable filamentous fungal host cell comprises the Aspergillus bacterial strain, as aspergillus oryzae, aspergillus niger or Aspergillus nidulans, and Fusarium or trichoderma.The fungal cell can transform by relating to following process: protoplastis formation, protoplast transformation and cell walls are regenerated by known mode own.The appropriate method that transforms the Aspergillus host cell has been described in EP238023 and US5679543.People such as Malardier 1989, the appropriate method that transforms Fusarium has been described among Gene 78:147-156 and the WO 96/00787.The example of suitable yeast host cell comprises bacterial strain (as yeast saccharomyces cerevisiae), Schizosaccharomyces, genus kluyveromyces, Pichia (as pichia pastoris phaff or P.Methanolica), Hansenula (as multiple-shaped nuohan inferior yeast) or the Yarrowia of saccharomyces.Yeast can use Becker and Guarente, In Abelson, J.N. and Simon, M.I., editors, Guide to Yeast Genetics and Molecular Biology, Methods in Enzymology Volume 194, pp 182-187, Academic Press, Inc., New York; People such as Ito, 1983, Journal of Bacteriology153:163; With people 1978 such as Hinnen, Proceedings of the National Academy ofSciences USA 75:1920; And by Clontech Laboratories, Inc, Palo Alto, CA, USA (Yeastmaker TMThe product manual of yeast conversion system test kit) method described in transforms.
The example of suitable yeast host cell comprises bacterial strain (as yeast saccharomyces cerevisiae), Schizosaccharomyces, genus kluyveromyces, Pichia (as pichia pastoris phaff or P.Methanolica), Hansenula (as multiple-shaped nuohan inferior yeast) or the Yarrowia of saccharomyces.With heterology DNA transformed yeast cell and the method for therefrom producing the heterology polypeptide by Clontech laboratory company, Palo Alto, CA, USA is (at Yeastmaker TMIn the description of product of yeast conversion system test kit), with by Reeves etc., FEMSMicrobiology Letters, 99, (1992) 193-198, Manivasakam and Schiestl, NucleicAcids Research, 1993, Vol.21, No.18,4414-4415 page or leaf and Ganeva etc., FEMSMicrobiology Letters 121 (1994) 159-164 are open.
The example of suitable insect host cell comprises lepidopteran clone, for example greedy noctuid (Sf9 or Sf21) in meadow or cabbage looper cell (High Five) (US 5,077,214).The conversion of insect cell and the production therein of heterology polypeptide can be undertaken by Invitrogen is described.
The example of suitable mammalian host cell comprises Chinese hamster ovary (CHO) clone, (CHO-K1 for example; ATCC CCL-61), grivet clone (COS) (for example COS 1 (ATCCCRL-1650), COS 7 (ATCC CRL-1651)); Mouse cell (for example NS/O), immature hamster kidney (BHK) clone (for example ATCC CRL-1632 or ATCC CCL-10) and people's cell (for example, HEK 293 (ATCC CRL-1573)), and the vegetable cell in the tissue culture.Other suitable clone is known in the art and can obtains from public depositary institution, American type culture collection for example, Rockville, Maryland.In addition, can modify such as the mammalian cell of Chinese hamster ovary celI to express sialytransferase, for example, 1, the 6-sialytransferase for example, press US 5,047, and 335 is described, so that the glycosylation of raising IFNG polypeptide variants.
The method that foreign DNA is introduced mammalian host cell comprises the transfection of transfection, electroporation, the mediation of DEAE-dextran of calcium phosphate mediation, liposome-mediated transfection, virus vector and by LifeTechnologies Ltd, Paisley, the transfection method that the described use of UK Lipofectamin2000 carries out.These methods are well known in the art, for example at people such as Ausbel (eds.), and 1996, CurrentProtocols in Molecular Biology, John Wiley ﹠amp; Sons, New York is described in the USA.The cultivation of mammalian cell is undertaken by the method for setting up, for example referring to Animal Cell Biotechnology, Methods and Protocols, Nigel Jenkins compiles, and 1999, Human Press Inc, Totowa, NewJersey, USA and Harrison MA and Rae IF, General Techniques of Cell Culture, Cambridge University Press 1997.
In order to produce glycosylated polypeptides, preferably use eukaryotic host cell, for example the eukaryotic host cell of the above-mentioned type.
In production method of the present invention, with methods known in the art culturing cell in being suitable for producing the nutritional medium of polypeptide variants.For example, cell can be in the laboratory by shake-flask culture, small-scale or large scale fermentation (comprise continuously, in batch, fed-batch or solid state fermentation) or suitable culture medium with allow to express and/or separate under the condition of described polypeptide variants and carry out industrial fermentation.Cultivation uses methods known in the art to carry out in the suitable nutrient medium that contains carbon source and nitrogenous source and inorganic salt.Suitable medium is commercially available maybe can be prepared by disclosed composition (for example, described in the catalogue of American type culture collection).If the polypeptide variants secretion is in nutritional medium, this polypeptide variants can directly reclaim from substratum.If polypeptide variants is not secreted, can from cell lysate, reclaim.
Can reclaim the gained polypeptide variants by methods known in the art.For example, can pass through ordinary method, include but not limited to centrifugal, filtration, ultrafiltration, extraction or precipitation, from nutritional medium, reclaim polypeptide variants.
Described polypeptide variants can be used the whole bag of tricks known in the art, includes but not limited to chromatography (for example, ion-exchange, affine, hydrophobic, chromatofocusing, and size exclusion), electrophoresis method (for example, the isoelectrofocusing of preparation type), different solvabilities (for example, ammonium sulfate precipitation), SDS-PAGE, or extract (referring to, for example, Protein Purification, J.-C.Janson and Lars Ryden, editors, VCHPublishers, New York, 1989) come purifying.The concrete purification process that shows the active polypeptide of IFNG is open in EP 110044 and careful Japanese patent application 186995/84.
The biologic activity of IFNG polypeptide variants can be measured with any suitable method known in the art.This assay method comprises the antibody neutralization of enantiopathy cytotoxic activity, to protein kinase, and oligomerization adenylic acid (AMP) 2, the inducing of 5-A synthetic enzyme or phosphodiesterase activity is as described in EP 41313B1.This assay method also comprise immunity modulation assay method (referring to, for example, US 4,753,795), growth-inhibiting assay method and measuring and the combining of the cell of expression Interferon Receptors.Concrete assay method is partly described at this paper material and method.
Medical composition and its use
The invention still further relates to treatment or preventing disease, improving one's methods of diseases associated with inflammation especially, described disease, interstitial lung disease for example is as the spontaneous lung fibrosis; Also comprise the granuloma disease; Cancer, especially ovarian cancer; Infect, as the lung atypical mycobacterial infection; Osteopathia (for example, the bone metabolism disease is as pernicious osteopetrosis); Autoimmune disease is as rheumatoid arthritis; And other disease, as multi-drug resistant tuberculosis; Cryptococcal meningitis; Cystic fibrosis and hepatic fibrosis especially are secondary to the hepatic fibrosis of hepatitis C, described method comprise to have in requisition for Mammals, especially human, use the polypeptide variants of the present invention or the present composition of significant quantity; Topmost advantage is to realize more effectively treatment with the low invasive medication than small frequency, but also may reduce with the therapeutic active compound immunoreactive danger takes place.
Molecule of the present invention is medication in the composition that comprises pharmaceutically acceptable carrier or vehicle preferably.In context, " pharmaceutically acceptable " means and do not cause in the patient of administration and anyly do not want or the carrier or the vehicle of deleterious effects.This class pharmaceutically acceptable carrier and vehicle be well known in the art (referring to, as Remington ' s Pharmaceutical Sciences, 18th edition, A.R.Gennaro, Ed., MackPublishing Company[1990]; Pharmaceutical Formulation Development ofPeptides and Proteins, S.Frokjaer and L.Hovgaard, Eds., Taylor ﹠amp; Francis[2000]; With Handbook of Pharmaceutical Excipients, 3rd edition, A.Kibbe, Ed., Pharmaceutical Press[2000]).
Molecule of the present invention can " with its form originally " and/or is used with the form of its salt.Suitable salt includes but not limited to, with basic metal or alkaline-earth metal, and sodium for example, potassium, the salt of calcium and magnesium and the salt that forms of zinc for example.These salt or mixture can exist with crystallization and/or unbodied structure.。
Conjugate of the present invention is with approximately similar in appearance to dosage used in using the therapy of implementing such as known IFNG commercial formulation such as Actimmune  or the dosage medication that limits in by EP 795332.The exact dosage desired of medication depends on particular case.In general, this dosage should be able to prevent or alleviate the symptom that will treat or the seriousness or the propagation of indication.The significant quantity that it is evident that conjugate of the present invention or composition to those skilled in the art depends on, disease particularly, dosage, the medication plan, polypeptide or conjugate or composition are to combine medication separately or with other therapeutical agent, the serum half life of composition and patient's overall health.
The invention still further relates to IFNG polypeptide variants of the present invention, or pharmaceutical composition of the present invention, as the purposes of medicine.
The invention still further relates to, i) IFNG polypeptide variants of the present invention or pharmaceutical composition ii) of the present invention are at the preparation medicine, the purposes of pharmaceutical composition or assembly medicine box, described medicine, pharmaceutical composition or assembly medicine box are used for the treatment of interstitial lung disease, especially the spontaneous lung fibrosis; Cancer, especially ovarian cancer; Infect, as the lung atypical mycobacterial infection; Osteopathia (for example, the bone metabolism disease is as pernicious osteopetrosis); The granuloma disease; Autoimmune disease is as rheumatoid arthritis; Multi-drug resistant tuberculosis; Cryptococcal meningitis; Cystic fibrosis and hepatic fibrosis especially are secondary to the hepatic fibrosis of hepatitis C.Most preferably described disease is an interstitial lung disease, especially the spontaneous lung fibrosis.
The invention also discloses improve one's methods (means) that transport described molecule or preparation (the optional glucocorticosteroid that also contains).
Preferred dosage is that the polypeptide composition of every kilogram of every dosage of patient body weight is the 1-4 microgram, more preferably the 2-3 microgram.Preferred dosage is every kilogram of every dosage 100-350 of patient body weight microgram, more preferably 100-150 microgram glucocorticosteroid.
The invention still further relates to the assembly medicine box that is applicable to the treatment interstitial lung disease, it comprises contains above-mentioned activeconstituents i) or first pharmaceutical composition ii) and second pharmaceutical composition that contains at least a glucocorticosteroid, every kind of composition is optional with pharmaceutically acceptable carrier and/or vehicle.
Variant of the present invention can be mixed with pharmaceutical composition with the method for knowing.Suitable preparaton is described by Remington ' s Pharmaceutical Sciences and the US 5,183,746 of E.W.Martin.
Pharmaceutical composition can be mixed with various forms, comprises liquid, colloid, dried frozen aquatic products, powder, compression solid, or any other suitable form.Preferred form depends on the concrete indication of being treated and is conspicuous to those skilled in the art.
Pharmaceutical composition can be by oral, subcutaneous, intravenously, and in the brain, in the nose, through skin, intraperitoneal, intramuscular, in the lung, intravaginal, rectum, intraocular or any other acceptable manner for example use PowderJect or ProLease technology to use.Although use technology well known in the art, for example to carry out bolus injection be acceptable for pump or implantation, and this preparaton can pass through the infusion continuous use.Preparaton can be used as solution or sprays is directly used in some cases.Preferred application method depends on the concrete indication of being treated and is conspicuous to those skilled in the art.
Can use pharmaceutical composition of the present invention in conjunction with other therapeutical agent.The part that these reagent can be used as same pharmaceutical composition is mixed or can be separated medication with polypeptide of the present invention or conjugate simultaneously or according to any other acceptable treatment procedure.In addition, polypeptide variants of the present invention or pharmaceutical composition can be used as the supplementary means of other treatment.The particularly described combination with glucocorticosteroid of EP 795332.
On the other hand, the present invention relates to treat the mammiferous method of circulating antibody with anti-huIFNG or rhuIFNG, this method comprise use have the IFNG biological activity and not with the compound of described antibody response.This compound conjugate preferably as herein described and Mammals are preferably human.The Mammals for the treatment of can suffer from any above-mentioned disease of IFNG as therapeutical agent.In addition, the present invention relates to prepare the method that is used for the treatment of mammiferous medicament production, wherein have the IFNG biological activity and be not mixed with preparaton injectable or that other is suitable with the compound of its reaction with anti-huIFNG or rhuIFNG circulating antibody.Term " circulating antibody " is meant the autoantibody that forms corresponding to treating with any commercially available IFNG preparation in Mammals.
The nucleotides sequence that the invention still further relates to code book invention IFNG polypeptide variants is listed in the purposes of gene therapy in using.Specifically, interesting being to use encodes above that title is the nucleotide sequence of the described IFNG polypeptide variants of " the IFNG variant of the present invention when non-polypeptide fraction is sugar component " joint.Therefore the glycosylation of polypeptide variants in the process of gene therapy, promptly realizes behind this nucleotide sequence of expression in human body.
The gene therapy that relates to is used and is comprised that this polypeptide of treatment expection can provide those diseases of effective treatment.
Use the local delivery of the IFNG variant of gene therapy to provide therapeutical agent, thereby avoid the genotoxic potential problem relevant with non-specific medication at the target area.
External and vivo gene methods of treatment all is related.
The certain methods that shifts the potential therapeutic genes to the cell colony of determining is known.For further reference, can be referring to for example, Mulligan, " The Basic Science Of GeneTherapy ", Science, 260, the 926-31 pages or leaves (1993).These methods comprise:
Direct gene shifts, and for example presses Wolff etc., and " Direct Gene transfer Into MouseMuscle In vivo ", Science 247, the 1465-68 pages or leaves (1990) are described;
Liposome-mediated DNA shifts, for example press Caplen etc., " Liposome-mediated CFTRGene Transfer to the Nasal Epithelium Of Patients With Cystic Fibrosis ", NatureMed., 3, the 39-46 pages or leaves (1995); Crystal, " The Gene As A Drug ", Nature Med., 1, the 15-17 (1995); Gao and Huang, " A Novel Cationic Liposome Reagent ForEfficient Transfection of Mammalian Cells ", Biochem.Biophys Res.Comm., 179, the 280-85 pages or leaves (1991) are described;
The DNA of retrovirus-mediated method shifts, for example press Kay etc., " In vivo Gene Therapy ofHemophilia B:Sustained Partial Correction In Factor IX-Deficient Dogs ", Science, 262, the 117-19 pages or leaves (1993); Anderson, " Human Gene Therapy ", Science, 256, the 808-13 pages or leaves (1992) are described;
The DNA of dna virus mediation shifts.This dna virus comprises adenovirus (being preferably based on the carrier of Ad-2 or Ad-5), simplexvirus (being preferably based on the carrier of hsv), (be preferably based on " defective type " or non-carrier with the parvovirus genus from the principal mode parvovirus, more preferably based on the carrier of adeno associated virus, most preferably based on the carrier of AAV-2).Referring to for example, Ali etc., " The Use Of DNAViruses as Vectors for Gene Therapy ", Gene Therapy, 1, the 367-84 page or leaf (1994); US 4,797, and 368 and US 5,139,941.
Parenteral administration agent (Parentals)
The example of pharmaceutical composition is the solution that is designed to parenteral administration.Although under many circumstances, the drug solution preparaton can provide to be applicable to the liquid form that uses immediately, and described parenteral route preparaton also can provide with freezing or lyophilized form.Under former instance, described composition must thaw before use.The stability of active ingredient under various storage requirements that back one formulation is generally used in the enhancing composition being comprised, as well known by persons skilled in the art, freeze-dried preparation is more stable than its liquid homologue usually.Described freeze-dried preparation is prepared again by adding one or more suitable pharmaceutically acceptable diluents such as sterile water for injection or stroke-physiological saline solution solution before use.
Under the situation of parenteral administration, they are made into the form of the freeze dried preparaton or the aqueous solution, method is as required, the polypeptide that will have required purity suitably mixes vehicle such as buffer reagent, stablizer, sanitas, isotonic agent, nonionogenic tenside, antioxidant and/or other various additives with pharmaceutically acceptable carrier, vehicle or the stablizer (being referred to as " vehicle ") that one or more this areas are used always.
Buffer reagent helps pH is maintained in the scope near physiological condition.They exist with the concentration range of about 2mM-50mM usually.The suitable buffer reagent that the present invention uses comprises organic and mineral acid and salt thereof such as citrate buffer agent (as, sodium dihydrogen citrate-disodium citrate mixture, citric acid-trisodium citrate mixture, citric acid-sodium dihydrogen citrate mixture etc.), the succinate buffer reagent (as, succsinic acid-succsinic acid one sodium mixture, succsinic acid-sodium hydroxide mixture, succsinic acid-disodium succinate mixture etc.), the tartrate buffer reagent (as, tartrate-sodium tartrate mixture, tartrate-soluble tartrate mixture, tartrate-sodium hydroxide mixture etc.), the fumarate buffer reagent (as, fumaric acid-fumaric acid one sodium mixture, fumaric acid-Disodium fumarate mixture, fumaric acid one sodium-Disodium fumarate mixture etc.), gluconate (gluconate) buffer reagent (as, gluconic acid-Sunmorl N 60S mixture, gluconic acid-sodium hydroxide mixture, gluconic acid-Potassium Gluconate mixture etc.), the oxalate buffer reagent (as, oxalic acid-sodium oxalate mixture, oxalic acid-sodium hydroxide mixture, oxalic acid-potassium oxalate mixture etc.), lactate buffer agent (as, lactic acid-Sodium.alpha.-hydroxypropionate mixture, lactic acid-sodium hydroxide mixture, lactic acid-potassium lactate mixture etc.) and acetate buffer (as, acetate-sodium acetate mixture, acetate-sodium hydroxide mixture etc.).Other possible buffer reagent is phosphate buffer, histidine buffer and front three amine salt such as Tris.
Can add sanitas and block microorganism growth, the amount of adding is about 0.2%-1% (w/v) usually.The suitable preservatives that the present invention uses comprises phenol, phenylcarbinol, meta-cresol, oxybenzene formic acid (paraben) methyl esters, propylparaben, octadecyl dimethyl benzene ammonio methacrylate, Ben Yajiaji halogenide (as Ben Yajiaji muriate, bromide or iodide), chlorination hexane diamine, oxybenzene alkyl formate such as methyl esters or propyl ester, catechol, Resorcinol, hexalin and 3-amylalcohol.
Can add isotonic agent and guarantee the isotonicity of liquid composition, isotonic agent comprises polyhydric sugar-alcohol, and preferred three hydroxyls or more senior sugar alcohol are as glycerine, tetrahydroxybutane, arabitol, Xylitol, Sorbitol Powder and mannitol.The amount of polyhydroxy-alcohol can be the 0.1%-25% weight ratio, is generally 1%-5%, with the amount calculating of other component relatively.
Stablizer relates to a big class vehicle, its envelop of function from swelling agent to the dissolution treatment agent or help to prevent sex change or with the adherent additive of wall of container.Common stablizer can be polyhydric sugar-alcohol (above enumerating); Amino acid such as arginine, Methionin, glycine, glutamine, l-asparagine, Histidine, L-Ala, omithine, L-leucine, 2-phenylalanine, L-glutamic acid, Threonine etc., organic sugar or sugar alcohol, as lactose, trehalose, stachyose, mannitol, Sorbitol Powder, Xylitol, ribitol, inositol, melampyrum, glycerine etc., comprise cyclic alcohol such as nucite; Polyoxyethylene glycol; Aminoacid polymers; The sulfur-bearing reductive agent, as urea, gsh, Thioctic Acid, Thioglycolic acid sodium salt, thioglycerin, α-single thioglycerin and Sulfothiorine; Low molecular weight polypeptide (residue promptly＜10); Protein such as human serum albumin, bovine serum albumin, gelatin or immunoglobulin (Ig); Hydrophilic polymer such as polyvinylpyrrolidone; Monose such as wood sugar, seminose, fructose and glucose; Disaccharides such as lactose, maltose and sucrose; Trisaccharide such as raffinose and polysaccharide such as dextran.Calculate based on active protein weight, the scope that exists that stablizer is common is the 0.1-10000 weight part.
Can exist nonionogenic tenside or stain remover (being also referred to as " wetting agent ") to assemble to avoid stirring inductive to help dissolution treatment agent and protection therapeutical peptide, it also allows preparaton to be exposed to shear surface pressure and does not cause the polypeptide sex change.Suitable ionic surfactant pack is drawn together polysorbate (polysorbate) (20,80 etc.), polyoxamer (184,188 etc.), Pluronic  polyvalent alcohol, polyoxyethylene sorbitan monoether (Tween  20, Tween  80 etc.).
Other various vehicle comprise swelling agent or weighting agent (as starch), sequestrant (as EDTA), antioxidant (as xitix, methionine(Met), vitamin-E) and cosolvent.
Active ingredient also can be wrapped in by, coascervation technology or for example by the prepared micro-capsule of interfacial polymerization, in Walocel MT 20.000PV, gelatin or poly--(methyl methacrylate) micro-capsule, be wrapped in the colloidal medicine and transport in the system (for example liposome, albumin microsphere, micro emulsion, nano particle and Nano capsule), or be wrapped in the big emulsion.These technology are disclosed in Remington ' s Pharmaceutical Sciences (the same).
The employed non-gastrointestinal preparation of vivo medicine-feeding must be aseptic.This process can be passed through, for example, and the filtration of degerming filter membrane and finishing easily.
In a preferred embodiment of the present invention, described pharmaceutical composition comprises i) IFNG variant of the present invention, ii) buffer reagent, especially organic acid salt, it can will stablize pH at 5.0-6.5, iii) stablizer, especially organic sugar or sugar alcohol, iv) nonionogenic tenside and v) sterilized water.More specifically, buffer reagent is selected from acetate, succinate, and Citrate trianion; Stablizer is N.F,USP MANNITOL or sorbyl alcohol, and nonionogenic tenside is Tween -20 or Tween -80.Preferred pharmaceutical compositions does not comprise any sanitas.
Extended release preparation
The suitable example of extended release preparation comprise the solid hydrophobic polymkeric substance that contains polypeptide or conjugate semi-permeable matrix, have the matrix of suitable form such as film or micro-capsule.The example that continues release matrix comprises polyester, hydrogel (for example, poly-(2-hydroxyethyl methyl acrylate) or poly-(vinyl alcohol)), polylactide, L-L-glutamic acid and the multipolymer of L-ethyl glutamate, nondegradable ethylene-ethyl acetate, degradable lactic acid-ethanol copolymer such as ProLease  technology or Lupron Depot  (Injectable microspheres that is made of lactic acid-ethanol copolymer and leuprorelin acetate) and poly--D-(-)-3-hydroxybutyric acid.Polymkeric substance such as ethylene-ethyl acetate and lactic acid-ethanol can discharge molecule for a long time as reaching or surpass 100 days, and some hydrogels discharges protein within a short period of time.When the polypeptide in the packing kept in vivo for a long time, they caused loss of bioactivity and may change immunogenicity because of expose sex change or gathering in the environment of 37 ℃ of humidities.Reasonably stable strategy can be according to related mechanism design.For example, if find to assemble mechanism is to exchange mutually by sulfo-disulphide to form intramolecularly S-S key, so can be by modifying sulfydryl, acidic solution freeze-drying, controlling moisture, suitable additive and the exploitation specificity polymer matrix composition of use being reached stable.
Oral medication
For oral medication, pharmaceutical composition can be solid or liquid form, for example, with capsule, tablet, suspension, the form of emulsion or solution.Pharmaceutical composition is preferably with the form preparation of the dose unit that contains the specified rate activeconstituents.Be used for the people or other mammiferous suitable dosage every day can change significantly according to patient's situation and other factors, but those skilled in the art can use ordinary method to measure.
The solid dosage of oral medication can comprise capsule, tablet, suppository, powder and particle.In this solid dosage, active compound can with at least a inert diluent, sucrose for example, lactose or starch mix.This formulation also can comprise, as the substance in the normal practice, and for example lubricant, for example Magnesium Stearate.For capsule, tablet and pill, formulation also can comprise buffer reagent.The also available casing preparation of tablet and pill.
Described variant can with such as lactose, sucrose, starch powder, the cellulose ester of paraffinic acid, stearic acid, talcum, Magnesium Stearate, magnesium oxide, phosphoric acid and vitriolic sodium and calcium salt, gum arabic, gelatin, sodiun alginate, polyethylene-tetramethyleneimine, and/or the adjuvant of polyvinyl alcohol mixes, and makes tablet or be bundled into capsule and be used for routine administration.As selection, they dissolve in salt solution, water, and polyoxyethylene glycol, propylene glycol, ethanol, oils (for example Semen Maydis oil, peanut oil, oleum gossypii seminis or sesame oil), tragacanth, and/or in the various damping fluid.Other adjuvant and application method are that pharmacy field is known.Carrier or thinner can comprise the time lag material, for example separately or with the Zerol or the Stearic diglyceride of wax, other material perhaps well known in the art.
Can carry out can containing conventional adjuvant to pharmaceutical composition such as the conventional pharmaceutical operations and/or the pharmaceutical composition of sterilization, sanitas for example, stablizer, wetting agent, emulsifying agent, damping fluid, weighting material, etc., for example, as described in this paper other places.
The liquid dosage form of oral medication can comprise pharmaceutical acceptable emulsion, solution, suspension, syrup and the elixir that contains such as this area of water inert diluent commonly used.But said composition is adjuvant also, for example wetting agent, sweeting agent, seasonings and flavouring agent.
Local application
The preparaton that is applicable to local application comprises liquid state or the semi liquid state preparation (for example, liniment, lotion, ointment, emulsifiable paste, or paste) that is suitable for transdermal and is suitable for eye, the drops of ear or nasal administration.
Pulmonary delivery
Be suitable for generally comprising water-soluble polypeptide variants with the preparaton that sprays or ultrasonic nebulizer uses, its concentration is that for example every mL solution about 0.01 arrives the 25mg variant, preferably approximately 0.1 to 10mg/mL.Preparaton also can comprise buffer reagent and simple carbohydrate (for example, be used for protein stabilization and osmotic pressure and regulate), and/or concentration range is from 0.1 to 10mg/ml human serum albumin.The example of spendable buffer reagent is a sodium acetate, Citrate trianion and glycine.Preferred reducing has and is suitable for solution is transferred to moiety and the volumetric molar concentration that pH is 3 to 9 scopes.In general, the buffer reagent volumetric molar concentration from 1mM to 50mM is suitable for this purpose.The example of spendable carbohydrate is a lactose, maltose, and mannitol, Sorbitol Powder, trehalose, and wood sugar, common content range are 1% to 10% of preparaton weight.
Spray formulations also can contain tensio-active agent to reduce or to prevent when forming aerosol the protein aggregation of the spatial induction that the atomizing by solution causes.Can use various conventional surfactants, for example polyoxyethylene fatty acid esters and alcohol, polyoxyethylene sorbitan aliphatic ester.Its content range be generally preparaton weight 0.001% and 4% between.The particularly preferred tensio-active agent that is used for the object of the invention is a polyoxyethylene sorbitanic monoleate.
The method of concrete preparaton and the suitable dispersive of generation liquid particle of the present invention is at WO94/20069, and US 5,915,378, and US 5,960,792, US 5,957,124, US 5,934, and 272, US 5,915,378, and US 5,855,564, US 5,826,570 and US 5,522,385 in describe, be hereby incorporated by reference.
The preparaton that uses with the inhaler device that has dose calibration generally comprises the powder of meticulous differentiation.This powder can and grind liquid conjugate preparaton then by freeze-drying and produce and also can contain stablizer, for example human serum albumin (HSA).In general, add the HAS that surpasses 0.5% (w/w).In addition, can in preparation, add one or more sugar or sugar alcohol if desired.Its example comprises lactose, maltose, mannitol, Sorbitol Powder, sorbose, trehalose, Xylitol, and wood sugar.The scope of the amount of this conjugate in the adding preparaton is from about 0.01 to 200% (w/w), preferably from about 1 to 50%.This preparaton of freeze-drying and grind into required granular size then.
Particle with suitable size is suspended in the propelling agent by means of tensio-active agent then.Propelling agent can be any conventional material that is used for this purpose, Chlorofluorocarbons for example, and hydrochlorofluorocarazeotropic, hydrogen fluorine carbon, or hydrocarbon polymer comprise trichlorofluoromethane, Refrigerant 12, dichloro-tetrafluoro ethanol and 1,1,1,2-Tetrafluoroethane, or its combination.Suitable tensio-active agent comprises sorbitanic trioleate and soybean lecithin.Oleic acid is useful as surfactants also.Then this mixture is packed in the delivery apparatus.The sucker example that is applicable to commercially available mensuration dosage of the present invention is by Glaxo Inc., Research Triangle Park, and the Ventolin that N.C produces measures the sucker of dosage.
The preparaton that is used for powder inhalator comprises the dry powder of the meticulous differentiation that contains conjugate and also can comprise swelling agent, lactose for example, Sorbitol Powder, sucrose, or mannitol, its content can help powder to scatter from device, for example, account for 50% to 90% of preparaton weight.Particles of powder should have air dynamic behaviour in lung, corresponding to having about 1g/cm 2The particle of density has the mean diameter less than 10 microns, preferably between 0.5 and 5 micron, most preferably between 1.5 and 3.5 microns.Example according to the suitable powder inhalator of the instruction of this paper is by Fisons Corp., Bedford, the Spinhaler powder inhalator that Mass produces.
With US 5,997,848, US 5,993,783, and US 5,985,248, and US 5,976574, and US 5,922,354, and US 5,785,049 and US 5,654,007 disclosed method can produce and/or send these the device in powder.
The mechanism that is designed for the pulmonary delivery of treatment product includes but not limited to atomizer, measures the sucker of dosage, and powder inhalator, and all these is appreciated by those skilled in the art.The object lesson that is applicable to the commercially available device that the present invention puts into practice is by Mallinckrodt, Inc., St.Louis, the Ultravent atomizer that Missouri produces; By Marquest Medical Products, Englewood, the Acorn II atomizer that Colorado produces; By Glaxo Inc., Research TrianglePark, the Ventolin that North Carolina produces measures the sucker of dosage; By Fisons Corp., Bedford, the Spinhaler powder inhalator that Massachusetts produces; Inhale TherapeuticSystems, Inc., San Carlos, " standing cloud " device of Calfornia; Alkermes, Cambridge, the AIR sucker that Massachusetts produces; With Aradigm Corporation, Hayward, the AERx pulmonary drug delivery system that California produces.
Further describe the present invention among the embodiment below.This embodiment should not be interpreted as the restriction to this specification sheets and claims scope by any way.
Material and method
Material
CHO-K1 cell (available from American type culture collection (ATCC#CCL-61)).
HeLa cell (available from American type culture collection (ATCC#CCL-2)).
ISRE-Luc is available from Stratagene, La Jolla USA.
PCDNA 3.1/hygro is available from Invitrogen, Carlsbad USA.
Restriction enzyme and polysaccharase are available from New England Biolabs Inc., Beverly, USA.
The DMEM substratum: Dulbecco modified form Eagle substratum (DMEM), 10% foetal calf serum and hygromycin B are available from Life Technologies A/S, Copenhagen, Denmark.
The LucLite substrate is available from Packard Bioscience, Groningen, The Netherlands.
The TopCount light-emitting appearance is available from Packard Bioscience, Groningen, The Netherlands.
The biotinylation polyclone is anti--and Ren IFNG antibody BAF285 is available from R; D Systems Inc., Minneapolis, USA.
Horseradish peroxidase type streptavidin P0397 is available from DAKO, Copenhagen, Denmark.
TMB trace reagent is available from KEM-EN-TEC, Copenhagen, Denmark.
Method
Interferon, rabbit test general introduction
Disclosed in the past: the IFNG acceptor interaction on IFNG and the HeLa cell also activates this receptor.Consequently, containing the promotor place activated transcription of IFN-stimulated response element (ISRE).Therefore by in the HeLa cell, using the agonist that can screen Interferon Receptors with luciferase reporter gene link coupled ISRE (ISRE-luc).
Tentative experiment (primary assay)
With ISRE-Luc and pCDNA 3.1/hygro cotransfection HeLa cell, by in containing the DMEM substratum of hygromycin B, selecting to set up transforming focus (cell clone).The luciferase activity of screening cell clone under the condition that has or do not exist IFNG.Demonstrate those the highest clones of luciferase activity ratio that stimulate and do not stimulate and be used for further test.
In order to screen polypeptide variants, in 96 well culture plates, inoculate 15,000 cells/well and incubated overnight in the DMEM substratum.In cell, added polypeptide variants and known standard substance at second day with various concentration.With Actimmune  conduct " known standard substance "; With a bottle Actimmune  DMEM, 5%FBS is diluted to 300IU/ml, be stored in-80 ℃ standby.
Dull and stereotyped at 37 ℃, 5%CO 2Cultivated 6 hours in the atmosphere surrounding.In each hole, add LucLite substrate (Packard Bioscience, Groningen, The Netherlands) subsequently.Seal plate is also measured luminous in SPC (single photon counting) mode in TopCount light-emitting appearance (Packard).
Each flat board contains the contrast as irriate of the hole that is incubated with IFNG, and other holes of containing normal substratum are as stimulating contrast.With the ratio of the luciferase activity that stimulates and do not stimulate as IFNG the inherent standard of error between active and experiment.Calculate unit (unit) number of each part IFNG sample, be expressed as AU with respect to Actimmune  standard substance.
Measure the increase of degree of glycosylation
In various degree glycosylated in order to measure IFNG variant monomer, under standard conditions, carry out the SDSPAGE gel electrophoresis, and be transferred on the nitrocellulose filter.Carry out the Western trace according to standard program, (BAF285 is from R ﹠amp with the anti-people IFNG of biotinylation polyclone antibody; D Systems) as first antibody, the streptavidin (P0397 is from DAKO) of using horseradish peroxidase is used TMB trace reagent (KEM-EN-TEC, Copenhagen, Denmark) dyeing then as second antibody.The monomeric distribution of IFNG variant that degree of glycosylation is different can be determined by the film that range estimation has been colored.
Measure AUCsc
AUCsc is subcutaneous to being measured with rat with the IFNG polypeptide variants of the present invention of equivalent (based on activity) by the form with 200 μ l bolus.
In these experiments, the female Sprag-Dawley rat of using body weight 220-260g.IFNG polypeptide sodium succinate (720mg/l), N.F,USP MANNITOL 40g/l, polysorbat20 (100mg/l), pH6.0 preparation.
Before the subcutaneous administration, get a blood sample, so that guarantee can not detect background IFNG activity from the tail vein.After the administration, in 10min, 20min, 40min, 60min, 120min, 240min, 480min, 720min, 1440min, 1620min, 1920min and 2880min when (also comprising 3600min sometimes) from tail vein blood sampling.The blood sample room temperature is left standstill 20min, it is solidified, the centrifugal 20min of room temperature 5000g makes serum then.Isolate serum then ,-80 ℃ of storages are in order to measuring the IFNG activity with above-mentioned " tentative experiment ".It should be noted that when the number of the unit (unit) in the rat blood serum sample of measuring PK research, with Actimmune  standard substance DMEM, 5%FBS and the dilution of 5% rat blood serum.
Then the quantity of unit in the serum (AU/ml) was mapped to the time (min), calculate AUCsc with GraphPad Prism3.01.
Glycosylation huIFNG and/or Actimmune  are similarly tested, so that the increase of the AUCsc that assessment IFNG polypeptide variants of the present invention is compared with glycosylation huIFNG and/or Actimmune .
The serum half life
The serum half life, is by being measured with rat the IFNG polypeptide variants of the present invention of equivalent (based on activity) is subcutaneous with the form of 200 μ l bolus.
In these experiments, the female Sprag-Dawley rat of using body weight 220-260g.IFNG polypeptide sodium succinate (720mg/l), N.F,USP MANNITOL 40g/l, polysorbat20 (100mg/l), pH6.0 preparation.
Before the subcutaneous administration, get a blood sample, so that guarantee can not detect background IFNG activity from the tail vein.After the administration, in 5min, 10min, 20min, 40min, 60min, 120min, 240min, 480min, 720min, 1440min, 1620min, when 1920min and 2880min from tail vein blood sampling.The blood sample room temperature is left standstill 20min, it is solidified, the centrifugal 20min of room temperature 5000g makes serum then.Isolate serum then ,-80 ℃ of storages are in order to measuring the IFNG activity with above-mentioned " tentative experiment ".It should be noted that when the units in the rat blood serum sample of measuring PK research, with Actimmune  standard substance DMEM, 5%FBS and the dilution of 5% rat blood serum.
Then with the quantity of unit in the serum (AU/ml) to time (min) mapping, calculate the serum half life with WinNonLin Pro3.3.
Glycosylation huIFNG and/or Actimmune  are similarly tested, so that the increase of the serum half life that assessment IFNG polypeptide variants of the present invention is compared with glycosylation huIFNG and/or Actimmune .
Be exposed to the evaluation of the amino-acid residue on surface
Structure
Utilize the experimental 3D structure of the huIFNG that the X-radiocrystallography measures to see Ealick etc., the report of Science 252:698-702 (1991) has wherein been pointed out the C-α track (trace) of IFNG homodimer.Walter etc., Nature 376:230-235 (1995) have reported the structure with two solubility IFNG acceptor molecule compound IFNG homodimers.The coordinate of this structure is from unexposed mistake.Thiel etc., Structure 8:927-936 (2000) have reported and the structure of two solubility IFNG acceptor molecule compound IFNG homodimers that the 3rd acceptor molecule do not interact with the IFNG homodimer in this structure.
Come-at-able surf zone (ASA)
Calculate the come-at-able surf zone (ASA) of each atom in this structure with computer program Access (B.Lee and F.M.Richards, J.Mol.Biol.55:379-400 (1971)) version 2 (Copyright (c) 1983 Yale University).This method is generally used the probe size of 1.4 , and come-at-able surf zone (ASA) is defined as the zone that is formed by probe core.Before the calculating, from system of coordinates (coordinateset), remove all water moleculess not directly related, hydrogen atom and other atom with this protein.
The ASA of the branch of side chain (fractional)
On behalf of the ASA value of the side chain atom of this residue type, the ASA of branch of side chain atom by calculate in the ALA-x-ALA tripeptides of ASA summation divided by extension with atom in the side chain.Referring to Hubbard, Campbell ﹠amp; Thornton (1991) J.Mol.Biol.:220,507-530.In this example, the CA atom is considered as glycine residue but not the part of the side chain of other residue.Following train value is used as the standard 100%ASA of side chain:
Ala??????69.23??????????Leu????140.76????
Arg??????200.35??? 2?????Lys????162.50???? 2
Asn??????106.25??? 2?????Met????156.08???? 2
Asp??????102.06??? 2?????Phe????163.90???? 2
Cys??????96.69???? 2?????Pro????119.65???? 2
Gln??????140.58??? 2?????Ser????78.16????? 2
Glu??????134.61??? 2?????Thr????101.67???? 2
Gly??????32.28???? 2?????Trp????210.89???? 2
His??????147.00??? 2?????Tyr????176.61???? 2
Ile??????137.91??? 2?????Val????114.14???? 2
The residue that does not detect in this structure is defined as 100% and exposes, because can think that these residues are positioned at Hookean region.
Measure interatomic distance:
Interatomic distance is used molecular modeling software, for example InsightII v.98.0, MSI INC measures.
Measure receptor binding site:
Receptor binding site is defined as all following residues, and they can change their come-at-able surf zone by receptors bind.This calculates by at least two kinds of ASA and measures: on the part of a kind of separation at the ligand/receptor mixture (isolated), a kind of on complete ligand/receptor mixture.
Embodiment
Embodiment 1-determines to be exposed to the amino-acid residue on surface
Used X-line structure is IFNG homodimer and two molecule solubility IFNG acceptor compound structures, in this structure, do not have and interactional the 3rd IFNG acceptor molecule takes place, referring to Thiel et.al.Structure 8:927-936 (2000) with the IFNG homodimer.Described structure is made up of such IFNG homodimer, two molecule yong A wherein and B mark.In order to make up, another methionine(Met) is placed by before the IFNG sequence of M0 mark, and at terminal 10 residues of brachymemma (in the constructed molecule, Q133 is last residue) of the C-of this sequence.In all calculating of present embodiment, M0 is removed from this structure.The structure of two IFNG monomers after residue 120 has extremely weak electron density, carries out residue is carried out modeling (modeled), until residue T126.Therefore, before the calculating of carrying out present embodiment, residue S121-T126 removes from this structure.Two receptor fragments that indicate C and D directly act on the IFNG homodimer, and the 3rd acceptor molecule that indicates E do not contact with the IFNG homodimer, also are not included in these calculating.
The surface exposes:
The homodimer of the molecule A that do not contain M0 and S121-T126 and B is carried out the ASA of branch calculate, result's following residue at least one monomer has and surpasses 25% side chain and be exposed to the surface: Q1, D2, P3, K6, E9, N10, K12, K13, Y14, N16, G18, H19, S20, D21, A23, D24, N25, G26, T27, G31, K34, N35, K37, E38, E39, S40, K55, K58, N59, K61, D62, D63, Q64, S65, Q67, K68, E71, T72, K74, E75, N78, V79, K80, N83, S84, N85, K86, K87, D90, E93, K94, N97, S99, T101, D102, L103, N104, H111, Q115, A118 and E119.
Following residue has the side chain above 50% to be exposed to the surface at least one monomer: Q1, D2, P3, K6, E9, N10, K13, N16, G18, H19, S20, D21, A23, D24, N25, G26, T27, G31, K34, K37, E38, E39, K55, K58, N59, D62, Q64, S65, K68, E71, E75, N83, S84, K86, K87, K94, N97, S99, T101, D102, L103, N104, Q115, A118, E119.
Homodimer to molecule A and B (do not contain M0 and S121-T126 and comprise acceptor molecule C and D) carries out the ASA of branch calculating, and result's following residue at least one monomer has the side chain above 25% to be exposed to the surface: Q1, D2, P3, K6, E9, N10, K13, Y14, N16, G18, H19, D21, N25, G26, G31, K34, N35, K37, E38, E39, S40, K55, K58, N59, K61, D62, D63, Q64, S65, Q67, K68, E71, T72, K74, E75, N78, V79, K80, N83, S84, N85, K86, K87, D90, E93, K94, N97, S99, T101, D102, L103, N104, E119.
Following residue has the side chain above 50% to be exposed to the surface at least one monomer: P3, K6, N10, K13, N16, D21, N25, G26, G31, K34, K37, E38, E39, K55, K58, N59, D62, Q64, S65, K68, E71, E75, N83, S84, K86, K87, K94, N97, S99, T101, D102, L103 and N104.
All above-mentioned positions all be the present invention modify at target.
Relatively this two row residue is found, by receptors bind, has removed K12, S20 from the described ASA that surpasses 25% side chain is listed as, A23, D24, T27, H111, Q115 and A118 have removed Q1, D2 from the described ASA that surpasses 50% side chain is listed as, E9, G18, H19, S20, A23, D24, T27, Q115, A118 and E119.
Undeterminate residue in this structure, i.e. residue S121, P122, A123, A124, K125, T126, G127, K128, R129, K130, R131, S132, Q133, M134, L135, F136, R137, G138, R139, R140, A141, S142, Q143 handles by being exposed to the surface fully.Different targets when these residues are also formed the present invention and introduced linking group (perhaps it can be considered as belonging to the amino-acid residue that is exposed to the surface, for example have surpass 25% or surpass 50% exposure side chain).
Embodiment 2-determines receptor binding site:
Calculate discovery by the above-mentioned ASA that carries out, at least one monomer of above-mentioned mixture, the following residue of IFNG molecule is compared the ASA:Q1 with minimizing, D2, Y4 with the calculation result on isolating dimer, V5, E9, K12, G18, H19, S20, D21, V22, A23, D24, N25, G26, T27, L30, K34, K37, K108, H111, E112, I114, Q115, A118, E119.
Embodiment 3-design can be to express the expression cassette of IFNG through the codon usage pattern of optimizing
The GenBank accession number is the full-length cDNA that the dna sequence dna of X13274 comprises encoding mature huIFNG and natural signals peptide thereof, this dna sequence dna is modified so that help efficiently express in Chinese hamster ovary celI.Codon to the huIFNG nucleotide sequence is modified, and method is to make the application of codon be partial to the codon that is usually used in people (homo sapiens).Some Nucleotide in this sequence replaces so that introduce the recognition site of DNA restriction endonuclease with other Nucleotide subsequently.The design primer is so that synthetic this gene.
By a step PCR primer is assembled into synthetic gene, wherein uses Platinum Pfx-polymerase kit (Life Technologies) and three step of standard PCR loop parameter.Gene through assembling increases by the PCR that uses the same terms, and it has the sequence shown in the SEQ ID NO:42.The synthetic gene clone is advanced between the BamHI and XbaI site of pcDNA3.1/hygro (In Vitrogen), obtain pIGY-22.
Utilize Lipofectaim2000 (Life Technologies) as transfection reagent with the pIGY-22 transfection to CHO K1 cell.Gather in the crops substratum after 24 hours, with elisa assay IFNG activity and concentration.Recording activity with above-mentioned tentative experiment is 1.4 * 10 7AU/ml.
Embodiment 4-site-directed mutagenesis
Preparation glycosylation variant
Introduce among the IFNG in order to suddenly change, design oligonucleotides is so that can will be introduced in the expression plasmid (pIGY-22) by the change that PCR produces by traditional two-step pcr method.
Use two kinds of carrier primers and specific mutant primer:
ADJ013:5 '-GATGGCTGGCAACTAGAAG-3 ' (antisense downstream carrier primer) (SEQID NO:43) and ADJ014:5 '-TGTACGGTGGGAGGTCTAT-3 ' (SEQ ID NO:44) (just upstream carrier primer).
The S99T variant is by traditional two-step pcr method preparation, it is the carrier primer with ADJ013 and ADJ014, be mutant primer, and be template with ADJ093 (5 '-GTTCAGGTCTGTCACGGTGTAATTGGTCAGCTT-3 ') (SEQ ID NO:45) and ADJ094 (5 '-AAGCTGACCAATTACACCGTGACAGACCTGAAC-3 ') (SEQ ID NO:46) with pIGY-22.With BamHI and Xbal with the PCR product subclone of 447bp to pcDNA3.1/Hygro (In Vitrogen), obtain plasmid pIGY-48.
With Lipofectaim2000 (Life Technologies) as transfection reagent, with the pIGY-48 transfection to CHO K1 cell.Gather in the crops substratum after 24 hours, analyze the IFNG activity.Measure following activity by tentative experiment described herein: 5.1 * 10 6AU/ml.
The E38N+S40T+S99T variant is by traditional two-step pcr method preparation, it is the carrier primer with ADJ013 and ADJ014, be mutant primer, and be template with ADJ091 (5 '-CATGATCTTCCGATCGGTCTCGTTCTTCCAATT-3 ') (SEQ ID NO:47) and ADJ092 (5 '-AATTGGAAGAACGAGACC GATCGGAAGATCATG-3 ') (SEQ ID NO:48) with pIGY-48.With BamHI and Xbal with the PCR product subclone of 447bp to pcDNA3.1/Hygro (In Vitrogen), obtain plasmid pIGY-54.
With Lipofectaim2000 (Life Technologies) as transfection reagent, with the pIGY-54 transfection to CHO K1 cell.Gather in the crops substratum after 24 hours, analyze the IFNG activity.Measure following activity by tentative experiment described herein: 1.3 * 10 7AU/ml.
Prepare multiple total length IFNG glycosylation variant with being similar to above-mentioned standard technique.These variants are compiled in the following table 1.
The IFNG variant of the terminal brachymemma of preparation C-
There is the terminal truncation type IFNG of a kind of C-variant that a terminator codon is arranged in the downstream of the codon that is right after Leu135, it is prepared as follows: with pIGY-22, pIGY-48 and pIGY-54 be template carry out one the step PCR, use then BamHI and XbaI with PCR product subclone to pcDNA3.1/Hygro (In VItrogen).The primer that is used to make up these variants is: ADJ014 (seeing above the upstream) and 5 '-GAGTCTAGATTACAGCATCTGGCTTCTCTT-3 ' (SEQ ID NO:49) (downstream).The gained plasmid is called pIGY-72 (part of wild-type IFNG after Leu135 cut out), pIGY-73 (part of S99T variant after Leu135 cut out) and pIGY-74 (part of E38N+S40T+S99T after Leu35 cut out).
Preparation contains the IFNG variant of halfcystine
The IFNG variant that contains cysteine residues is prepared according to producer's explanation with Stratagene ' s QuikChange ' XL site-directed mutagenesis test kit.Obtain 7 kinds of IFNG variants with pIGY-48 as template, every kind of halfcystine that comprises an introducing: N10C+S99T, N16C+S99T, E38C+S99T, N59C+S99T, N83C+S99T, K94C+S99T and S99T+N104C.Similarly, obtain 6 kinds of IFNG variants with pIGY-54 as template, the every kind of halfcystine that comprises an introducing: N10C+E38N+S40T+S99T, N16C+E38N+S40T+S99T, E38N+S40T+N59C+S99T, E38N+S40T+N83C+S99T, E38N+S40T+K94C+S99T and E38N+S40T+S99T+N104C.
Embodiment 5-contains the PEGization of the variant of halfcystine
The deionization before use of all damping fluids.Protein concentration is assessed by measuring A280.
Utilize OPSS coupling chemistry carry out PEGization
With the IFNG variant N16C+S99T (total length) of 1.3mg/ml at the 5mM sodium succinate, 4% N.F,USP MANNITOL, 0.01%Tween 20, the solution 7.2ml among the pH6.0 with 300 μ l 0.5M DTT incubated at room 30 minutes, makes its reduction.Make the desalination of IFNG variant, method is that (50mM sodium phosphate, 1mM EDTA pH8.1) load NAP25 gel-filtration column (Pharmacia) with buffer A with 3 2.5ml equal portions.Each equal portions wash-out is 3.5ml.
With mPEG-OPSS (10KDa) be dissolved in the buffer A to concentration be 2mg/ml, it is added in the IFNG variant of reduction and desalination with equivalent, hatch 60min in the gentle vibration of room temperature.
With 11ml reaction mixture Vivaspin20 post (VivaScience) simmer down to 1-6ml, remaining mPEG is with removing through gel-filtration through buffer A equilibrated Sephacryl S-100 post (Pharmacia).
Use Vivaspin 6 posts (VivaScience) at the 5mM sodium succinate PEGization IFNG variant, 4% N.F,USP MANNITOL, 0.01%Tween 20, diafiltration among the pH6.0.The PEGization IFNG variant specific activity of purifying is 1.3 * 10 6AU/mg, as the tentative experiment of this paper survey (for corresponding not PEGization IFNG variant specific activity 15%).
Utilize MAL coupling chemistry carry out PEGization
With the IFNG variant N59C+S99T (total length) of 1.5mg/ml at the 5mM sodium succinate, 4% N.F,USP MANNITOL, 0.01%Tween 20, the solution 1.6ml among the pH6.0 with 64 μ l 0.5M DTT incubated at room 30 minutes, makes its reduction.(50mM sodium phosphate, 1mM EDTA pH8.1) make the desalination of IFNG variant on NAP25 gel-filtration column (Pharmacia) with buffer A.Each equal portions wash-out is 3.5ml.
With mPEG-MAL (5kDa) be dissolved in the buffer A to concentration be 0.5mg/ml, it is added in the IFNG variant of reduction and desalination with equivalent, hatch 120min in the gentle vibration of room temperature.
Adding ammonium sulfate to concentration is 0.9M, this PEGization IFNG variant is loaded on uses buffer B (the 20mM sodium phosphate, 0.9M ammonium sulfate is pH6.6) on the equilibrated 1ml Resource phenyl post (Pharmacia).Buffer B with 5 column volumes is washed post, and (the 20mM sodium phosphate is pH6.6) with 30 PEGization IFNG variants that the column volume wash-out is combined to use the damping fluid C of 0-50% linear gradient then.PEGization IFNG variant about 0.6M ammonium sulfate by wash-out.
The fraction that will contain PEGization IFNG variant gathers, at the 5mM sodium succinate, and 4% N.F,USP MANNITOL, 0.01%Tween 20, carry out diafiltration with Vivaspin20 post (VivaScience) among the pH6.0.The specific activity of the PEGization IFNG variant behind the purifying is 2.4 * 10 6AU/mg, as the tentative experiment of this paper survey (for corresponding not PEGization IFNG variant specific activity 15%).
Embodiment 6-IFNG and the expression of IFNG variant in mammalian cell
For transient expression IFNG, cell grows to 95% and is paved with in substratum, described substratum is Dulbecco ' s MEM/Nut.-mix F-12 (Ham) L-glutaminate, 15mM Hepes, pyridoxol-HCl (Life Technologies catalog number (Cat.No.) 31330-038) wherein contains 1: 10 foetal calf serum (Bio Whittaker catalog number (Cat.No.) 02-701F), 1: 100 penicillin and Streptomycin sulphate (Bio Whittaker catalog number (Cat.No.) 17-602E).The plasmid of coding IFNG is illustrated that according to producer transfection is to cell with Lipofectaim2000 (Life Technologies).Gather in the crops substratum after 24 hours, analyze the IFNG activity.In addition, for the relative populations of the quantitative glycosylation site that utilizes, carry out the Western trace with the substratum of gathering in the crops.
The stable clone of expressing IFNG is prepared as follows: with the plasmid transfection CHO K1 cell of coding IFNG, then these cells are hatched in the substratum that contains the 0.36mg/ml Totomycin.Isolate the cell of stable transfection, carry out subclone with limiting dilution assay.The clone who produces high-level IFNG identifies by ELISA.
Embodiment 7-mass preparation
The stabilized cell of expressing IFNG or variant is tied up to 1700cm 2Roll bottle (Corning, be cultured in the substratum #431200) and be paved with, described substratum is Dulbecco ' s MEM/Nut.-mix F-12 (Ham) L-glutaminate, 15mM Hepes, pyridoxol-HCl (Life Technologies catalog number (Cat.No.) 31330-038) wherein contains 1: 10 foetal calf serum (Bio Whittaker catalog number (Cat.No.) 02-701F), 1: 100 penicillin and Streptomycin sulphate (Bio Whittaker catalog number (Cat.No.) 17-602E).Then substratum is changed into the 300ml UltraCHO (Bio Whittaker catalog number (Cat.No.) 12-724Q) that contains L-glutaminate, and to wherein adding 1: 500 EX-CYTE VLE (Serological Proteins Inc.#81-129), 1: 100 penicillin and Streptomycin sulphate (Bio Whittaker catalog number (Cat.No.) 17-602E).Cultivate after 48 hours, substratum is changed into the fresh UltraCHO that contains identical additive.After cultivating 48 hours again, change substratum into Dulbecco ' s MEM/Nut.-mix F-12 (Ham) L-glutaminate, pyridoxol-HCl (LifeTechnologies catalog number (Cat.No.) 21041-025), wherein add 1: 100 ITS-A (Gibco/BRL#51300-044), the penicillin and the Streptomycin sulphate (Bio Whittaker catalog number (Cat.No.) 17-602E) of 1: 500 EX-CYTE VLE (Serological Proteins Inc.#81-129) and 1: 100.Gathered in the crops substratum every 24 hours then, and replace fresh serum free medium with identical additive.The substratum of collecting is filtered 0.22 μ m filter membrane so that remove cell.
Embodiment 8-purifying
Filtrate is through micro-filtration (0.22 μ m), then with the ultrafiltration of Millipore TFF system to being about 1/15 volume.In same system, with this enriched material 10mM Tris, pH7.6 carries out diafiltration.Adding ammonium sulfate to concentration is 1.7M, after the stirring, by precipitation being removed with centrifugal 25 minutes of 8000rpm with the GS3 rotor in the Sorvall whizzer.
Supernatant is loaded on uses 10mM Tris, 1.7M ammonium sulfate is in pH7.6 equilibrated 25mlPhenyl High Performance (Pharmacia) post.Use the 10mM Tris of 3 column volumes then, 1.7M sodium sulfate, pH7.6 washes post, uses through 10 column volume gradual changes to 100%10mM Tris the IFNG variant that the linear gradient elution of pH7.6 is combined again.Make the IFNG variant fractional separation of effluent and wash-out.The fraction that is rich in the IFNG variant is gathered, by at 10mM Tris, be worth 10 with Vivaflow200 system (VivaScience) with molecular cut-off among the pH9.0,000Da carries out diafiltration and exchange buffering liquid.
Then the IFNG variant is loaded on and uses 10mM Tris, in pH9.0 equilibrated 18mlQ-sepharose Fast Flow (Pharmacia) post.Use the 10mM Tris of 3 column volumes then, pH9.0 washes post, uses through the 10mM Tris of 15 column volumes by 0% to 100% linear gradient, 0.5MNaCl, the IFNG variant that the pH9.0 wash-out is combined again.Make the IFNG variant fractional separation of effluent and wash-out.The fraction that is rich in the IFNG variant is gathered, by at the 10mM sodium phosphate, be worth 10 with VivaSpin20 post (VivaScience) with molecular cut-off among the pH7.0,000Da carries out diafiltration and exchange buffering liquid.
Then the IFNG variant is loaded on and uses the 10mM sodium phosphate, in the pH7.0 equilibrated 8ml CHT pottery hydroxyapatite column (Biorad).Use the 10mM sodium phosphate of 5 column volumes then, pH7.0 washes post, uses through the 500mM sodium phosphate of 30 column volumes by 0% to 60% linear gradient, the IFNG variant that the pH7.0 wash-out is combined again.Make the IFNG variant fractional separation of effluent and wash-out.The fraction that is rich in the IFNG variant is gathered, with the VivaSpin20 post (VivaScience) at the 5mM sodium succinate, 4% N.F,USP MANNITOL, exchange buffering liquid among the pH6.0, add subsequently Tween 20 to concentration be 0.01%.With this IFNG variant filtration sterilization, be kept at-80 ℃.
Also can carry out purifying to the IFNG variant according to following purification scheme:
Filtrate uses the ultrafiltration of Millipore TFF system to about 1/15 volume through micro-filtration (0.22 μ m) then.In same system, with this enriched material 10mM Tris, pH7.6 carries out diafiltration, then pH is transferred to 9.0, and will precipitate by micro-and remove by filter.
Sample is loaded on uses 10mM Tris, in pH9.0 equilibrated Q-sepharose Fast Flow (Pharmacia) post.Use the 10mM Tris of 3 column volumes then, pH9.0 washes post, uses through the 10mM Tris of 15 column volumes by 0% to 100% linear gradient, 0.5M NaCl, the IFNG variant that the pH9.0 wash-out is combined again.Make the IFNG variant fractional separation of effluent and wash-out.The fraction that is rich in the IFNG variant is gathered, pH is transferred to 7.6.Add ammonium sulfate to 1.5M, after the stirring, by the centrifugal precipitation of removing.
Then the IFNG variant is loaded on and uses 10mM Tris, 1.5M ammonium sulfate is in pH7.6 equilibrated Phenyl Sepharose High Performance (Pharmacia) post.Use the 10mM Tris of 3 column volumes then, 1.5M ammonium sulfate, pH7.6 washes post, uses the 10mM Tris through 10 column volume gradual changes to 100% again, the IFNG variant that the pH7.6 linear gradient elution is combined.Make the IFNG variant fractional separation of effluent and wash-out.The fraction that is rich in the IFNG variant is gathered, and ammonium sulfate is adjusted to 1.7M.
Then the IFNG variant is loaded on and uses the 10mM sodium phosphate, 1.7M ammonium sulfate is in the pH7.6 equilibrated Butyl Sepharose post.Use the 10mM sodium phosphate then, 1.7M ammonium sulfate, pH7.6 washes post, uses the 10mM sodium phosphate again, the IFNG variant that the pH6.5 wash-out is combined.Make the IFNG variant fractional separation of effluent and wash-out.
The fraction that is rich in the IFNG variant is gathered, be loaded on and use the 10mM sodium phosphate, in the pH6.5 equilibrated hydroxyapatite column.With the 10mM sodium phosphate of 5 column volumes, pH6.5 washes post, uses through 30 column volumes by 0% to 100% 500mM sodium phosphate, the IFNG variant that the pH6.5 linear gradient elution is combined again.Make the IFNG variant fractional separation of effluent and wash-out.
The fraction that will contain the IFNG variant gathers, with buffer exchange for containing the 5mM sodium succinate, 4% N.F,USP MANNITOL, the damping fluid of pH6.0.Add subsequently Tween 20 to concentration be 0.01%.With this IFNG variant filtration sterilization, be kept at-80 ℃.
The activity of embodiment 9-variant and PEGization variant
Measure following activity data (behind the transient transfection) with above-mentioned " preliminary experiment ":
Active in the active % of total length wt
Sudden change
(AU/ml)
Wild-type (total length) 1.4 * 10 7-
S99T (total length) 5.1 * 10 636%
E38N (total length) 1.4 * 10 7100%
E38N+S40T (total length) 9.9 * 10 671%
E38N+S40T+S99T (total length) 1.3 * 10 793%
E38N+K61T (total length) 1.2 * 10 786%
E38N+K61T+S99T (total length) 1.4 * 10 610%
N10C+S99T (total length) 2.5 * 10 618%
N16C+S99T (total length) 1.1 * 10 779%
E38C+S99T (total length) 1.0 * 10 771%
S99T+N104C (total length) 5.0 * 10 636%
N10C+E38N+S40T+S99T (total length) 1.5 * 10 611%
N16C+E38N+S40T+S99T (total length) 3.7 * 10 626%
E38N+S40T+N59C+S99T (total length) 1.1 * 10 779%
E38N+S40T+N83C+S99T (total length) 7.2 * 10 55%
E38N+S40T+K94C+S99T (total length) 9.4 * 10 57%
E38N+S40T+S99T+N104C (total length) 2.3 * 10 616%
Wild-type (truncation type) 6.3 * 10 645%
S99T (truncation type) 3.5 * 10 625%
E38N+S40T+S99T (truncation type) 4.0 * 10 629%
Table 1: the activity behind full-length and the truncation type rhuIFNG polypeptide variants transient transfection
Measure following activity data (behind the purifying) with above-mentioned " preliminary experiment ":
Wt is active for the specific activity total length
Sudden change
(AU/mg)??????????????????％
Wild-type (total length) 2.1 * 10 7-
S99T (total length) 2.2 * 10 7105%
E38N+S40T+S99T (total length) 1.4 * 10 767%
N10C+S99T (total length) 3.8 * 10 618%
N16C+S99T (total length) 2.3 * 10 611%
N16C+S99T (total length+10kDa mPEG) 1.3 * 10 66%
E38C+S99T (total length) 3.4 * 10 616%
N59C+S99T (total length) 6.3 * 10 630%
N59C+S99T (total length+5kDa mPEG) 2.4 * 10 611%
S99T+N104C (total length) 3.5 * 10 617%
Table 2: the activity behind the total length rhuIFNG polypeptide variants purifying
Measure the activity of a plurality of PEGization variants, specifically be with the PEGization product with the identical PEGization process (seeing embodiment 5) of experience but in fact not in reaction medium the sample of interpolation PEG compare.The result is compiled in the following table 3:
With respect to experience " PEGization process "
Sudden change
The activity of PEGization product (%) not
N10C+S99T (total length+5kDa mPEG) 23
N16C+S99T (total length+5kDa mPEG) 59
E38C+S99T (total length+10kDa mPEG) 1) 41
S99T+N104C (total length+5kDa mPEG) 42
Table 3: the activity of the PEGization variant of total length rhuIFNG polypeptide
1) utilized ODSS coupling chemistry.All other PEGization variants have utilized MAL coupling chemistry.
Should emphasize that activity data shown in the table 1 has reflected the combination of expression level in specific activity and the CHO-K1 cell.Therefore can reach a conclusion, all variants are compared with rhuIFNG, demonstrate suitable expression level/specific activity.
As shown in table 2, all halfcystine variants are compared with rhuIFNG, show the specific activity that reduces, and contain E38N, and the variant of S40T and/or S99T sudden change has kept the specific activity suitable with rhuIFNG.When the halfcystine variant with after 5 or the PEG of 10kDa are connected, find that specific activity further reduces 2-3 doubly (table 3).Be not subjected to any concrete one theory, the reduction of inferring specific activity is attributable to the steric restriction that link coupled PEG group causes and causes receptors bind to reduce.
Embodiment 10-assessment is to the utilization of N-glycosylation site
For the relative populations of the quantitative glycosylation site that utilizes, carry out western trace (see figure 1) with the substratum of gathering in the crops.Estimate that wild-type rhuIFNG (total length) has 50% to utilize whole two glycosylation sites (2N) approximately, have 40% to utilize one of them glycosylation site (1N) approximately, have 10% approximately not by glycosylation (0N).These data with before this by Hooker et al., 1998, J.Interferon and CytokineRes.18,287-295 and Sarenva et al., 1995, Biochem J., 308, the disclosed unanimity of 9-14.
As shown in Figure 1, S99T variant (total length) significantly more effectively utilizes two glycosylation site than corresponding wild-type.Estimate that the S99T variant has 90% to utilize whole two glycosylation sites (2N) approximately, have 7% to utilize one of them glycosylation site (1N) approximately, have 3% approximately not by glycosylation (0N).
Also can be as can be seen from Figure 1, variant E38N+S40T (total length) significantly is better than the utilization of the variant E38N (total length) of not optimization to it to the utilization of introducing the 38th glycosylation site.
These data clearly show, no matter glycosylation site is natural or introduces, to the more good utilisation in these sites, can by in the position for asparagine residue+2 introduce threonine residues rather than serine residue is realized.
Embodiment 11-pharmacokinetic
The AUC of subcutaneous rat administration (AUCsc) measures as described in multiple IFNG variant as preamble.The results are summarized in table 4 and Fig. 2, Fig. 3.
AUCsc/ agent AUC Sc VariantAUC Sc VariantT Max, sc
Variant (min xg)/ml AUC Sc, ActimmuneAUC Sc, total length, wt(min)
Actimmune???????0.3-0.4????????-??????????????????0.013-0.027???????43
RhuIFNG (total length) 15-24 37-80-362-446
E38N+S40T+S99T 1)?111-192????????277-640????????????4.6-13????????????308-374
N16C+S99T 2)??????37?????????????92-123?????????????1.5-2.5???????????247
N16C+9 3)?????????114????????????285-380????????????4.8-7.6???????????249
Table 4: the pharmacokinetic data of subcutaneous rat administration
1) total length
2) total length, 5kDa mPEG links to each other with the cysteine residues of introducing
3) total length, 10kDa mPEG links to each other with the cysteine residues of introducing
From Fig. 2, Fig. 3 and table 4 can find out obviously that when subcutaneous administration, described variant (comprising the PEGization variant) is compared with rhuIFNG, especially compares with commercially available Actimmune , have significantly higher AUC.According to shown in Figure 3, it shall yet further be noted that the dosage of two kinds of PEGization variants reduces 2.5 times than [E38N+S40T+S99T] variant.
Obviously, this has started a kind of possibility, promptly uses more low dosage, thereby reduces side effect, and/or makes the active required administration number of times of realization than still less present, thereby improves patient's conformability.
Sequence table
＜110〉Maxigen Holdings Co., Ltd (Maxygen Holdings)
＜120〉interferon gamma polypeptide variants
＜130〉231wo410-INFG variant
<140>
<141>
<160>49
<170>PatentIn?Ver.2.1
<210>1
<211>143
<212>PRT
＜213〉artificial sequence
<220>
＜223〉description of artificial sequence: [S99T] huIFNG
<400>1
Gln?Asp?Pro?Tyr?Val?Lys?Glu?Ala?Glu?Asn?Leu?Lys?Lys?Tyr?Phe?Asn
1???????????????5??????????????????10??????????????????15
Ala?Gly?His?Ser?Asp?Val?Ala?Asp?Asn?Gly?Thr?Leu?Phe?Leu?Gly?Ile
20??????????????????25??????????????????30
Leu?Lys?Asn?Trp?Lys?Glu?Glu?Ser?Asp?Arg?Lys?Ile?Met?Gln?Ser?Gln
35??????????????????40??????????????????45
Ile?Val?Ser?Phe?Tyr?Phe?Lys?Leu?Phe?Lys?Asn?Phe?Lys?Asp?Asp?Gln
50??????????????????55??????????????????60
Ser?Ile?Gln?Lys?Ser?Val?Glu?Thr?Ile?Lys?Glu?Asp?Met?Asn?Val?Lys
65??????????????????70??????????????????75??????????????????80
Phe?Phe?Asn?Ser?Asn?Lys?Lys?Lys?Arg?Asp?Asp?Phe?Glu?Lys?Leu?Thr
85??????????????????90??????????????????95
Asn?Tyr?Thr?Val?Thr?Asp?Leu?Asn?Val?Gln?Arg?Lys?Ala?Ile?His?Glu
100?????????????????105?????????????????110
Leu?Ile?Gln?Val?Met?Ala?Glu?Leu?Ser?Pro?Ala?Ala?Lys?Thr?Gly?Lys
115?????????????????120?????????????????125
Arg?Lys?Arg?Ser?Gln?Met?Leu?Phe?Arg?Gly?Arg?Arg?Ala?Ser?Gln
130?????????????????135?????????????????140
<210>2
<211>142
<212>PRT
＜213〉artificial sequence
<220>
＜223〉description of artificial sequence: C-terminal is by [S99T] huIFNG of brachymemma
<400>2
Gln?Asp?Pro?Tyr?Val?Lys?Glu?Ala?Glu?Asn?Leu?Lys?Lys?Tyr?Phe?Asn
1???????????????5??????????????????10??????????????????15
Ala?Gly?His?Ser?Asp?Val?Ala?Asp?Asn?Gly?Thr?Leu?Phe?Leu?Gly?Ile
20??????????????????25??????????????????30
Leu?Lys?Asn?Trp?Lys?Glu?Glu?Ser?Asp?Arg?Lys?Ile?Met?Gln?Ser?Gln
35??????????????????40??????????????????45
Ile?Val?Ser?Phe?Tyr?Phe?Lys?Leu?Phe?Lys?Asn?Phe?Lys?Asp?Asp?Gln
50??????????????????55??????????????????60
Ser?Ile?Gln?Lys?Ser?Val?Glu?Thr?Ile?Lys?Glu?Asp?Met?Asn?Val?Lys
65??????????????????70??????????????????75??????????????????80
Phe?Phe?Asn?Ser?Asn?Lys?Lys?Lys?Arg?Asp?Asp?Phe?Glu?Lys?Leu?Thr
85??????????????????90??????????????????95
Asn?Tyr?Thr?Val?Thr?Asp?Leu?Asn?Val?Gln?Arg?Lys?Ala?Ile?His?Glu
100?????????????????105?????????????????110
Leu?Ile?Gln?Val?Met?Ala?Glu?Leu?Ser?Pro?Ala?Ala?Lys?Thr?Gly?Lys
115?????????????????120?????????????????125
Arg?Lys?Arg?Ser?Gln?Met?Leu?Phe?Arg?Gly?Arg?Arg?Ala?Ser
130?????????????????135?????????????????140
<210>3
<211>141
<212>PRT
＜213〉artificial sequence
<220>
＜223〉description of artificial sequence: C-terminal is by [S99T] huIFNG of brachymemma
<400>3
Gln?Asp?Pro?Tyr?Val?Lys?Glu?Ala?Glu?Asn?Leu?Lys?Lys?Tyr?Phe?Asn
1???????????????5??????????????????10??????????????????15
Ala?Gly?His?Ser?Asp?Val?Ala?Asp?Asn?Gly?Thr?Leu?Phe?Leu?Gly?Ile
20??????????????????25??????????????????30
Leu?Lys?Asn?Trp?Lys?Glu?Glu?Ser?Asp?Arg?Lys?Ile?Met?Gln?Ser?Gln
35??????????????????40??????????????????45
Ile?Val?Ser?Phe?Tyr?Phe?Lys?Leu?Phe?Lys?Asn?Phe?Lys?Asp?Asp?Gln
50??????????????????55??????????????????60
Ser?Ile?Gln?Lys?Ser?Val?Glu?Thr?Ile?Lys?Glu?Asp?Met?Asn?Val?Lys
65??????????????????70??????????????????75??????????????????80
Phe?Phe?Asn?Ser?Asn?Lys?Lys?Lys?Arg?Asp?Asp?Phe?Glu?Lys?Leu?Thr
85??????????????????90??????????????????95
Asn?Tyr?Thr?Val?Thr?Asp?Leu?Asn?Val?Gln?Arg?Lys?Ala?Ile?His?Glu
100?????????????????105?????????????????110
Leu?Ile?Gln?Val?Met?Ala?Glu?Leu?Ser?Pro?Ala?Ala?Lys?Thr?Gly?Lys
115?????????????????120?????????????????125
Arg?Lys?Arg?Ser?Gln?Met?Leu?Phe?Arg?Gly?Arg?Arg?Ala
130?????????????????135?????????????????140
<210>4
<211>140
<212>PRT
＜213〉artificial sequence
<220>
＜223〉description of artificial sequence: C-terminal is by [S99T] huIFNG of brachymemma
<400>4
Gln?Asp?Pro?Tyr?Val?Lys?Glu?Ala?Glu?Asn?Leu?Lys?Lys?Tyr?Phe?Asn
1???????????????5??????????????????10??????????????????15
Ala?Gly?His?Ser?Asp?Val?Ala?Asp?Asn?Gly?Thr?Leu?Phe?Leu?Gly?Ile
20??????????????????25??????????????????30
Leu?Lys?Asn?Trp?Lys?Glu?Glu?Ser?Asp?Arg?Lys?Ile?Met?Gln?Ser?Gln
35??????????????????40??????????????????45
Ile?Val?Ser?Phe?Tyr?Phe?Lys?Leu?Phe?Lys?Asn?Phe?Lys?Asp?Asp?Gln
50??????????????????55??????????????????60
Ser?Ile?Gln?Lys?Ser?Val?Glu?Thr?Ile?Lys?Glu?Asp?Met?Asn?Val?Lys
65??????????????????70??????????????????75??????????????????80
Phe?Phe?Asn?Ser?Asn?Lys?Lys?Lys?Arg?Asp?Asp?Phe?Glu?Lys?Leu?Thr
85??????????????????90??????????????????95
Asn?Tyr?Thr?Val?Thr?Asp?Leu?Asn?Val?Gln?Arg?Lys?Ala?Ile?His?Glu
100?????????????????105?????????????????110
Leu?Ile?Gln?Val?Met?Ala?Glu?Leu?Ser?Pro?Ala?Ala?Lys?Thr?Gly?Lys
115?????????????????120?????????????????125
Arg?Lys?Arg?Ser?Gln?Met?Leu?Phe?Arg?Gly?Arg?Arg
130?????????????????135?????????????????140
<210>5
<211>139
<212>PRT
＜213〉artificial sequence
<220>
＜223〉description of artificial sequence: C-terminal is by [S99T] huIFNG of brachymemma
<400>5
Gln?Asp?Pro?Tyr?Val?Lys?Glu?Ala?Glu?Asn?Leu?Lys?Lys?Tyr?Phe?Asn
1???????????????5??????????????????10??????????????????15
Ala?Gly?His?Ser?Asp?Val?Ala?Asp?Asn?Gly?Thr?Leu?Phe?Leu?Gly?Ile
20??????????????????25??????????????????30
Leu?Lys?Asn?Trp?Lys?Glu?Glu?Ser?Asp?Arg?Lys?Ile?Met?Gln?Ser?Gln
35??????????????????40??????????????????45
Ile?Val?Ser?Phe?Tyr?Phe?Lys?Leu?Phe?Lys?Ash?Phe?Lys?Asp?Asp?Gln
50??????????????????55??????????????????60
Ser?Ile?Gln?Lys?Ser?Val?Glu?Thr?Ile?Lys?Glu?Asp?Met?Asn?Val?Lys
65??????????????????70??????????????????75??????????????????80
Phe?Phe?Asn?Ser?Asn?Lys?Lys?Lys?Arg?Asp?Asp?Phe?Glu?Lys?Leu?Thr
85??????????????????90??????????????????95
Asn?Tyr?Thr?Val?Thr?Asp?Leu?Asn?Val?Gln?Arg?Lys?Ala?Ile?His?Glu
100?????????????????105?????????????????110
Leu?Ile?Gln?Val?Met?Ala?Glu?Leu?Ser?Pro?Ala?Ala?Lys?Thr?Gly?Lys
115?????????????????120?????????????????125
Arg?Lys?Arg?Ser?Gln?Met?Leu?Phe?Arg?Gly?Arg
130?????????????????135
<210>6
<211>138
<212>PRT
＜213〉artificial sequence
<220>
＜223〉description of artificial sequence: C-terminal is by [S99T] huIFNG of brachymemma
<400>6
Gln?Asp?Pro?Tyr?Val?Lys?Glu?Ala?Glu?Asn?Leu?Lys?Lys?Tyr?Phe?Asn
1???????????????5??????????????????10??????????????????15
Ala?Gly?His?Ser?Asp?Val?Ala?Asp?Asn?Gly?Thr?Leu?Phe?Leu?Gly?Ile
20??????????????????25??????????????????30
Leu?Lys?Asn?Trp?Lys?Glu?Glu?Ser?Asp?Arg?Lys?Ile?Met?Gln?Ser?Gln
35??????????????????40??????????????????45
Ile?Val?Ser?Phe?Tyr?Phe?Lys?Leu?Phe?Lys?Asn?Phe?Lys?Asp?Asp?Gln
50??????????????????55??????????????????60
Ser?Ile?Gln?Lys?Ser?Val?Glu?Thr?Ile?Lys?Glu?Asp?Met?Asn?Val?Lys
65??????????????????70??????????????????75??????????????????80
Phe?Phe?Asn?Ser?Asn?Lys?Lys?Lys?Arg?Asp?Asp?Phe?Glu?Lys?Leu?Thr
85??????????????????90??????????????????95
Asn?Tyr?Thr?Val?Thr?Asp?Leu?Asn?Val?Gln?Arg?Lys?Ala?Ile?His?Glu
100?????????????????105?????????????????110
Leu?Ile?Gln?Val?Met?Ala?Glu?Leu?Ser?Pro?Ala?Ala?Lys?Thr?Gly?Lys
115?????????????????120?????????????????125
Arg?Lys?Arg?Ser?Gln?Met?Leu?Phe?Arg?Gly
130?????????????????135
<210>7
<211>137
<212>PRT
＜213〉artificial sequence
<220>
＜223〉description of artificial sequence: C-terminal is by [S99T] huIFNG of brachymemma
<400>7
Gln?Asp?Pro?Tyr?Val?Lys?Glu?Ala?Glu?Asn?Leu?Lys?Lys?Tyr?Phe?Asn
1???????????????5??????????????????10??????????????????15
Ala?Gly?His?Ser?Asp?Val?Ala?Asp?Asn?Gly?Thr?Leu?Phe?Leu?Gly?Ile
20??????????????????25??????????????????30
Leu?Lys?Asn?Trp?Lys?Glu?Glu?Ser?Asp?Arg?Lys?Ile?Met?Gln?Ser?Gln
35??????????????????40??????????????????45
Ile?Val?Ser?Phe?Tyr?Phe?Lys?Leu?Phe?Lys?Asn?Phe?Lys?Asp?Asp?Gln
50??????????????????55??????????????????60
Ser?Ile?Gln?Lys?Ser?Val?Glu?Thr?Ile?Lys?Glu?Asp?Met?Asn?Val?Lys
65??????????????????70??????????????????75??????????????????80
Phe?Phe?Asn?Ser?Asn?Lys?Lys?Lys?Arg?Asp?Asp?Phe?Glu?Lys?Leu?Thr
85??????????????????90??????????????????95
Asn?Tyr?Thr?Val?Thr?Asp?Leu?Asn?Val?Gln?Arg?Lys?Ala?Ile?His?Glu
100?????????????????105?????????????????110
Leu?Ile?Gln?Val?Met?Ala?Glu?Leu?Ser?Pro?Ala?Ala?Lys?Thr?Gly?Lys
115?????????????????120?????????????????125
Arg?Lys?Arg?Ser?Gln?Met?Leu?Phe?Arg
130?????????????????135
<210>8
<211>136
<212>PRT
＜213〉artificial sequence
<220>
＜223〉description of artificial sequence: C-terminal is by [S99T] huIFNG of brachymemma
<400>8
Gln?Asp?Pro?Tyr?Val?Lys?Glu?Ala?Glu?Asn?Leu?Lys?Lys?Tyr?Phe?Asn
1???????????????5??????????????????10??????????????????15
Ala?Gly?His?Ser?Asp?Val?Ala?Asp?Asn?Gly?Thr?Leu?Phe?Leu?Gly?Ile
20??????????????????25??????????????????30
Leu?Lys?Asn?Trp?Lys?Glu?Glu?Ser?Asp?Arg?Lys?Ile?Met?Gln?Ser?Gln
35??????????????????40??????????????????45
Ile?Val?Ser?Phe?Tyr?Phe?Lys?Leu?Phe?Lys?Asn?Phe?Lys?Asp?Asp?Gln
50??????????????????55??????????????????60
Ser?Ile?Gln?Lys?Ser?Val?Glu?Thr?Ile?Lys?Glu?Asp?Met?Asn?Val?Lys
65??????????????????70??????????????????75??????????????????80
Phe?Phe?Asn?Ser?Asn?Lys?Lys?Lys?Arg?Asp?Asp?Phe?Glu?Lys?Leu?Thr
85??????????????????90??????????????????95
Asn?Tyr?Thr?Val?Thr?Asp?Leu?Asn?Val?Gln?Arg?Lys?Ala?Ile?His?Glu
100?????????????????105?????????????????110
Leu?Ile?Gln?Val?Met?Ala?Glu?Leu?Ser?Pro?Ala?Ala?Lys?Thr?Gly?Lys
115?????????????????120?????????????????125
Arg?Lys?Arg?Ser?Gln?Met?Leu?Phe
130?????????????????135
<210>9
<211>135
<212>PRT
＜213〉artificial sequence
<220>
＜223〉description of artificial sequence: C-terminal is by [S99T] huIFNG of brachymemma
<400>9
Gln?Asp?Pro?Tyr?Val?Lys?Glu?Ala?Glu?Asn?Leu?Lys?Lys?Tyr?Phe?Asn
1???????????????5??????????????????10??????????????????15
Ala?Gly?His?Ser?Asp?Val?Ala?Asp?Asn?Gly?Thr?Leu?Phe?Leu?Gly?Ile
20??????????????????25??????????????????30
Leu?Lys?Asn?Trp?Lys?Glu?Glu?Ser?Asp?Arg?Lys?Ile?Met?Gln?Ser?Gln
35??????????????????40??????????????????45
Ile?Val?Ser?Phe?Tyr?Phe?Lys?Leu?Phe?Lys?Asn?Phe?Lys?Asp?Asp?Gln
50??????????????????55??????????????????60
Ser?Ile?Gln?Lys?Ser?Val?Glu?Thr?Ile?Lys?Glu?Asp?Met?Asn?Val?Lys
65??????????????????70??????????????????75??????????????????80
Phe?Phe?Asn?Ser?Asn?Lys?Lys?Lys?Arg?Asp?Asp?Phe?Glu?Lys?Leu?Thr
85??????????????????90??????????????????95
Asn?Tyr?Thr?Val?Thr?Asp?Leu?Asn?Val?Gln?Arg?Lys?Ala?Ile?His?Glu
100?????????????????105?????????????????110
Leu?Ile?Gln?Val?Met?Ala?Glu?Leu?Ser?Pro?Ala?Ala?Lys?Thr?Gly?Lys
115?????????????????120?????????????????125
Arg?Lys?Arg?Ser?Gln?Met?Leu
130?????????????????135
<210>10
<211>134
<212>PRT
＜213〉artificial sequence
<220>
＜223〉description of artificial sequence: C-terminal is by [S99T] huIFNG of brachymemma
<400>10
Gln?Asp?Pro?Tyr?Val?Lys?Glu?Ala?Glu?Asn?Leu?Lys?Lys?Tyr?Phe?Asn
1???????????????5??????????????????10??????????????????15
Ala?Gly?His?Ser?Asp?Val?Ala?Asp?Asn?Gly?Thr?Leu?Phe?Leu?Gly?Ile
20??????????????????25??????????????????30
Leu?Lys?Asn?Trp?Lys?Glu?Glu?Ser?Asp?Arg?Lys?Ile?Met?Gln?Ser?Gln
35??????????????????40??????????????????45
Ile?Val?Ser?Phe?Tyr?Phe?Lys?Leu?Phe?Lys?Asn?Phe?Lys?Asp?Asp?Gln
50??????????????????55??????????????????60
Ser?Ile?Gln?Lys?Ser?Val?Glu?Thr?Ile?Lys?Glu?Asp?Met?Asn?Val?Lys
65??????????????????70??????????????????75??????????????????80
Phe?Phe?Asn?Ser?Asn?Lys?Lys?Lys?Arg?Asp?Asp?Phe?Glu?Lys?Leu?Thr
85??????????????????90??????????????????95
Asn?Tyr?Thr?Val?Thr?Asp?Leu?Asn?Val?Gln?Arg?Lys?Ala?Ile?His?Glu
100?????????????????105?????????????????110
Leu?Ile?Gln?Val?Met?Ala?Glu?Leu?Ser?Pro?Ala?Ala?Lys?Thr?Gly?Lys
115?????????????????120?????????????????125
Arg?Lys?Arg?Ser?Gln?Met
130
<210>11
<211>133
<212>PRT
＜213〉artificial sequence
<220>
＜223〉description of artificial sequence: C-terminal is by [S99T] huIFNG of brachymemma
<400>11
Gln?Asp?Pro?Tyr?Val?Lys?Glu?Ala?Glu?Asn?Leu?Lys?Lys?Tyr?Phe?Asn
1???????????????5??????????????????10??????????????????15
Ala?Gly?His?Ser?Asp?Val?Ala?Asp?Asn?Gly?Thr?Leu?Phe?Leu?Gly?Ile
20??????????????????25??????????????????30
Leu?Lys?Asn?Trp?Lys?Glu?Glu?Ser?Asp?Arg?Lys?Ile?Met?Gln?Ser?Gln
35??????????????????40??????????????????45
Ile?Val?Ser?Phe?Tyr?Phe?Lys?Leu?Phe?Lys?Asn?Phe?Lys?Asp?Asp?Gln
50??????????????????55??????????????????60
Ser?Ile?Gln?Lys?Ser?Val?Glu?Thr?Ile?Lys?Glu?Asp?Met?Asn?Val?Lys
65??????????????????70??????????????????75??????????????????80
Phe?Phe?Asn?Ser?Asn?Lys?Lys?Lys?Arg?Asp?Asp?Phe?Glu?Lys?Leu?Thr
85??????????????????90??????????????????95
Asn?Tyr?Thr?Val?Thr?Asp?Leu?Asn?Val?Gln?Arg?Lys?Ala?Ile?His?Glu
100?????????????????105?????????????????110
Leu?Ile?Gln?Val?Met?Ala?Glu?Leu?Ser?Pro?Ala?Ala?Lys?Thr?Gly?Lys
115?????????????????120?????????????????125
Arg?Lys?Arg?Ser?Gln
130
<210>12
<211>132
<212>PRT
＜213〉artificial sequence
<220>
＜223〉description of artificial sequence: C-terminal is by [S99T] huIFNG of brachymemma
<400>12
Gln?Asp?Pro?Tyr?Val?Lys?Glu?Ala?Glu?Asn?Leu?Lys?Lys?Tyr?Phe?Asn
1???????????????5??????????????????10??????????????????15
Ala?Gly?His?Ser?Asp?Val?Ala?Asp?Asn?Gly?Thr?Leu?Phe?Leu?Gly?Ile
20??????????????????25??????????????????30
Leu?Lys?Asn?Trp?Lys?Glu?Glu?Ser?Asp?Arg?Lys?Ile?Met?Gln?Ser?Gln
35??????????????????40??????????????????45
Ile?Val?Ser?Phe?Tyr?Phe?Lys?Leu?Phe?Lys?Asn?Phe?Lys?Asp?Asp?Gln
50??????????????????55??????????????????60
Ser?Ile?Gln?Lys?Ser?Val?Glu?Thr?Ile?Lys?Glu?Asp?Met?Asn?Val?Lys
65??????????????????70??????????????????75??????????????????80
Phe?Phe?Asn?Ser?Asn?Lys?Lys?Lys?Arg?Asp?Asp?Phe?Glu?Lys?Leu?Thr
85??????????????????90??????????????????95
Asn?Tyr?Thr?Val?Thr?Asp?Leu?Asn?Val?Gln?Arg?Lys?Ala?Ile?His?Glu
100?????????????????105?????????????????110
Leu?Ile?Gln?Val?Met?Ala?Glu?Leu?Ser?Pro?Ala?Ala?Lys?Thr?Gly?Lys
115?????????????????120?????????????????125
Arg?Lys?Arg?Ser
130
<210>13
<211>131
<212>PRT
＜213〉artificial sequence
<220>
＜223〉description of artificial sequence: C-terminal is by [S99T] huIFNG of brachymemma
<400>13
Gln?Asp?Pro?Tyr?Val?Lys?Glu?Ala?Glu?Asn?Leu?Lys?Lys?Tyr?Phe?Asn
1???????????????5??????????????????10??????????????????15
Ala?Gly?His?Ser?Asp?Val?Ala?Asp?Asn?Gly?Thr?Leu?Phe?Leu?Gly?Ile
20??????????????????25??????????????????30
Leu?Lys?Asn?Trp?Lys?Glu?Glu?Ser?Asp?Arg?Lys?Ile?Met?Gln?Ser?Gln
35??????????????????40??????????????????45
Ile?Val?Ser?Phe?Tyr?Phe?Lys?Leu?Phe?Lys?Asn?Phe?Lys?Asp?Asp?Gln
50??????????????????55??????????????????60
Ser?Ile?Gln?Lys?Ser?Val?Glu?Thr?Ile?Lys?Glu?Asp?Met?Asn?Val?Lys
65??????????????????70??????????????????75??????????????????80
Phe?Phe?Asn?Ser?Asn?Lys?Lys?Lys?Arg?Asp?Asp?Phe?Glu?Lys?Leu?Thr
85??????????????????90??????????????????95
Asn?Tyr?Thr?Val?Thr?Asp?Leu?Asn?Val?Gln?Arg?Lys?Ala?Ile?His?Glu
100?????????????????105?????????????????110
Leu?Ile?Gln?Val?Met?Ala?Glu?Leu?Ser?Pro?Ala?Ala?Lys?Thr?Gly?Lys
115?????????????????120?????????????????125
Arg?Lys?Arg
130
<210>14
<211>130
<212>PRT
＜213〉artificial sequence
<220>
＜223〉description of artificial sequence: C-terminal is by [S99T] huIFNG of brachymemma
<400>14
Gln?Asp?Pro?Tyr?Val?Lys?Glu?Ala?Glu?Asn?Leu?Lys?Lys?Tyr?Phe?Asn
1???????????????5??????????????????10??????????????????15
Ala?Gly?His?Ser?Asp?Val?Ala?Asp?Asn?Gly?Thr?Leu?Phe?Leu?Gly?Ile
20??????????????????25??????????????????30
Leu?Lys?Asn?Trp?Lys?Glu?Glu?Ser?Asp?Arg?Lys?Ile?Met?Gln?Ser?Gln
35??????????????????40??????????????????45
Ile?Val?Ser?Phe?Tyr?Phe?Lys?Leu?Phe?Lys?Asn?Phe?Lys?Asp?Asp?Gln
50??????????????????55??????????????????60
Ser?Ile?Gln?Lys?Ser?Val?Glu?Thr?Ile?Lys?Glu?Asp?Met?Asn?Val?Lys
65??????????????????70??????????????????75??????????????????80
Phe?Phe?Asn?Ser?Asn?Lys?Lys?Lys?Arg?Asp?Asp?Phe?Glu?Lys?Leu?Thr
85??????????????????90??????????????????95
Asn?Tyr?Thr?Val?Thr?Asp?Leu?Asn?Val?Gln?Arg?Lys?Ala?Ile?His?Glu
100?????????????????105?????????????????110
Leu?Ile?Gln?Val?Met?Ala?Glu?Leu?Ser?Pro?Ala?Ala?Lys?Thr?Gly?Lys
115?????????????????120?????????????????125
Arg?Lys
130
<210>15
<211>129
<212>PRT
＜213〉artificial sequence
<220>
＜223〉description of artificial sequence: C-terminal is by [S99T] huIFNG of brachymemma
<400>15
Gln?Asp?Pro?Tyr?Val?Lys?Glu?Ala?Glu?Asn?Leu?Lys?Lys?Tyr?Phe?Asn
1???????????????5??????????????????10??????????????????15
Ala?Gly?His?Ser?Asp?Val?Ala?Asp?Asn?Gly?Thr?Leu?Phe?Leu?Gly?Ile
20??????????????????25??????????????????30
Leu?Lys?Asn?Trp?Lys?Glu?Glu?Ser?Asp?Arg?Lys?Ile?Met?Gln?Ser?Gln
35??????????????????40??????????????????45
Ile?Val?Ser?Phe?Tyr?Phe?Lys?Leu?Phe?Lys?Asn?Phe?Lys?Asp?Asp?Gln
50??????????????????55??????????????????60
Ser?Ile?Gln?Lys?Ser?Val?Glu?Thr?Ile?Lys?Glu?Asp?Met?Asn?Val?Lys
65??????????????????70??????????????????75??????????????????80
Phe?Phe?Asn?Ser?Asn?Lys?Lys?Lys?Arg?Asp?Asp?Phe?Glu?Lys?Leu?Thr
85??????????????????90??????????????????95
Asn?Tyr?Thr?Val?Thr?Asp?Leu?Asn?Val?Gln?Arg?Lys?Ala?Ile?His?Glu
100?????????????????105?????????????????110
Leu?Ile?Gln?Val?Met?Ala?Glu?Leu?Ser?Pro?Ala?Ala?Lys?Thr?Gly?Lys
115?????????????????120?????????????????125
Arg
<210>16
<211>128
<212>PRT
＜213〉artificial sequence
<220>
＜223〉description of artificial sequence: C-terminal is by [S99T] huIFNG of brachymemma
<400>16
Gln?Asp?Pro?Tyr?Val?Lys?Glu?Ala?Glu?Asn?Leu?Lys?Lys?Tyr?Phe?Asn
1???????????????5??????????????????10??????????????????15
Ala?Gly?His?Ser?Asp?Val?Ala?Asp?Asn?Gly?Thr?Leu?Phe?Leu?Gly?Ile
20??????????????????25??????????????????30
Leu?Lys?Asn?Trp?Lys?Glu?Glu?Ser?Asp?Arg?Lys?Ile?Met?Gln?Ser?Gln
35??????????????????40??????????????????45
Ile?Val?Ser?Phe?Tyr?Phe?Lys?Leu?Phe?Lys?Asn?Phe?Lys?Asp?Asp?Gln
50??????????????????55??????????????????60
Ser?Ile?Gln?Lys?Ser?Val?Glu?Thr?Ile?Lys?Glu?Asp?Met?Asn?Val?Lys
65??????????????????70??????????????????75??????????????????80
Phe?Phe?Asn?Ser?Asn?Lys?Lys?Lys?Arg?Asp?Asp?Phe?Glu?Lys?Leu?Thr
85??????????????????90??????????????????95
Asn?Tyr?Thr?Val?Thr?Asp?Leu?Asn?Val?Gln?Arg?Lys?Ala?Ile?His?Glu
100?????????????????105?????????????????110
Leu?Ile?Gln?Val?Met?Ala?Glu?Leu?Ser?Pro?Ala?Ala?Lys?Thr?Gly?Lys
115?????????????????120?????????????????125
<210>17
<211>143
<212>PRT
＜213〉people (Homo sapiens)
<400>17
Gln?Asp?Pro?Tyr?Val?Lys?Glu?Ala?Glu?Asn?Leu?Lys?Lys?Tyr?Phe?Asn
1???????????????5??????????????????10??????????????????15
Ala?Gly?His?Ser?Asp?Val?Ala?Asp?Asn?Gly?Thr?Leu?Phe?Leu?Gly?Ile
20??????????????????25??????????????????30
Leu?Lys?Asn?Trp?Lys?Glu?Glu?Ser?Asp?Arg?Lys?Ile?Met?Gln?Ser?Gln
35??????????????????40??????????????????45
Ile?Val?Ser?Phe?Tyr?Phe?Lys?Leu?Phe?Lys?Asn?Phe?Lys?Asp?Asp?Gln
50??????????????????55??????????????????60
Ser?Ile?Gln?Lys?Ser?Val?Glu?Thr?Ile?Lys?Glu?Asp?Met?Asn?Val?Lys
65??????????????????70??????????????????75??????????????????80
Phe?Phe?Asn?Ser?Asn?Lys?Lys?Lys?Arg?Asp?Asp?Phe?Glu?Lys?Leu?Thr
85??????????????????90??????????????????95
Asn?Tyr?Ser?Val?Thr?Asp?Leu?Asn?Val?Gln?Arg?Lys?Ala?Ile?His?Glu
100?????????????????105?????????????????110
Leu?Ile?Gln?Val?Met?Ala?Glu?Leu?Ser?Pro?Ala?Ala?Lys?Thr?Gly?Lys
115?????????????????120?????????????????125
Arg?Lys?Arg?Ser?Gln?Met?Leu?Phe?Arg?Gly?Arg?Arg?Ala?Ser?Gln
130?????????????????135?????????????????140
<210>18
<211>166
<212>PRT
＜213〉people (Homo sapiens)
<400>18
Met?Lys?Tyr?Thr?Ser?Tyr?Ile?Leu?Ala?Phe?Gln?Leu?Cys?Ile?Val?Leu
1???????????????5??????????????????10??????????????????15
Gly?Ser?Leu?Gly?Cys?Tyr?Cys?Gln?Asp?Pro?Tyr?Val?Lys?Glu?Ala?Glu
20??????????????????25??????????????????30
Asn?Leu?Lys?Lys?Tyr?Phe?Asn?Ala?Gly?His?Ser?Asp?Val?Ala?Asp?Asn
35??????????????????40??????????????????45
Gly?Thr?Leu?Phe?Leu?Gly?Ile?Leu?Lys?Asn?Trp?Lys?Glu?Glu?Ser?Asp
50??????????????????55??????????????????60
Arg?Lys?Ile?Met?Gln?Ser?Gln?Ile?Val?Ser?Phe?Tyr?Phe?Lys?Leu?Phe
65??????????????????70??????????????????75??????????????????80
Lys?Asn?Phe?Lys?Asp?Asp?Gln?Ser?Ile?Gln?Lys?Ser?Val?Glu?Thr?Ile
85??????????????????90??????????????????95
Lys?Glu?Asp?Met?Asn?Val?Lys?Phe?Phe?Asn?Ser?Asn?Lys?Lys?Lys?Arg
100?????????????????105?????????????????110
Asp?Asp?Phe?Glu?Lys?Leu?Thr?Asn?Tyr?Ser?Val?Thr?Asp?Leu?Asn?Val
115?????????????????120?????????????????125
Gln?Arg?Lys?Ala?Ile?His?Glu?Leu?Ile?Gln?Val?Met?Ala?Glu?Leu?Ser
130?????????????????135?????????????????140
Pro?Ala?Ala?Lys?Thr?Gly?Lys?Arg?Lys?Arg?Ser?Gln?Met?Leu?Phe?Arg
145?????????????????150?????????????????155?????????????????160
Gly?Arg?Arg?Ala?Ser?Gln
165
<210>19
<211>142
<212>PRT
＜213〉artificial sequence
<220>
＜223〉description of artificial sequence: C-terminal is by the huIFNG of brachymemma
<400>19
Gln?Asp?Pro?Tyr?Val?Lys?Glu?Ala?Glu?Asn?Leu?Lys?Lys?Tyr?Phe?Asn
1???????????????5??????????????????10??????????????????15
Ala?Gly?His?Ser?Asp?Val?Ala?Asp?Asn?Gly?Thr?Leu?Phe?Leu?Gly?Ile
20??????????????????25??????????????????30
Leu?Lys?Asn?Trp?Lys?Glu?Glu?Ser?Asp?Arg?Lys?Ile?Met?Gln?Ser?Gln
35??????????????????40??????????????????45
Ile?Val?Ser?Phe?Tyr?Phe?Lys?Leu?Phe?Lys?Asn?Phe?Lys?Asp?Asp?Gln
50??????????????????55??????????????????60
Ser?Ile?Gln?Lys?Ser?Val?Glu?Thr?Ile?Lys?Glu?Asp?Met?Asn?Val?Lys
65??????????????????70??????????????????75??????????????????80
Phe?Phe?Asn?Ser?Asn?Lys?Lys?Lys?Arg?Asp?Asp?Phe?Glu?Lys?Leu?Thr
85??????????????????90??????????????????95
Asn?Tyr?Ser?Val?Thr?Asp?Leu?Asn?Val?Gln?Arg?Lys?Ala?Ile?His?Glu
100?????????????????105?????????????????110
Leu?Ile?Gln?Val?Met?Ala?Glu?Leu?Ser?Pro?Ala?Ala?Lys?Thr?Gly?Lys
115?????????????????120?????????????????125
Arg?Lys?Arg?Ser?Gln?Met?Leu?Phe?Arg?Gly?Arg?Arg?Ala?Ser
130?????????????????135?????????????????140
<210>20
<211>141
<212>PRT
＜213〉artificial sequence
<220>
＜223〉description of artificial sequence: C-terminal is by the huIFNG of brachymemma
<400>20
Gln?Asp?Pro?Tyr?Val?Lys?Glu?Ala?Glu?Asn?Leu?Lys?Lys?Tyr?Phe?Asn
1???????????????5??????????????????10??????????????????15
Ala?Gly?His?Ser?Asp?Val?Ala?Asp?Asn?Gly?Thr?Leu?Phe?Leu?Gly?Ile
20??????????????????25??????????????????30
Leu?Lys?Asn?Trp?Lys?Glu?Glu?Ser?Asp?Arg?Lys?Ile?Met?Gln?Ser?Gln
35??????????????????40??????????????????45
Ile?Val?Ser?Phe?Tyr?Phe?Lys?Leu?Phe?Lys?Asn?Phe?Lys?Asp?Asp?Gln
50??????????????????55??????????????????60
Ser?Ile?Gln?Lys?Ser?Val?Glu?Thr?Ile?Lys?Glu?Asp?Met?Asn?Val?Lys
65??????????????????70??????????????????75??????????????????80
Phe?Phe?Ash?Ser?Asn?Lys?Lys?Lys?Arg?Asp?Asp?Phe?Glu?Lys?Leu?Thr
85??????????????????90??????????????????95
Asn?Tyr?Ser?Val?Thr?Asp?Leu?Asn?Val?Gln?Arg?Lys?Ala?Ile?His?Glu
100?????????????????105?????????????????110
Leu?Ile?Gln?Val?Met?Ala?Glu?Leu?Ser?Pro?Ala?Ala?Lys?Thr?Gly?Lys
115?????????????????120?????????????????125
Arg?Lys?Arg?Ser?Gln?Met?Leu?Phe?Arg?Gly?Arg?Arg?Ala
130?????????????????135?????????????????140
<210>21
<211>140
<212>PRT
＜213〉artificial sequence
<220>
＜223〉description of artificial sequence: C-terminal is by the huIFNG of brachymemma
<400>21
Gln?Asp?Pro?Tyr?Val?Lys?Glu?Ala?Glu?Asn?Leu?Lys?Lys?Tyr?Phe?Asn
1???????????????5??????????????????10??????????????????15
Ala?Gly?His?Ser?Asp?Val?Ala?Asp?Asn?Gly?Thr?Leu?Phe?Leu?Gly?Ile
20??????????????????25??????????????????30
Leu?Lys?Asn?Trp?Lys?Glu?Glu?Ser?Asp?Arg?Lys?Ile?Met?Gln?Ser?Gln
35??????????????????40??????????????????45
Ile?Val?Ser?Phe?Tyr?Phe?Lys?Leu?Phe?Lys?Asn?Phe?Lys?Asp?Asp?Gln
50??????????????????55??????????????????60
Ser?Ile?Gln?Lys?Ser?Val?Glu?Thr?Ile?Lys?Glu?Asp?Met?Asn?Val?Lys
65??????????????????70??????????????????75??????????????????80
Phe?Phe?Asn?Ser?Asn?Lys?Lys?Lys?Arg?Asp?Asp?Phe?Glu?Lys?Leu?Thr
85??????????????????90??????????????????95
Asn?Tyr?Ser?Val?Thr?Asp?Leu?Asn?Val?Gln?Arg?Lys?Ala?Ile?His?Glu
100?????????????????105?????????????????110
Leu?Ile?Gln?Val?Met?Ala?Glu?Leu?Ser?Pro?Ala?Ala?Lys?Thr?Gly?Lys
115?????????????????120?????????????????125
Arg?Lys?Arg?Ser?Gln?Met?Leu?Phe?Arg?Gly?Arg?Arg
130?????????????????135?????????????????140
<210>22
<211>139
<212>PRT
＜213〉artificial sequence
<220>
＜223〉description of artificial sequence: C-terminal is by the huIFNG of brachymemma
<400>22
Gln?Asp?Pro?Tyr?Val?Lys?Glu?Ala?Glu?Asn?Leu?Lys?Lys?Tyr?Phe?Asn
1???????????????5??????????????????10??????????????????15
Ala?Gly?His?Ser?Asp?Val?Ala?Asp?Asn?Gly?Thr?Leu?Phe?Leu?Gly?Ile
20??????????????????25??????????????????30
Leu?Lys?Asn?Trp?Lys?Glu?Glu?Ser?Asp?Arg?Lys?Ile?Met?Gln?Ser?Gln
35??????????????????40??????????????????45
Ile?Val?Ser?Phe?Tyr?Phe?Lys?Leu?Phe?Lys?Asn?Phe?Lys?Asp?Asp?Gln
50??????????????????55??????????????????60
Ser?Ile?Gln?Lys?Ser?Val?Glu?Thr?Ile?Lys?Glu?Asp?Met?Asn?Val?Lys
65??????????????????70??????????????????75??????????????????80
Phe?Phe?Asn?Ser?Asn?Lys?Lys?Lys?Arg?Asp?Asp?Phe?Glu?Lys?Leu?Thr
85??????????????????90??????????????????95
Asn?Tyr?Ser?Val?Thr?Asp?Leu?Asn?Val?Gln?Arg?Lys?Ala?Ile?His?Glu
100?????????????????105?????????????????110
Leu?Ile?Gln?Val?Met?Ala?Glu?Leu?Ser?Pro?Ala?Ala?Lys?Thr?Gly?Lys
115?????????????????120?????????????????125
Arg?Lys?Arg?Ser?Gln?Met?Leu?Phe?Arg?Gly?Arg
130?????????????????135
<210>23
<211>138
<212>PRT
＜213〉artificial sequence
<220>
＜223〉description of artificial sequence: C-terminal is by the huIFNG of brachymemma
<400>23
Gln?Asp?Pro?Tyr?Val?Lys?Glu?Ala?Glu?Asn?Leu?Lys?Lys?Tyr?Phe?Asn
1???????????????5??????????????????10??????????????????15
Ala?Gly?His?Ser?Asp?Val?Ala?Asp?Asn?Gly?Thr?Leu?Phe?Leu?Gly?Ile
20??????????????????25??????????????????30
Leu?Lys?Asn?Trp?Lys?Glu?Glu?Ser?Asp?Arg?Lys?Ile?Met?Gln?Ser?Gln
35??????????????????40??????????????????45
Ile?Val?Ser?Phe?Tyr?Phe?Lys?Leu?Phe?Lys?Asn?Phe?Lys?Asp?Asp?Gln
50??????????????????55??????????????????60
Ser?Ile?Gln?Lys?Ser?Val?Glu?Thr?Ile?Lys?Glu?Asp?Met?Asn?Val?Lys
65??????????????????70??????????????????75??????????????????80
Phe?Phe?Asn?Ser?Asn?Lys?Lys?Lys?Arg?Asp?Asp?Phe?Glu?Lys?Leu?Thr
85??????????????????90??????????????????95
Asn?Tyr?Ser?Val?Thr?Asp?Leu?Asn?Val?Gln?Arg?Lys?Ala?Ile?His?Glu
100?????????????????105?????????????????110
Leu?Ile?Gln?Val?Met?Ala?Glu?Leu?Ser?Pro?Ala?Ala?Lys?Thr?Gly?Lys
115?????????????????120?????????????????125
Arg?Lys?Arg?Ser?Gln?Met?Leu?Phe?Arg?Gly
130?????????????????135
<210>24
<211>137
<212>PRT
＜213〉artificial sequence
<220>
＜223〉description of artificial sequence: C-terminal is by the huIFNG of brachymemma
<400>24
Gln?Asp?Pro?Tyr?Val?Lys?Glu?Ala?Glu?Asn?Leu?Lys?Lys?Tyr?Phe?Asn
1???????????????5??????????????????10??????????????????15
Ala?Gly?His?Ser?Asp?Val?Ala?Asp?Asn?Gly?Thr?Leu?Phe?Leu?Gly?Ile
20??????????????????25??????????????????30
Leu?Lys?Asn?Trp?Lys?Glu?Glu?Ser?Asp?Arg?Lys?Ile?Met?Gln?Ser?Gln
35??????????????????40??????????????????45
Ile?Val?Ser?Phe?Tyr?Phe?Lys?Leu?Phe?Lys?Asn?Phe?Lys?Asp?Asp?Gln
50??????????????????55??????????????????60
Ser?Ile?Gln?Lys?Ser?Val?Glu?Thr?Ile?Lys?Glu?Asp?Met?Asn?Val?Lys
65??????????????????70??????????????????75??????????????????80
Phe?Phe?Asn?Ser?Asn?Lys?Lys?Lys?Arg?Asp?Asp?Phe?Glu?Lys?Leu?Thr
85??????????????????90??????????????????95
Asn?Tyr?Ser?Val?Thr?Asp?Leu?Asn?Val?Gln?Arg?Lys?Ala?Ile?His?Glu
100?????????????????105?????????????????110
Leu?Ile?Gln?Val?Met?Ala?Glu?Leu?Ser?Pro?Ala?Ala?Lys?Thr?Gly?Lys
115?????????????????120?????????????????125
Arg?Lys?Arg?Ser?Gln?Met?Leu?Phe?Arg
130?????????????????135
<210>25
<211>136
<212>PRT
＜213〉artificial sequence
<220>
＜223〉description of artificial sequence: C-terminal is by the huIFNG of brachymemma
<400>25
Gln?Asp?Pro?Tyr?Val?Lys?Glu?Ala?Glu?Asn?Leu?Lys?Lys?Tyr?Phe?Asn
1???????????????5??????????????????10??????????????????15
Ala?Gly?His?Ser?Asp?Val?Ala?Asp?Asn?Gly?Thr?Leu?Phe?Leu?Gly?Ile
20??????????????????25??????????????????30
Leu?Lys?Asn?Trp?Lys?Glu?Glu?Ser?Asp?Arg?Lys?Ile?Met?Gln?Ser?Gln
35??????????????????40??????????????????45
Ile?Val?Ser?Phe?Tyr?Phe?Lys?Leu?Phe?Lys?Asn?Phe?Lys?Asp?Asp?Gln
50??????????????????55??????????????????60
Ser?Ile?Gln?Lys?Ser?Val?Glu?Thr?Ile?Lys?Glu?Asp?Met?Asn?Val?Lys
65??????????????????70??????????????????75??????????????????80
Phe?Phe?Asn?Ser?Asn?Lys?Lys?Lys?Arg?Asp?Asp?Phe?Glu?Lys?Leu?Thr
85??????????????????90??????????????????95
Asn?Tyr?Ser?Val?Thr?Asp?Leu?Asn?Val?Gln?Arg?Lys?Ala?Ile?His?Glu
100?????????????????105?????????????????110
Leu?Ile?Gln?Val?Met?Ala?Glu?Leu?Ser?Pro?Ala?Ala?Lys?Thr?Gly?Lys
115?????????????????120?????????????????125
Arg?Lys?Arg?Ser?Gln?Met?Leu?Phe
130?????????????????135
<210>26
<211>135
<212>PRT
＜213〉artificial sequence
<220>
＜223〉description of artificial sequence: C-terminal is by the huIFNG of brachymemma
<400>26
Gln?Asp?Pro?Tyr?Val?Lys?Glu?Ala?Glu?Asn?Leu?Lys?Lys?Tyr?Phe?Asn
1???????????????5??????????????????10??????????????????15
Ala?Gly?His?Ser?Asp?Val?Ala?Asp?Asn?Gly?Thr?Leu?Phe?Leu?Gly?Ile
20??????????????????25??????????????????30
Leu?Lys?Asn?Trp?Lys?Glu?Glu?Ser?Asp?Arg?Lys?Ile?Met?Gln?Ser?Gln
35??????????????????40??????????????????45
Ile?Val?Ser?Phe?Tyr?Phe?Lys?Leu?Phe?Lys?Asn?Phe?Lys?Asp?Asp?Gln
50??????????????????55??????????????????60
Ser?Ile?Gln?Lys?Ser?Val?Glu?Thr?Ile?Lys?Glu?Asp?Met?Asn?Val?Lys
65??????????????????70??????????????????75??????????????????80
Phe?Phe?Asn?Ser?Asn?Lys?Lys?Lys?Arg?Asp?Asp?Phe?Glu?Lys?Leu?Thr
85??????????????????90??????????????????95
Asn?Tyr?Ser?Val?Thr?Asp?Leu?Asn?Val?Gln?Arg?Lys?Ala?Ile?His?Glu
100?????????????????105?????????????????110
Leu?Ile?Gln?Val?Met?Ala?Glu?Leu?Ser?Pro?Ala?Ala?Lys?Thr?Gly?Lys
115?????????????????120?????????????????125
Arg?Lys?Arg?Ser?Gln?Met?Leu
130?????????????????135
<210>27
<211>134
<212>PRT
＜213〉artificial sequence
<220>
＜223〉description of artificial sequence: C-terminal is by the huIFNG of brachymemma
<400>27
Gln?Asp?Pro?Tyr?Val?Lys?Glu?Ala?Glu?Asn?Leu?Lys?Lys?Tyr?Phe?Asn
1???????????????5??????????????????10??????????????????15
Ala?Gly?His?Ser?Asp?Val?Ala?Asp?Asn?Gly?Thr?Leu?Phe?Leu?Gly?Ile
20??????????????????25??????????????????30
Leu?Lys?Asn?Trp?Lys?Glu?Glu?Ser?Asp?Arg?Lys?Ile?Met?Gln?Ser?Gln
35??????????????????40??????????????????45
Ile?Val?Ser?Phe?Tyr?Phe?Lys?Leu?Phe?Lys?Asn?Phe?Lys?Asp?Asp?Gln
50??????????????????55??????????????????60
Ser?Ile?Gln?Lys?Ser?Val?Glu?Thr?Ile?Lys?Glu?Asp?Met?Asn?Val?Lys
65??????????????????70??????????????????75??????????????????80
Phe?Phe?Asn?Ser?Asn?Lys?Lys?Lys?Arg?Asp?Asp?Phe?Glu?Lys?Leu?Thr
85??????????????????90??????????????????95
Asn?Tyr?Ser?Val?Thr?Asp?Leu?Asn?Val?Gln?Arg?Lys?Ala?Ile?His?Glu
100?????????????????105?????????????????110
Leu?Ile?Gln?Val?Met?Ala?Glu?Leu?Ser?Pro?Ala?Ala?Lys?Thr?Gly?Lys
115?????????????????120?????????????????125
Arg?Lys?Arg?Ser?Gln?Met
130
<210>28
<211>133
<212>PRT
＜213〉artificial sequence
<220>
＜223〉description of artificial sequence: C-terminal is by the huIFNG of brachymemma
<400>28
Gln?Asp?Pro?Tyr?Val?Lys?Glu?Ala?Glu?Asn?Leu?Lys?Lys?Tyr?Phe?Asn
1???????????????5??????????????????10??????????????????15
Ala?Gly?His?Ser?Asp?Val?Ala?Asp?Asn?Gly?Thr?Leu?Phe?Leu?Gly?Ile
20??????????????????25??????????????????30
Leu?Lys?Asn?Trp?Lys?Glu?Glu?Ser?Asp?Arg?Lys?Ile?Met?Gln?Ser?Gln
35??????????????????40??????????????????45
Ile?Val?Ser?Phe?Tyr?Phe?Lys?Leu?Phe?Lys?Asn?Phe?Lys?Asp?Asp?Gln
50??????????????????55??????????????????60
Ser?Ile?Gln?Lys?Ser?Val?Glu?Thr?Ile?Lys?Glu?Asp?Met?Asn?Val?Lys
65??????????????????70??????????????????75??????????????????80
Phe?Phe?Asn?Ser?Asn?Lys?Lys?Lys?Arg?Asp?Asp?Phe?Glu?Lys?Leu?Thr
85??????????????????90??????????????????95
Asn?Tyr?Ser?Val?Thr?Asp?Leu?Asn?Val?Gln?Arg?Lys?Ala?Ile?His?Glu
100?????????????????105?????????????????110
Leu?Ile?Gln?Val?Met?Ala?Glu?Leu?Ser?Pro?Ala?Ala?Lys?Thr?Gly?Lys
115?????????????????120?????????????????125
Arg?Lys?Arg?Ser?Gln
130
<210>29
<211>132
<212>PRT
＜213〉artificial sequence
<220>
＜223〉description of artificial sequence: C-terminal is by the huIFNG of brachymemma
<400>29
Gln?Asp?Pro?Tyr?Val?Lys?Glu?Ala?Glu?Asn?Leu?Lys?Lys?Tyr?Phe?Asn
1???????????????5??????????????????10??????????????????15
Ala?Gly?His?Ser?Asp?Val?Ala?Asp?Asn?Gly?Thr?Leu?Phe?Leu?Gly?Ile
20??????????????????25??????????????????30
Leu?Lys?Asn?Trp?Lys?Glu?Glu?Ser?Asp?Arg?Lys?Ile?Met?Gln?Ser?Gln
35??????????????????40??????????????????45
Ile?Val?Ser?Phe?Tyr?Phe?Lys?Leu?Phe?Lys?Asn?Phe?Lys?Asp?Asp?Gln
50??????????????????55??????????????????60
Ser?Ile?Gln?Lys?Ser?Val?Glu?Thr?Ile?Lys?Glu?Asp?Met?Asn?Val?Lys
65??????????????????70??????????????????75??????????????????80
Phe?Phe?Asn?Ser?Asn?Lys?Lys?Lys?Arg?Asp?Asp?Phe?Glu?Lys?Leu?Thr
85??????????????????90??????????????????95
Asn?Tyr?Ser?Val?Thr?Asp?Leu?Asn?Val?Gln?Arg?Lys?Ala?Ile?His?Glu
100?????????????????105?????????????????110
Leu?Ile?Gln?Val?Met?Ala?Glu?Leu?Ser?Pro?Ala?Ala?Lys?Thr?Gly?Lys
115?????????????????120?????????????????125
Arg?Lys?Arg?Ser
130
<210>30
<211>131
<212>PRT
＜213〉artificial sequence
<220>
＜223〉description of artificial sequence: C-terminal is by the huIFNG of brachymemma
<400>30
Gln?Asp?Pro?Tyr?Val?Lys?Glu?Ala?Glu?Asn?Leu?Lys?Lys?Tyr?Phe?Asn
1???????????????5??????????????????10??????????????????15
Ala?Gly?His?Ser?Asp?Val?Ala?Asp?Asn?Gly?Thr?Leu?Phe?Leu?Gly?Ile
20??????????????????25??????????????????30
Leu?Lys?Asn?Trp?Lys?Glu?Glu?Ser?Asp?Arg?Lys?Ile?Met?Gln?Ser?Gln
35??????????????????40??????????????????45
Ile?Val?Ser?Phe?Tyr?Phe?Lys?Leu?Phe?Lys?Asn?Phe?Lys?Asp?Asp?Gln
50??????????????????55??????????????????60
Ser?Ile?Gln?Lys?Ser?Val?Glu?Thr?Ile?Lys?Glu?Asp?Met?Asn?Val?Lys
65??????????????????70??????????????????75??????????????????80
Phe?Phe?Asn?Ser?Asn?Lys?Lys?Lys?Arg?Asp?Asp?Phe?Glu?Lys?Leu?Thr
85??????????????????90??????????????????95
Asn?Tyr?Ser?Val?Thr?Asp?Leu?Asn?Val?Gln?Arg?Lys?Ala?Ile?His?Glu
100?????????????????105?????????????????110
Leu?Ile?Gln?Val?Met?Ala?Glu?Leu?Ser?Pro?Ala?Ala?Lys?Thr?Gly?Lys
115?????????????????120?????????????????125
Arg?Lys?Arg
130
<210>31
<21l>130
<212>PRT
＜213〉artificial sequence
<220>
＜223〉description of artificial sequence: C-terminal is by the huIFNG of brachymemma
<400>31
Gln?Asp?Pro?Tyr?Val?Lys?Glu?Ala?Glu?Asn?Leu?Lys?Lys?Tyr?Phe?Asn
1???????????????5??????????????????10??????????????????15
Ala?Gly?His?Ser?Asp?Val?Ala?Asp?Asn?Gly?Thr?Leu?Phe?Leu?Gly?Ile
20??????????????????25??????????????????30
Leu?Lys?Asn?Trp?Lys?Glu?Glu?Ser?Asp?Arg?Lys?Ile?Met?Gln?Ser?Gln
35??????????????????40??????????????????45
Ile?Val?Ser?Phe?Tyr?Phe?Lys?Leu?Phe?Lys?Asn?Phe?Lys?Asp?Asp?Gln
50??????????????????55??????????????????60
Ser?Ile?Gln?Lys?Ser?Val?Glu?Thr?Ile?Lys?Glu?Asp?Met?Asn?Val?Lys
65??????????????????70??????????????????75??????????????????80
Phe?Phe?Asn?Ser?Asn?Lys?Lys?Lys?Arg?Asp?Asp?Phe?Glu?Lys?Leu?Thr
85??????????????????90??????????????????95
Asn?Tyr?Ser?Val?Thr?Asp?Leu?Asn?Val?Gln?Arg?Lys?Ala?Ile?His?Glu
100?????????????????105?????????????????110
Leu?Ile?Gln?Val?Met?Ala?Glu?Leu?Ser?Pro?Ala?Ala?Lys?Thr?Gly?Lys
115?????????????????120?????????????????125
Arg?Lys
130
<210>32
<211>129
<212>PRT
＜213〉artificial sequence
<220>
＜223〉description of artificial sequence: C-terminal is by the huIFNG of brachymemma
<400>32
Gln?Asp?Pro?Tyr?Val?Lys?Glu?Ala?Glu?Asn?Leu?Lys?Lys?Tyr?Phe?Asn
1???????????????5??????????????????10??????????????????15
Ala?Gly?His?Ser?Asp?Val?Ala?Asp?Asn?Gly?Thr?Leu?Phe?Leu?Gly?Ile
20??????????????????25??????????????????30
Leu?Lys?Asn?Trp?Lys?Glu?Glu?Ser?Asp?Arg?Lys?Ile?Met?Gln?Ser?Gln
35??????????????????40??????????????????45
Ile?Val?Ser?Phe?Tyr?Phe?Lys?Leu?Phe?Lys?Asn?Phe?Lys?Asp?Asp?Gln
50??????????????????55??????????????????60
Ser?Ile?Gln?Lys?Ser?Val?Glu?Thr?Ile?Lys?Glu?Asp?Met?Asn?Val?Lys
65??????????????????70??????????????????75??????????????????80
Phe?Phe?Asn?Ser?Asn?Lys?Lys?Lys?Arg?Asp?Asp?Phe?Glu?Lys?Leu?Thr
85??????????????????90??????????????????95
Asn?Tyr?Ser?Val?Thr?Asp?Leu?Asn?Val?Gln?Arg?Lys?Ala?Ile?His?Glu
100?????????????????105?????????????????110
Leu?Ile?Gln?Val?Met?Ala?Glu?Leu?Ser?Pro?Ala?Ala?Lys?Thr?Gly?Lys
115?????????????????120?????????????????125
Arg
<210>33
<211>128
<212>PRT
＜213〉artificial sequence
<220>
＜223〉description of artificial sequence: C-terminal is by the huIFNG of brachymemma
<400>33
Gln?Asp?Pro?Tyr?Val?Lys?Glu?Ala?Glu?Asn?Leu?Lys?Lys?Tyr?Phe?Asn
1???????????????5??????????????????10??????????????????15
Ala?Gly?His?Ser?Asp?Val?Ala?Asp?Asn?Gly?Thr?Leu?Phe?Leu?Gly?Ile
20??????????????????25??????????????????30
Leu?Lys?Asn?Trp?Lys?Glu?Glu?Ser?Asp?Arg?Lys?Ile?Met?Gln?Ser?Gln
35??????????????????40??????????????????45
Ile?Val?Ser?Phe?Tyr?Phe?Lys?Leu?Phe?Lys?Asn?Phe?Lys?Asp?Asp?Gln
50??????????????????55??????????????????60
Ser?Ile?Gln?Lys?Ser?Val?Glu?Thr?Ile?Lys?Glu?Asp?Met?Asn?Val?Lys
65??????????????????70??????????????????75??????????????????80
Phe?Phe?Asn?Ser?Asn?Lys?Lys?Lys?Arg?Asp?Asp?Phe?Glu?Lys?Leu?Thr
85??????????????????90??????????????????95
Asn?Tyr?Ser?Val?Thr?Asp?Leu?Asn?Val?Gln?Arg?Lys?Ala?Ile?His?Glu
100?????????????????105?????????????????110
Leu?Ile?Gln?Val?Met?Ala?Glu?Leu?Ser?Pro?Ala?Ala?Lys?Thr?Gly?Lys
115?????????????????120?????????????????125
<210>34
<211>140
<212>PRT
＜213〉artificial sequence
<220>
＜223〉description of artificial sequence: Actimmune (r)
<400>34
Met?Gln?Asp?Pro?Tyr?Val?Lys?Glu?Ala?Glu?Asn?Leu?Lys?Lys?Tyr?Phe
1???????????????5??????????????????10??????????????????15
Asn?Ala?Gly?His?Ser?Asp?Val?Ala?Asp?Asn?Gly?Thr?Leu?Phe?Leu?Gly
20??????????????????25??????????????????30
Ile?Leu?Lys?Asn?Trp?Lys?Glu?Glu?Ser?Asp?Arg?Lys?Ile?Met?Gln?Ser
35??????????????????40??????????????????45
Gln?Ile?Val?Ser?Phe?Tyr?Phe?Lys?Leu?Phe?Lys?Asn?Phe?Lys?Asp?Asp
50??????????????????55??????????????????60
Gln?Ser?Ile?Gln?Lys?Ser?Val?Glu?Thr?Ile?Lys?Glu?Asp?Met?Asn?Val
65??????????????????70??????????????????75??????????????????80
Lys?Phe?Phe?Asn?Ser?Asn?Lys?Lys?Lys?Arg?Asp?Asp?Phe?Glu?Lys?Leu
85??????????????????90??????????????????95
Thr?Asn?Tyr?Ser?Val?Thr?Asp?Leu?Asn?Val?Gln?Arg?Lys?Ala?Ile?His
100?????????????????105?????????????????110
Glu?Leu?Ile?Gln?Val?Met?Ala?Glu?Leu?Ser?Pro?Ala?Ala?Lys?Thr?Gly
115?????????????????120?????????????????125
Lys?Arg?Lys?Arg?Ser?Gln?Met?Leu?Phe?Arg?Gly?Arg
130?????????????????135?????????????????140
<210>35
<211>6
<212>PRT
＜213〉artificial sequence
<220>
＜223〉description of artificial sequence: mark
<400>35
His?His?His?His?His?His
1???????????????5
<210>36
<211>8
<212>PRT
＜213〉artificial sequence
<220>
＜223〉description of artificial sequence: mark
<400>36
Met?Lys?His?His?His?His?His?His
1???????????????5
<210>37
<211>10
<212>PRT
＜213〉artificial sequence
<220>
＜223〉description of artificial sequence: mark
<400>37
Met?Lys?His?His?Ala?His?His?Gln?His?His
1???????????????5??????????????10
<210>38
<211>14
<212>PRT
＜213〉artificial sequence
<220>
＜223〉description of artificial sequence: mark
<400>38
Met?Lys?His?Gln?His?Gln?His?Gln?His?Gln?His?Gln?His?Gln
1???????????????5??????????????10
<210>39
<211>10
<212>PRT
＜213〉artificial sequence
<220>
＜223〉description of artificial sequence: mark
<400>39
Glu?Gln?Lys?Leu?Ile?Ser?Glu?Glu?Asp?Leu
1???????????????5??????????????10
<210>40
<211>8
<212>PRT
＜213〉artificial sequence
<220>
＜223〉description of artificial sequence: mark
<400>40
Asp?Tyr?Lys?Asp?Asp?Asp?Asp?Lys
1???????????????5
<210>41
<211>9
<212>PRT
＜213〉artificial sequence
<220>
＜223〉description of artificial sequence: mark
<400>41
Tyr?Pro?Tyr?Asp?Val?Pro?Asp?Tyr?Ala
1???????????????5
<210>42
<211>498
<212>DNA
＜213〉artificial sequence
<220>
＜223〉description of artificial sequence: be used for making the expression cassette of interferon-gamma in the Chinese hamster ovary celI optimization expression
<400>42
atgaagtaca?caagctatat?cctggccttt?cagctgtgca?tcgtgctggg?ctccctgggc?60
tgctattgcc?aggaccctta?cgtgaaggag?gccgagaacc?tgaagaagta?ctttaacgcc?120
ggccacagcg?atgtggccga?caatggcaca?ctgtttctgg?gcatcctgaa?gaattggaag?180
gaggagagcg?atcggaagat?catgcagtcc?cagatcgtgt?ccttctattt?caagctgttt?240
aagaatttca?aggacgatca?gtccatccag?aagtccgtgg?agaccatcaa?ggaggacatg?300
aacgtgaagt?ttttcaatag?caataagaag?aagagagacg?atttcgagaa?gctgaccaat?360
tactccgtga?cagacctgaa?cgtgcagaga?aaggccatcc?acgagctgat?ccaggtgatg?420
gccgagctgt?cccccgccgc?caagaccggc?aagagaaaga?gaagccagat?gctgttcaga?480
ggcagacggg?ccagccag???????????????????????????????????????????????498
<210>43
<211>19
<212>DNA
＜213〉artificial sequence
<220>
＜223〉description of artificial sequence: primer
<400>43
gatggctggc?aactagaag??????19
<210>44
<211>19
<212>DNA
＜213〉artificial sequence
<220>
＜223〉description of artificial sequence: primer
<400>44
tgtacggtgg?gaggtctat??????19
<210>45
<211>33
<212>DNA
＜213〉artificial sequence
<220>
＜223〉description of artificial sequence: primer
<400>45
gttcaggtct?gtcacgctgt?aattggtcag?ctt??????33
<210>46
<211>33
<212>DNA
＜213〉artificial sequence
<220>
＜223〉description of artificial sequence: primer
<400>46
aagctgacca?attacaccgt?gacagacctg?aac?????33
<210>47
<211>33
<212>DNA
＜213〉artificial sequence
<220>
＜223〉description of artificial sequence: primer
<400>47
catgatcttc?cgatcggtct?cgttcttcca?att?????33
<210>48
<211>33
<212>DNA
＜213〉artificial sequence
<220>
＜223〉description of artificial sequence: primer
<400>48
aattggaaga?acgagaccga?tcggaagatc?atg?????33
<210>49
<211>30
<212>DNA
＜213〉artificial sequence
<220>
＜223〉description of artificial sequence: primer
<400>49
gagtctagat?tacagcatct?ggcttctctt?????????30

Claims (62)

1. it is active and have interferon-gamma (IFNG) polypeptide variants of aminoacid sequence shown in the SEQ ID NO:1 to have IFNG, or it has the active fragment of IFNG.
2. the variant of claim 1, wherein said variant has aminoacid sequence shown in the SEQ ID NO:1.
3. the variant of claim 1, wherein said variant is the fragment of aminoacid sequence shown in the SEQ ID NO:1, it in the terminal brachymemma of C-1-15 amino-acid residue.
4. the variant of claim 2, wherein said fragment has the SEQ of being selected from ID NO:2, SEQ IDNO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, the aminoacid sequence of SEQ ID NO:15 or SEQ ID NO:16.
5. the variant of one of claim 1-4, wherein said variant is by glycosylation.
6. the variant of one of claim 1-5, wherein said variant comprises at least one extra modification and has the IFNG activity.
7. the variant of claim 6, wherein said variant is compared with aminoacid sequence shown in the SEQ ID NO:1, comprises 1-10 modification.
8. the variant of claim 6, wherein said variant be selected from SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ BD NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ IDNO:8, SEQ ID NO:9, SEQ ID NO:1 0, SEQ B NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, the aminoacid sequence of SEQ ID NO:15 or SEQ ID NO:16 is compared, and comprises 1-10 modification.
9. claim 7 or 8 variant, wherein said modification is to replace.
10. the variant of one of claim 6-9, wherein said variant comprises amino-acid residue at least one introducing and/or that at least one is removed, and described amino-acid residue comprises the linking group corresponding to non-polypeptide fraction.
11. the variant of claim 10, wherein said variant comprises the glycosylation site of at least one introducing.
12. the variant of claim 11, wherein said glycosylation site are the N-glycosylation site.
13. the variant of claim 12, wherein said N-glycosylation site are introduced into such position, this position comprise have at least 25% its side chain be exposed to the surface amino-acid residue (as described in this paper embodiment 1).
14. the variant of claim 13, wherein said N-glycosylation site are introduced into such position, this position comprise have at least 50% its side chain be exposed to the surface amino-acid residue (as described in this paper embodiment 1).
15. the variant of claim 13 or 14, wherein said N-glycosylation site is introduced by replacement.
16. the variant of claim 15, wherein said replacement is selected from K12S, K12T, G18S, G18T, E38N, E38N+S40T, K61S, K61T, N85S, N85T, K94N, Q106S or Q106T.
17. the variant of claim 16, wherein said replacement is selected from K12T, G18T, E38N+S40T, K61T, N85T, K94N or Q106T.
18. the variant of claim 17, wherein said replacement is E38N+S40T.
19. the variant of claim 10, wherein said variant comprises the cysteine residues of at least one introducing.
20. the variant of claim 19, wherein said cysteine residues are introduced into such position, this position comprise have at least 25% its side chain be exposed to the surface amino-acid residue (as described in this paper embodiment 1).
21. the variant of claim 20, wherein said cysteine residues are introduced into such position, this position comprise have at least 50% its side chain be exposed to the surface amino-acid residue (as described in this paper embodiment 1).
22. the variant of claim 20 or 21, wherein said cysteine residues is introduced by replacement.
23. the variant of claim 22, wherein said replacement is selected from N10C, N16C, E38C, N59C, N83C, K94C, N104C or A124C.
24. the variant of one of claim 19-23, wherein said cysteine residues links to each other with non-polypeptide fraction covalency.
25. the variant of claim 24, wherein said non-polypeptide fraction is a polymer molecule.
26. the variant of claim 25, wherein said polymer molecule are linearity or branched chair polymacrogol.
27. the variant of claim 10, wherein said variant comprise the N-glycosylation site of at least one introducing and the cysteine residues of at least one introducing.
28. the variant of claim 27, wherein said N-glycosylation site are introduced into each described position of claim 13-18, and described cysteine residues is introduced into each described position of claim 20-23.
29. the variant of claim 28, wherein said variant comprise the replacement that is selected from down group: K12T+N16C, K12I+E38C, K12T+N59C, K12I+N83C, K12T+K94C, K12T+N104C, K12T+A124C, G18T+N10C, G18T+E38C, G18T+N59C, G18T+N83C, G18T+K94C, G18T+N104C, G18T+A124C, G18N+S20T+N10C, G18N+S20T+N16C, G18N+S20T+E38C, G18N+S20T+N59C, G18N+S20T+N83C, G18N+S20T+K94C, G18N+S20T+N104C, G18N+S20T+A124C, E38N+S40T+N10C, E38N+S40T+N16C, E38N+S40T+N59C, E38N+S40T+N83C, E38N+S40T+K94C, E38N+S40T+N104C, the last A124C of E38N+S40T, K61T+N10C, K61T+N16C, K61T+E38C, K61T+N83C, K61T+K94C, K61T+N104C, K61T+A124C, N85T+N10C, N85T+N16C, N85T+E38C, N85T+N59C, N85T+K94C, N85T+N104C, N85T+A124C, K94N+N10C, K94N+N16C, K94N+E38C, K94N+N59C, K94N+N83C, K94N+N104C, K94N+A124C, Q106T+N10C, Q106T+N16C, Q106T+E38C, Q106T+N59C, Q106T+N83C, Q106T+K94C or Q106T+A124C.
30. the variant of claim 29, wherein said variant comprise the replacement that is selected from down group: E38N+S40T+N10C, E38N+S40T+N16C, E38N+S40T+N59C, E38N+S40T+N83C, E38N+S40T+K94C, E38N+S40T+N104C or E38N+S40T+A124C.
31. the variant of one of claim 27-30, wherein said cysteine residues links to each other with non-polypeptide fraction covalency.
32. the variant of claim 31, wherein said non-polypeptide fraction is limited by one of claim 25-26.
33. the variant of one of claim 6-32, wherein said variant comprise the replacement that is selected from down group: G26F, G26N, G26Y, G26Q, G26V, G26A, G26M, G26I, G26K, G26R, G26T, G26H, G26C or G26S.
34. the variant of claim 33, wherein said variant comprise the replacement that is selected from down group: G26A, G26M, G26I, G26K, G26R, G26T, G26H, G26C or G26S.
35. comprising, the variant of claim 34, wherein said variant replace G26A or G26S.
36. comprising, the variant of claim 35, wherein said variant replace G26A.
37. the variant of claim 10, wherein said variant comprise the cysteine residues of at least one N-glycosylation site of removing and at least one introducing.
38. the variant of claim 37, wherein said variant comprises at least one N-glycosylation site of removing, the N-glycosylation site of at least one introducing, with the cysteine residues of at least one introducing, the position that the N glycosylation site of wherein said introducing is introduced into is different from the described N-glycosylation site position occupied that is removed.
39. the variant of claim 37 or 38, wherein said cysteine residues links to each other with non-polypeptide fraction covalency.
40. the variant of claim 39, wherein said non-polypeptide fraction is limited by one of claim 25-26.
41. a nucleotide sequence, the polypeptide variants of one of its coding claim 1-40.
42. an expression vector, it comprises the nucleotide sequence of claim 41.
43. a glycosylation host cell, it comprises the nucleotide sequence of claim 41 or the expression vector of claim 42.
44. the host cell of claim 43, it is Chinese hamster ovary celI or bhk cell.
45.IFNG polypeptide variants group, or IFNG polypeptide variants group's composition, wherein said colony comprise at least 70% according to the described IFNG polypeptide variants of one of claim 1-40.
46. a pharmaceutical composition, it comprises polypeptide variants and acceptable diluents, carrier or the auxiliary of one of claim 1-40.
47. the polypeptide variants of one of claim 1-40 or the pharmaceutical composition of claim 46 are as the purposes of medicine.
48. the polypeptide variants of one of claim 1-40 or the pharmaceutical composition of claim 46 are used for the treatment of purposes in the medicine of interstitial lung disease in preparation.
49. the purposes of claim 48, wherein said interstitial lung disease are the spontaneous lung fibrosiss.
50. the method for treatment or prevention interstitial lung disease, described method comprises the Mammals of needs is arranged, people especially, described polypeptide variants of one of claim 1-40 that uses significant quantity or the described pharmaceutical composition of claim 46.
51. the method for claim 50, wherein said interstitial lung disease are the spontaneous lung diseases.
52. increase the method for the interior N-degree of glycosylation of body of parent IFNG polypeptide, described parent IFNG polypeptide comprises N-glycosylation site at least one body with aminoacid sequence N-X-S, wherein X is any amino-acid residue except proline(Pro), described method comprises the serine residue in the described N-X-S aminoacid sequence is replaced with threonine residues, so that obtain a kind of IFNG variant.
53. the method for claim 52, wherein said parent IFNG polypeptide has aminoacid sequence shown in the SEQ ID NO:17.
54. the method for claim 52, wherein said parent IFNG polypeptide are the fragments of aminoacid sequence shown in the SEQ ID NO:17, it in the terminal brachymemma of C-1-15 amino-acid residue.
55. the method for claim 54, wherein said fragment have the SEQ of being selected from ID NO:19, SEQID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQID NO:29, SEQ ID NO:30, SEQ ID NO:31, the aminoacid sequence of SEQ ID NO:32 or SEQ ID NO:33.
56. the method for the IFNG polypeptide variants of one of preparation claim 1-40, this method comprises
(a) cultivate the glycosylation host cell, this cell contains the nucleotide sequence of one of coding claim 1-40 described IFNG polypeptide variants, and used culture condition helps the expression of this polypeptide variants;
(b) optionally make described polypeptide variants and non-polypeptide fraction help taking place to carry out under the link coupled condition vitro reactions; With
(c) reclaim described polypeptide variants.
57. the method for claim 56, wherein said method comprises
(a) cultivate the glycosylation host cell, this cell contains the nucleotide sequence of one of coding claim 1-40 described IFNG polypeptide variants, and used culture condition helps the expression of this polypeptide variants;
(b) make described polypeptide variants and non-polypeptide fraction help taking place to carry out under the link coupled condition vitro reactions; With
(c) reclaim described polypeptide variants.
58. the method for claim 57, wherein said variant is limited by one of claim 19-40.
59. the method for claim 56, wherein said method comprises
(a) cultivate the glycosylation host cell, this cell contains the nucleotide sequence of one of coding claim 1-40 described IFNG polypeptide variants, and used culture condition helps the expression of this polypeptide variants; With
(b) reclaim described polypeptide variants.
60. the method for claim 61, wherein said polypeptide variants have the SEQ of being selected from ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, the aminoacid sequence of SEQ ID NO:15 or SEQID NO:16.
61. the method for claim 59, wherein said variant comprise at least one other modification.
62. the method for claim 60, wherein said variant is limited by one of one of claim 11-18 or 33-36.
CNB028078918A 2001-04-06 2002-04-04 Interferon gamma polypeptide variants Expired - Fee Related CN1257186C (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DKPA200100579 2001-04-06
DKPA200100579 2001-04-06
DKPA200100714 2001-05-07
DKPA200100714 2001-05-07
DKPA200200198 2002-02-11
DKPA200200198 2002-02-11

Publications (2)

Publication Number Publication Date
CN1537117A true CN1537117A (en) 2004-10-13
CN1257186C CN1257186C (en) 2006-05-24

Family

ID=27222504

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028078918A Expired - Fee Related CN1257186C (en) 2001-04-06 2002-04-04 Interferon gamma polypeptide variants

Country Status (15)

Country Link
EP (1) EP1412382A2 (en)
JP (1) JP2005518183A (en)
KR (1) KR20030094336A (en)
CN (1) CN1257186C (en)
BG (1) BG108256A (en)
BR (1) BR0208596A (en)
CA (1) CA2443277A1 (en)
HK (1) HK1069834A1 (en)
HU (1) HUP0303645A3 (en)
IL (1) IL157896A0 (en)
MX (1) MXPA03009082A (en)
NO (1) NO20034432L (en)
NZ (1) NZ528651A (en)
PL (1) PL366705A1 (en)
WO (1) WO2002081507A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103550757A (en) * 2005-09-20 2014-02-05 纽约大学 Method for treating lung diseases by using interferon

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070172446A1 (en) 2003-05-16 2007-07-26 Intermune, Inc. Synthetic chemokine receptor ligands and methods of use thereof
JP4707327B2 (en) * 2004-01-27 2011-06-22 旭化成ファーマ株式会社 Polypeptides adsorption inhibitors
US7597884B2 (en) * 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
JP2008513356A (en) * 2004-08-09 2008-05-01 アリオス バイオファーマ インク． Synthetic advanced glycosylated protease resistant polypeptide variants, oral formulations and methods using the same
US7625555B2 (en) 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
JP5769142B2 (en) * 2007-09-04 2015-08-26 独立行政法人酒類総合研究所 Method for high secretion of heterologous proteins in Pichia yeast
EP2039764A1 (en) * 2007-09-19 2009-03-25 Pevion Biotech AG Truncated secretory aspartyl proteinase 2
BG66517B1 (en) 2008-04-08 2016-02-29 Tigo Gmbh Inhibitor of endogenous human interferon - gamma
RU2446821C2 (en) * 2010-07-15 2012-04-10 Олег Ильич Эпштейн Drug preparation for treating infectious diseases accompanied by neurotoxic disorders, and method of treating infectious diseases accompanied by neurotoxic disorders
GB201621728D0 (en) 2016-12-20 2017-02-01 Ucb Biopharma Sprl Methods
BG67190B1 (en) 2017-03-29 2020-11-16 Tigo Gmbh Anti-gama mutant protein against endogenous human gamma interferon
WO2023182947A1 (en) * 2022-03-22 2023-09-28 Chiang Mai University A modified protein of interferon gamma and its use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9203641A (en) * 1983-12-16 1992-07-01 Genentech Inc RECOMBINANT GAMMA INTERFERONS THAT HAVE IMPROVED STABILITY AND BIOTECHNOLOGICAL METHODS FOR THEIR OBTAINING.
BG52073B2 (en) * 1990-01-24 1996-04-30 Inst Molekuljarna Biolog Method for the preparation of recombinant human noncystein -interferon, free of n-end methionine
DE4036856C1 (en) * 1990-11-19 1992-05-27 Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung Ev, 8000 Muenchen, De

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103550757A (en) * 2005-09-20 2014-02-05 纽约大学 Method for treating lung diseases by using interferon

Also Published As

Publication number Publication date
JP2005518183A (en) 2005-06-23
HK1069834A1 (en) 2005-06-03
NO20034432L (en) 2003-10-29
CA2443277A1 (en) 2002-10-17
HUP0303645A2 (en) 2004-01-28
WO2002081507A3 (en) 2004-02-12
PL366705A1 (en) 2005-02-07
HUP0303645A3 (en) 2005-12-28
BR0208596A (en) 2004-03-09
CN1257186C (en) 2006-05-24
IL157896A0 (en) 2004-03-28
NZ528651A (en) 2006-06-30
KR20030094336A (en) 2003-12-11
BG108256A (en) 2004-12-30
MXPA03009082A (en) 2004-11-22
WO2002081507A2 (en) 2002-10-17
NO20034432D0 (en) 2003-10-03
EP1412382A2 (en) 2004-04-28

Similar Documents

Publication Publication Date Title
US7419805B2 (en) Polynucleotides encoding S99T interferon gamma polypeptide variants and means of expression
CN1188172C (en) G-CSF conjugates
US7504237B2 (en) Polynucleotides encoding interferon gamma polypeptides
CN1103782C (en) Compositions and methods for stimulating megakaryocyte growth and differentiation
CN1729018A (en) G-CSF conjugates
CN1897812A (en) Glycopegylated granulocyte colony stimulating factor
CN1522159A (en) Interferon formulations
CN101062419A (en) Polymer conjugates of interferon beta-1a and uses
CN1257186C (en) Interferon gamma polypeptide variants
CN1309423C (en) Interferon gamma conjugates
US7390638B2 (en) S99T C-11 Truncated polynucleotides encoding interferon gamma polypeptide variants
CN1501815A (en) New interferon beta-like molecules
CN1738640A (en) Interferon-alpha polypeptides and conjugates
RU2268749C2 (en) Interferon-gamma conjugates
RU2296130C2 (en) Variants of gamma-interferon polypeptide
AU2002252971B2 (en) Interferon gamma polypeptide variants
AU782635B2 (en) Interferon gamma conjugates
AU2002252971A1 (en) Interferon gamma polypeptide variants
CN101172160A (en) Interferon gamma conjugates
ZA200308376B (en) Interferon gamma polypeptide variants.
CZ20033016A3 (en) Interferon gamma polypeptide variants

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1069834

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20060524